Researcher basic information

• 医学博士, 北海道大学

• https://researchmap.jp/ShunsukeOhnishi?lang=en

• https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201201094568895124
• http://kaken.nii.ac.jp/d/r/10443475.ja.html

• 201201094568895124

• 消化器病学
• 再生医療
• 薬理学
• 発現抑制
• 核酸
• シグナル伝達

• Life Science, Gastroenterology

• Bachelor's degree program, School of Pharmaceutical Sciences and Pharmacy
• Master's degree program, Graduate School of Life Science
• Doctoral (PhD) degree program, Graduate School of Life Science

Research activity information

• Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.
  Takatsugu Tanaka; Goki Suda; Masatsugu Ohara; Daisuke Yokoyama; Shoichi Kitano; Osamu Maehara; Tomoka Yoda; Qingjie Fu; Zijian Yang; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Shunsuke Ohnishi; Naoya Sakamoto
  Journal of cachexia, sarcopenia and muscle, 17, 3, e70305, Jun. 2026, [International Magazine]
  English, Scientific journal, BACKGROUND: Cachexia and sarcopenia are prevalent, inflammation-linked syndromes in chronic liver disease that worsen outcomes. To our knowledge, their coexistence in a single chronic liver disease cohort has not been systematically examined. In this study, we evaluated the prevalence, clinical features and prognostic impact of cachexia and sarcopenia-alone and combined-in chronic liver disease. METHODS: We retrospectively screened 776 patients with liver cirrhosis (LC) and/or hepatocellular carcinoma (HCC) at Hokkaido University Hospital (August 2014-May 2025). The inclusion criteria were grip strength, CT-based muscle mass and complete clinical data, yielding 307 patients; 469 did not meet one of the inclusion criteria. Cachexia was determined following the Asian Working Group for Cachexia criteria, and sarcopenia was determined following Japan Society of Hepatology guidelines. Patients were grouped as no cachexia/sarcopenia, cachexia only, sarcopenia only or cachexia+sarcopenia. The outcomes were overall survival, time to liver-related events and time to readmission (Kaplan-Meier and Cox-proportional models). RESULTS: Among 776 patients, 307 were included in the final-analysis. Of 307 patients, 206 (67.1%) were male, the median age was 70 years (range, 19-90 years), 262 patients (85.3%) had LC and 188 patients (61.2%) had HCC. The patients were grouped as no cachexia/sarcopenia (213; 69.4%), cachexia only (54; 17.6%), sarcopenia only (17; 5.5%) and cachexia+sarcopenia (23; 7.5%). The combined group compared with the others had the lowest body mass index, psoas-muscle-index and grip strength (all p < 0.001). Overall survival (OS), liver-related events, LC progression and readmissions were compared between 246 patients with and without cachexia or sarcopenia, after excluding those who visited the hospital on or after July 2023 and had ≤ 3 months of follow-up. OS was shorter in the cachexia only (median 61.8 [95% CI 40.90-not reached (NR)] months, p = 0.046) and cachexia+sarcopenia (median 59.6 [95% CI 14.26-NR] months, p = 0.027) groups than in the no cachexia/sarcopenia group. Multivariable analysis showed that cachexia+sarcopenia (hazard ratio 2.48, p = 0.010), HCC (hazard ratio 3.40, p < 0.001) and diabetes mellitus (hazard ratio 1.80, p = 0.013) independently predicted mortality. The combined group compared with the other groups had a shorter time to liver-related events and readmission. CONCLUSIONS: The coexistence of cachexia and sarcopenia-rather than either alone-can be used as an indicator for identifying patients with chronic liver disease at the highest risk of poor outcomes. Concurrent assessment and early, targeted interventions may improve outcomes in this population.
• Topical amnion‐derived mesenchymal stem cell conditioned medium attenuates chronic ultraviolet B‐induced skin photodamage in hairless mice
  Shintaro Mitamura; Kosuke Ishikawa; Hiroko Takahashi; Yuki Sasaki; Shunsuke Ohnishi; Taku Maeda
  Photochemistry and Photobiology, 10 May 2026
  Scientific journal
• A Novel Bioabsorbable Covered Stent for Advancing Bile Duct Injury Management: A Preclinical Study in a Porcine Model (With Video).
  Mitsuo Miyazawa; Masayasu Aikawa; Junpei Takashima; Hirotoshi Kobayashi; Takuya Minagawa; Osamu Itano; Shunsuke Ohnishi
  DEN open, 6, 1, e70162, Apr. 2026, [International Magazine]
  English, Scientific journal, Self-expandable metallic and plastic stents have been used for biliary tract injuries, but they are not entirely adequate as treatments. This study investigated the potential of our novel self-expandable bioabsorbable covered stent (SEBCS) to treat bile duct injuries. We developed a novel SEBCS by covering a self-expandable bioabsorbable stent with a bioabsorbable tube. Five pigs underwent laparotomy after being placed under general anesthesia. A 5-mm incision was made in the extrahepatic bile duct, followed by the insertion of an SEBCS. Postoperatively, hepatobiliary enzyme levels were measured. At 10 weeks postoperatively, a histological evaluation of the injured area and cholangiogram were performed. The SEBCS was successfully inserted into the extrahepatic bile ducts of all animals. The histological evaluation at 10 weeks postoperatively showed epithelial regeneration with numerous peribiliary glands, including at the injury site. Cholangiography revealed no stenosis in the injured area. Hematological and biochemical analyses revealed mild elevation of biliary enzyme levels on day 10 postoperatively compared with preoperative levels; these levels returned to preoperative values by week 10. This novel SEBCS technique demonstrated the potential to regenerate bile ducts at the site of extrahepatic bile duct injury and may be a promising endoscopic treatment for biliary tract injuries.
• Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.
  Takatsugu Tanaka; Goki Suda; Masatsugu Ohara; Osamu Maehara; Tomoka Yoda; Qingjie Fu; Zijian Yang; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Shunsuke Ohnishi; Naoya Sakamoto
  Frontiers in nutrition, 13, 1730695, 1730695, 2026, [International Magazine]
  English, Scientific journal, BACKGROUND: Cachexia is associated with poor prognosis in chronic liver disease (CLD), yet robust predictors remain poorly defined. This study examined clinical factors and serum biomarkers associated with cachexia in patients with CLD. METHODS: We analyzed 356 of 526 patients with CLD who had complete cachexia assessment and available stored serum samples. In a discovery cohort (n = 240; Aug 2014-Jun 2023), serum fibroblast growth factor 21 (FGF21), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were measured. Multivariable logistic regression and receiver operating characteristic analyses were used to identify independent predictors and optimal cutoff values. Findings were subsequently evaluated in an independent validation cohort (n = 116; Jul 2023-May 2025). RESULTS: Median age was 68 years (range 19-90), 65.8% of participants were male, and 24.6% had cachexia, which independently predicted worse overall survival (hazard ratio 1.64; 95% CI 1.03-2.62; p = 0.038). Patients with cachexia had higher serum FGF21 concentrations than those without cachexia (median, 292 vs. 177 pg./mL; p = 0.002), whereas IL-6 and TNF-α levels did not differ significantly between groups. FGF21 was the only biomarker independently associated with cachexia (odds ratio, 1.71; 95% CI, 1.10-2.66; p = 0.016). Advanced Child-Pugh class and platelet count were identified as additional independent clinical predictors. CONCLUSION: Serum FGF21 independently predicts cachexia in CLD and may facilitate earlier identification of at-risk patients, enabling timely intervention to improve clinical outcomes.
• 消化器内視鏡医が挑む,産学官連携によるデバイス開発の最前線 現状とそこから見える課題
  大野 正芳; 大西 俊介; 坂本 直哉
  日本消化器病学会雑誌, 122, 臨増大会, A437, A437, (一財)日本消化器病学会, Oct. 2025
  Japanese
• Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
  Masatsugu Ohara; Goki Suda; Risako Kohya; Yutaka Yasui; Kaoru Tsuchiya; Masayuki Kurosaki; Joji Tani; Shinya Maekawa; Nobuyuki Enomoto; Makoto Chuma; Manabu Morimoto; Shun Kaneko; Mina Nakagawa; Yasuhiro Asahina; Atsumasa Komori; Yuki Kugiyama; Masaru Baba; Akihisa Nakamura; Jun Ito; Ren Yamada; Shunichi Hosoda; Yoshiya Yamamoto; Sonoe Yoshida; Takuya Sho; Takashi Sasaki; Tomoka Yoda; Akimitsu Meno; Naohiro Yasuura; Qingjie Fu; Zijian Yang; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Koji Ogawa; Naoya Sakamoto
  Hepatology international, 28 Aug. 2025, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality. Although the atezolizumab/bevacizumab regimen demonstrated impressive efficacy in the IMbrave150 clinical trial, long-term outcomes, particularly 3-year overall survival (OS), remain unestablished because of limited follow-up. Long-term outcomes have been reported for the tremelimumab/durvalumab combination, highlighting the need for comparable data on atezolizumab/bevacizumab. We aimed to elucidate the 3-year OS in patients with unresectable HCC (uHCC) treated with atezolizumab plus bevacizumab. METHODS: This retrospective multicenter study included patients with uHCC who received atezolizumab/bevacizumab. Among the 506 patients treated at the participating institutions, only those who initiated therapy between October 2020 and January 2022 were included. Comprehensive clinical, laboratory, and imaging data were collected, and the patients were followed up until March 2025. RESULTS: A total of 257 patients were analyzed, with a median follow-up of 48.23 months (range, 36.23-53.60 months). The 2- and 3-year OS rates were 39.2% and 25.3%, respectively. Among patients meeting the IMbrave150 criteria, the 3-year OS rate was 31.6%. Multivariate regression analysis identified baseline alpha-fetoprotein level > 116 ng/mL (odds ratio [OR] 0.41; 95% confidence interval [CI] 0.20-0.84; p = 0.015) and modified albumin-bilirubin grade 1-2a (OR 2.50; 95% CI 1.18-5.32; p = 0.017) as significant factors associated with 3-year OS. CONCLUSIONS: In a real-world setting, the 3-year OS for uHCC patients treated with atezolizumab/bevacizumab was 25.3%, rising to 31.6% among those meeting the IMbrave150 criteria. Survival outcomes underscore the clinical value of atezolizumab/bevacizumab in improving long-term prognosis and guiding first-line treatment decisions for patients with unresectable HCC.
• Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes.
  Takashi Kitagataya; Goki Suda; Takatsugu Tanaka; Shoichi Kitano; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Qingjie Fu; Shunichi Hosoda; Sonoe Yoshida; Osamu Maehara; Shunsuke Ohnishi; Masatsugu Ohara; Masato Nakai; Takuya Sho; Kosuke Nakamura; Suguru Ishizaka; Naoya Sakamoto
  Hepatology research : the official journal of the Japan Society of Hepatology, 19 Jun. 2025, [International Magazine]
  English, Scientific journal, AIM: Cirrhotic cardiomyopathy (CCM) is a significant complication of liver cirrhosis; however, its prevalence and impact in Asian populations remain unclear. The aim of this study was to assess the prevalence of CCM in Japanese patients with liver cirrhosis and to evaluate its impact on clinical outcomes. METHODS: In this retrospective study, 80 patients with liver cirrhosis confirmed using transient elastography (liver stiffness ≥ 12.5 kPa) were included. Study was performed at Hokkaido University Hospital between January 2014 and April 2024. CCM was diagnosed using the 2019 Cirrhotic Cardiomyopathy Consortium criteria. Subsequently, patient characteristics, survival, and the incidences of decompensation and cardiovascular events were analyzed. RESULTS: The prevalence of CCM was 46.3% (37/80), with 78.4% of patients with CCM showing isolated systolic dysfunction based on global longitudinal strain. Patients with CCM were significantly older, had lower serum ammonia and bilirubin levels, and had higher platelet counts. CCM was associated with a significantly higher incidence of decompensation events (hazard ratio 3.97, 95% confidence interval 1.64-9.61, p = 0.003) and was an independent risk factor for decompensation in the multivariate analysis (hazard ratio 3.24, 95% confidence interval 1.29-8.11, p = 0.012). Patients with and without CCM showed no significant differences in overall survival or cardiovascular events. CONCLUSIONS: CCM is prevalent among Japanese patients with liver cirrhosis and is associated with an increased risk of hepatic decompensation. These findings highlight the importance of cardiac evaluation in patients with cirrhosis and suggest that CCM should be considered in the management of liver cirrhosis to improve patient outcomes.
• Sa1178: EXTRACELLULAR VESICLES OBTAINED FROM AMNION-DERIVED MESENCHYMAL STEM CELLS PREVENT ESOPHAGEAL STRICTURE AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION IN PIGS
  Takayuki Sone; Masayoshi Ono; Hiroki Egami; Shoko Ono; Shunsuke Ohnishi; Naoya Sakamoto
  Gastroenterology, 169, 1, S, 388, Elsevier BV, May 2025
  Scientific journal
• Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.
  Risako Kohya; Goki Suda; Masatsugu Ohara; Shunichi Hosoda; Takuya Sho; Makoto Chuma; Atsumasa Komori; Yuki Kugiyama; Yutaka Yasui; Kaoru Tsuchiya; Masayuki Kurosaki; Joji Tani; Shun Kaneko; Mina Nakagawa; Yasuhiro Asahina; Shinya Maekawa; Nobuyuki Enomoto; Yoshiya Yamamoto; Masaru Baba; Ren Yamada; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
  JHEP reports : innovation in hepatology, 7, 5, 101364, 101364, May 2025, [International Magazine]
  English, Scientific journal, BACKGROUND & AIMS: Fibroblast growth factor 21 (FGF21) is a crucial regulator of cell metabolism. Tumour-secreted FGF21 has shown immune-checkpoint factor functions, and high FGF21 levels are associated with a poor prognosis for patients. However, its prognostic value and impact on treatment response in patients with hepatocellular carcinoma (HCC) treated with immune-checkpoint inhibitors (ICIs) remain unclear. Thus, this study investigated the potential of high FGF21 levels as a prognostic marker and whether traditional ICI-based therapy can improve the prognosis of patients with high FGF21 levels. METHODS: In this retrospective multicentre study, patients with unresectable HCC who received atezolizumab/bevacizumab in the NORTE study group (n = 117) were classified into high (≥915 pg/ml; n = 29) and non-high (n = 88) FGF21 groups. For validation, we investigated patients treated with atezolizumab/bevacizumab in an independent cohort (n = 285). Overall survival, progression-free survival, and treatment response were compared between patients with and without high baseline FGF21 levels. RESULTS: The median overall survival (p <0.001) and progression-free survival (p = 0.045) were significantly shorter in the high FGF21 group than in the non-high FGF21 group. Independent cohort analysis validated these results. In the overall cohort, the median progression-free survival (5.75 vs. 8.84 months; p = 0.027) and median overall survival (14.13 vs. 22.08 months; p <0.001) were significantly shorter in the high FGF21 group than in the non-high FGF21 group. The durable response (≥6 months) + complete response rate was significantly decreased in the high FGF21 group (p = 0.045). No patient with a high FGF21 level achieved a complete response, whereas this was achieved in 4.1% (13/319) of patients with non-high FGF21 levels. Multivariate Cox regression analysis identified high baseline serum FGF21 as an independent poor prognostic factor for overall survival (hazard ratio 2.20, p <0.001). CONCLUSIONS: Serum FGF21 may be a robust, non-invasive prognostic and treatment response marker for unresectable HCC treated with atezolizumab/bevacizumab. IMPACT AND IMPLICATIONS: FGF21 has been reported to act as a secreted immune-checkpoint factor, and elevated levels of FGF21 are associated with a poor prognosis in patients with HCC. It is not fully understood whether ICIs can overcome the impact of high FGF21 levels on the shortened prognosis of patients with HCC. In this multicentre retrospective study, patients with HCC and high baseline levels of serum FGF21 who received atezolizumab/bevacizumab treatment exhibited a significantly shorter overall survival and shorter progression-free survival. These findings suggest serum FGF21 as a robust prognostic marker and an indicator of treatment response in unresectable HCC treated with ICI-based therapy. These findings could be crucial for the implementation of personalised treatment strategies for unresectable HCC. However, identifying optimal therapeutic options for patients with unresectable HCC and high serum FGF21 levels remains an urgent and critical clinical issue.
• Extracellular matrix modulating effects of amnion‐derived mesenchymal stem cells on aging skin wounds in α‐Klotho knockout mice
  Yuki Sasaki; Shunsuke Ohnishi; Hiroko Takahashi; Kosuke Ishikawa; Takahiro Miura; Emi Funayama; Naoto Okubo; Yuhei Yamamoto; Taku Maeda
  Geriatrics & Gerontology International, 25, 5, 701, 708, May 2025, [Domestic magazines]
  English, Scientific journal, AIM: Wounds in the elderly are frequently recalcitrant and chronic as a result of the effects of skin aging and associated complications. The objective of this study is to utilize an α-Klotho knockout (KO) mice wound model to assess the capacity of amnion-derived mesenchymal stem cells (AMSCs) to facilitate wound healing in aging skin. METHODS: AMSCs were applied topically to the wound after extraction and gelatinization of the conditioned medium (CM). Animal experiments were performed with two distinct mouse strains: α-Klotho KO mice and wild-type mice. Full-thickness skin defect models with a diameter of 8 mm were created by incising the skin on the left and right sides of the dorsum. On day 8 after wound creation, the mice were sacrificed, and wound tissue was collected for analysis through histological and immunohistochemical evaluations, as well as through quantitative polymerase chain reaction. RESULTS: The topical application of CM gel to wounds of α-Klotho KO mice demonstrated that wound healing was significantly higher than that observed in control, reaching the wound closure rate of wild-type mice on day 8. Additionally, gene expression analysis of wound tissue indicated that AMSC-CM may regulate extracellular matrix formation and fibrosis. Moreover, histological analysis indicated that AMSC-CM may facilitate wound contraction of aging skin wounds of α-Klotho KO mice by inducing myofibroblast differentiation and promoting granulation and collagen formation, which are the primary components of the extracellular matrix. CONCLUSIONS: AMSC-CM may facilitate wound healing in aging skin of α-Klotho KO mice by regulating the extracellular matrix. Geriatr Gerontol Int 2025; 25: 701-708.
• 消化器疾患再生医療の近未来 羊膜間葉系幹細胞由来細胞外小胞はESD後の食道狭窄を予防する
  曽根 孝之; 大野 正芳; 江上 太基; 早坂 秀平; 小野 尚子; 坂本 直哉; 大西 俊介
  日本消化器病学会雑誌, 122, 臨増総会, A48, A48, (一財)日本消化器病学会, Mar. 2025
  Japanese
• Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.
  Zijian Yang; Goki Suda; Takuya Sho; Osamu Maehara; Masatsugu Ohara; Tomoka Yoda; Qingjie Fu; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Yoshiya Yamamoto; Masaru Baba; Ren Yamada; Tomoe Kobayashi; Minhu Chen; Naoya Sakamoto
  Hepatology research : the official journal of the Japan Society of Hepatology, 55, 3, 433, 443, Mar. 2025, [International Magazine]
  English, Scientific journal, AIM: Atezolizumab/bevacizumab is a first-line therapy for unresectable hepatocellular carcinoma (HCC). Among several adverse events, grade ≥2 proteinuria is considered a significant adverse event that may cause bevacizumab interruption. Studies have shown that proteinuria might predict improved prognosis, although data are scarce and the association remains controversial, and the mechanisms and predictive factors remain unclear. We aimed to clarify these. METHODS: In this multicenter retrospective study, we screened patients with HCC treated with atezolizumab/bevacizumab. The prognostic impact of grade ≥2 proteinuria was examined in patients with proper clinical data and preserved serum for growth factor analysis. For biomarker analysis predicting proteinuria, baseline serum vascular endothelial growth factor (VEGF)-A, VEGF-C, and VEGF-D levels were analyzed. RESULTS: This study included 75 patients, and 32 (42.7%) experienced grade ≥2 proteinuria. No significant differences were observed between those with or without proteinuria, except for aspartate transaminase and alanine transaminase levels. Time-dependent Cox proportional hazards analysis revealed that grade ≥2 proteinuria was significantly associated with better prognosis (hazard ratio 0.221; 95% confidence interval 0.082-0.592; p = 0.003). In biomarker analysis, low baseline serum VEGF-C and VEGF-D levels were significantly associated with proteinuria, and multivariate analysis demonstrated that baseline serum VEGF-D level was significantly associated with grade ≥2 proteinuria (hazard ratio 0.101; 95% confidence interval 0.029-0.357; p < 0.001). CONCLUSIONS: Grade ≥2 proteinuria in patients with unresectable HCC treated with atezolizumab/bevacizumab indicates a better prognosis, and baseline serum VEGF-D levels can help predict its occurrence. These findings can help in managing adverse events and prognosis in advanced HCC treated with atezolizumab/bevacizumab.
• A novel mouse model for studies of burn wound conversion using a top hat–shaped brass template
  Norifumi Matsuda; Chigusa Sato; Kosuke Ishikawa; Takahiro Miura; Emi Funayama; Yuhei Yamamoto; Kanako Fuyama; Shunsuke Ohnishi; Taku Maeda
  Burns, 51, 2, 107348, 107348, Mar. 2025, [International Magazine]
  English, Scientific journal, INTRODUCTION: The pathophysiology of burn wound conversion is not fully understood. Animal models are needed to elucidate the underlying mechanisms and develop treatments. Here, we established a new reproducible mouse model that simulates this process, thereby facilitating studies of burn wound conversion. MATERIALS AND METHODS: After anesthesia and depilation, 75 mice were randomly assigned to 5-, 15-, and 25-s contact groups, and a top hat-shaped brass template was heated in boiling water and applied to the lateral abdomen. The wound area was calculated from photographs and the percentage of the surviving area was determined. Histological samples were collected 1-96 h after injury. RESULTS: A 15-s contact time produced the desired 50 %-75 % interspace necrosis at 96 h after injury. The 5-s contact group had a mostly preserved interspace, while the 25-s contact group exhibited near-complete necrosis. Histologically, significant differences between the 5- and 15-s contact groups were seen in cutaneous appendage denaturation and panniculus carnosus denaturation early after injury. CONCLUSION: Exposing mice to the heated template for 15 s provides a reproducible model for studying burn wound conversion mechanisms and treatments, facilitating further elucidation of burn pathophysiology and evaluation of therapies to prevent burn wound conversion.
• Efficacy of Rikkunshito on Chemotherapy-Induced Nausea and Vomiting in Patients With Uterine Corpus or Cervical Cancer Treated With Cisplatin-Based Regimen-Placebo-controlled, Double-Blind, Randomized Confirmatory Study (JORTC-KMP03).
  Yosuke Konno; Shunsuke Ohnishi; Shinichiro Minobe; Eiji Nomura; Takayuki Nagasawa; Etsuko Fujimoto; Tatsuru Ohara; Shin Nishio; Hisamori Kato; Yoshihito Yokoyama; Etsuko Miyagi; Hideki Tokunaga; Koji Nishino; Akira Kikuchi; Yoshio Yoshida; Takashi Iwata; Daito Noguchi; Wataru Kudaka; Shunsuke Oyamada; Keisuke Ariyoshi; Kota Kihara; Hidemichi Watari
  Integrative cancer therapies, 24, 15347354251329346, 15347354251329346, 2025, [International Magazine]
  English, Scientific journal, BACKGROUND: The current standard treatment for chemotherapy-induced nausea and vomiting (CINV) with standard antiemetics is insufficient. Rikkunshito, a Japanese traditional herbal medicine, has been shown to improve cisplatin-induced anorexia and functional dyspepsia, and our exploratory study found that rikkunshito has an additive beneficial effect on CINV in patients with uterine corpus and cervical cancer receiving cisplatin containing chemotherapy (JORTC KMP-02). METHODS: One hundred eighty patients with uterine corpus or cervical cancer who were scheduled to receive treatment with a cisplatin based regimen as initial chemotherapy were enrolled across 17 Japanese institutions. Patients were randomized with a 1:1 equal allocation ratio to the rikkunshito group or placebo groups and given oral administration on days 1 to 5 with standard antiemetics (granisetron, aprepitant, and dexamethasone). The primary endpoint was complete response (CR; no vomiting or rescue medication) during the delayed phase (24-120 hours after cisplatin treatment). The secondary endpoints were complete control (CC; CR without significant nausea) and total control (TC; CR without nausea) rates during the overall (0-120 hours), acute (0-24 hours), and delayed phases, as well as the CR rate during the overall and acute phases, time to treatment failure, degree of nausea and appetite during the overall phase, and adherence to the intervention. RESULTS: The CR rate in the delayed phase was similar between the rikkunshito group and control groups (50.6% vs 58.9%, P = .2631), as were the secondary endpoints: CR rates in the overall and acute phases, CC and TC rates in the overall, acute, and delayed phases, degrees of nausea and appetite, and time to treatment failure. CONCLUSION: Rikkunshito had no additive effect on CINV prevention in patients with uterine corpus or cervical cancer who were treated with a cisplatin based regimen and standard antiemetics. CLINICAL TRIAL REGISTRATION: https://jrct.mhlw.go.jp/re/reports/detail/66957, identifier jRCT1011190007.
• Hochuekkito accelerates recovery from cisplatin induced-muscle atrophy accompanied by slow-twitch fiber-specific microRNA upregulation in mice.
  Hitomi Sekine; Chinami Matsumoto; Naoki Fujitsuka; Sachiko Mogami; Shunsuke Ohnishi; Hiroshi Takeda
  Frontiers in pharmacology, 16, 1502563, 1502563, 2025, [International Magazine]
  English, Scientific journal, INTRODUCTION: Cis-diamine-dichloro-platinum (II) (cisplatin) is a widely prescribed anticancer drug known to induce severe side effects, including skeletal muscle atrophy. As muscle atrophy negatively impacts the prognosis and survival of cancer patients, elucidation of its pathogenesis and development of preventive and treatment methods is important. Hochuekkito (HET), a Japanese Kampo medicine, has been reported to improve decreased physical activity and muscle weight in various animal models, but not in cisplatin-induced muscle atrophy. Therefore, this study aimed to clarify the characteristics of cisplatin-induced muscle atrophy and the therapeutic effects of HET, especially with emphasis in the recovery phase. METHOD: Eight-week-old male C57BL/6J mice were administered with cisplatin (3 mg/kg/day, intraperitoneally) from Day0 to Day3 and provided HET-containing food from 2 weeks before cisplatin administration until Day14. Muscle weight and performance were evaluated and the underlying mechanisms were investigated by using gene expression, immunohistochemistry, and microRNA (miRNA)-sequence analyses. RESULTS: Cisplatin administration continued to reduce gastrocnemius muscle weight until Day14, even after recovery from transient decrease in food intake and body weight and was accompanied by decreased locomotor activity and grip strength, presumably due to the continuous suppression of the mRNA expression of Myogenic differentiation 1. Although HET did not suppress the activation of muscle protein degradation or increase myogenic regulatory factor expression, it restored decreased locomotor activity and gastrocnemius muscle weight by inducing an increase in the weight of the red muscle region, which contains slow-twitch fibers. Immunohistochemical analysis showed that red muscle slow-twitch fiber cross-sectional area was increased by HET treatment. The levels of miRNAs involved in muscle atrophy and aging, such as miR-29a/b and miR-34a, were increased by cisplatin; conversely, HET increased the expression of miR-1a-1 and miR-1a-2, which reportedly enhance muscle differentiation, and miR-206, which enhances slow muscle fiber differentiation and thickening. CONCLUSION: HET increased locomotor activity and muscle weight in cisplatin-induced muscle atrophy model mice, probably by enhancing myogenesis in slow-twitch fibers, which was related to miRNA expression changes. Thus, HET may be useful in treating cisplatin-induced muscle atrophy.
• Thymidine Phosphorylase Imaging Probe for Differential Diagnosis of Metabolic dysfunction-associated Steatohepatitis.
  Kei Higashikawa; Riho Uehara; Sawako Horiguchi; Yuki Shibata; Naoto Okubo; Yuki Mizuno; Hironobu Yasui; Shunsuke Ohnishi; Hiroshi Takeda; Yuji Kuge
  Molecular imaging and biology, 26, 6, 1036, 1045, Dec. 2024, [International Magazine]
  English, Scientific journal, PURPOSE: Metabolic dysfunction-associated steatotic liver disease (MASLD) comprises simple steatosis (SS), which has a low risk of mortality, and metabolic dysfunction-associated steatohepatitis (MASH), which can progress to liver cirrhosis and hepatocellular carcinoma. Because differentiation between MASH and SS is the most important issue in the diagnosis of MASLD, the establishment of noninvasive diagnostic methods is urgently needed. In this study, we evaluated the potential of [123I]IIMU, a thymidine phosphorylase (TYMP) targeted SPECT imaging probe, for differential diagnosis of MASLD in a preclinical animal model. PROCEDURES: SS and MASH mice were prepared by feeding db/db mice with a standard diet and a methionine/choline-deficient diet, respectively. Control mice were prepared by feeding m/m mice with a standard diet. TYMP expression in the liver was evaluated by RT-PCR, western blotting, and immunohistochemistry. The biodistribution of [125I]IIMU in the three model mice was evaluated at 30 min post-injection. SPECT/CT imaging studies of the three model mice were performed 30 min after injection of [123I]IIMU. RESULTS: Hepatic TYMP expression level was the highest in the SS mice and the lowest in the MASH mice at both mRNA and protein levels. The immunohistochemistry experiment showed a patchy distribution of TYMP only in the liver of MASH mice. In the biodistribution study, the hepatic accumulation of [125I]IIMU was the highest in the SS mice and the lowest in the MASH mice. The SPECT/CT imaging study showed similar results to the biodistribution experiment. CONCLUSION: Hepatic TYMP expression level may serve as a promising imaging biomarker for differential diagnosis of SS and MASH. SPECT imaging using [123I]IIMU potentially provides a novel noninvasive diagnostic method to differentiate MASH and SS.
• Hypoxic culture enhances the antimicrobial activity of amnion-derived mesenchymal stem cells, thereby reducing bacterial load and promoting wound healing in diabetic mice
  Riku Ishii; Shunsuke Ohnishi; Masahiro Hojo; Kosuke Ishikawa; Emi Funayama; Takahiro Miura; Naoto Okubo; Kazufumi Okada; Yuhei Yamamoto; Taku Maeda
  Biochemical and Biophysical Research Communications, 739, 150903, 150903, Elsevier BV, Oct. 2024, [International Magazine]
  English, Scientific journal, BACKGROUND: Conditioned medium from amnion-derived mesenchymal stem cells (AMSCs) enhances wound healing, a process that is further improved under hypoxic culture conditions. Diabetic foot ulcers are difficult to treat and are frequently complicated by a high rate of bacterial infections, mainly Staphylococcus aureus, which can lead to limb amputation and death. Here, we topically applied conditioned medium from AMSCs cultured under hypoxic conditions to S. aureus-infected wounds in diabetic mice to investigate its effect on bacterial counts and wound healing. METHODS: We prepared conditioned medium by culturing AMSCs under 21 % or 1 % O2 and investigated its effects on S. aureus. We infected skin wounds of diabetic mice with S. aureus and treated these with hydrogels containing the conditioned medium to examine its effect on bacterial inhibition and wound healing. RESULTS: Conditioned medium from AMSCs cultured under 1 % O2 contained higher levels of the antimicrobial peptide LL-37. It significantly inhibited S. aureus growth in vitro, reduced bacterial counts in infected wounds, and facilitated wound closure in diabetic mice. CONCLUSIONS: Hydrogels containing conditioned medium from hypoxically cultured AMSCs inhibited the growth of S. aureus and promoted wound healing in a mouse model of diabetic wounds.
• Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.
  Naohiro Yasuura; Goki Suda; Masatsugu Ohara; Akimitsu Meno; Takuya Sho; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Tomoya Saitou; Masaya Sugiyama; Takasuke Fukuhara; Masaru Baba; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Akinobu Taketomi; Naoya Sakamoto
  Alimentary pharmacology & therapeutics, 60, 10, 1315, 1324, 04 Sep. 2024, [International Magazine]
  English, Scientific journal, BACKGROUND AND AIMS: The prognostic impact of previous-HBV-infection (pHBV) in non-HBV-related hepatocellular carcinoma (non-HBV-related-HCC) and the prevalence, characteristics and significance of recently developed high-sensitivity HBs antigen positivity (hHBsAg+) in these patients remain unclear. We aimed to close these gaps. METHODS: We retrospectively screened patients with newly diagnosed non-HBV-related-HCC (standard HBsAg-test negative) at Hokkaido University. Patients with complete clinical information and preserved serum for hHBsAg+ were included. We evaluated the prevalence, characteristics and prognostic impact of pHBV and hHBsAg+ in non-HBV-related-HCC. RESULTS: A total of 401 non-HBV-related-HCC patients were included (288 with pHBV/113 without pHBV). In non-HBV-related-HCC, pHBV did not affect overall survival (OS). Among non-HBV-related-HCC patients with pHBV, 11.8% (34/288) were hHBsAg+ and had more advanced stages of HCC, higher AFP levels, higher vascular invasion rates, and significantly shorter OS than others (OS: 19.3 vs. 61.4 months, p = 0.012). Comparison of OS among non-HBV-related-HCC patients without pHBV (group 1), those with pHBV and without hHBsAg+ (group 2), and those with pHBV and hHBsAg+ (group 3) revealed significantly shorter OS in group 3 (19.3, 56.6 and 66.4 months in groups 1, 2 and 3, respectively; p = 0.036). Multivariate Cox regression indicated that compared with group 1, only group 3 was significantly and independently associated with shorter OS (HR: 2.044, p = 0.011). Subgroup analysis revealed that this association was particularly evident in non-HBV-related-HCC patients with non-B-non-C aetiology and advanced HCC. CONCLUSIONS: In non-HBV-related-HCC patients, hHBsAg+, not pHBV, is significantly and independently associated with poor prognosis.
• Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
  Takuya Sho; Goki Suda; Masatsugu Ohara; Risako Kohya; Takashi Sasaki; Sonoe Yoshida; Shunichi Hosoda; Koji Ogawa; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Masaru Baba; Yoshiya Yamamoto; Yoko Tsukuda; Takashi Meguro; Ren Yamada; Tomoe Kobayashi; Tomofumi Takagi; Naoya Sakamoto
  Targeted oncology, 19, 5, 769, 778, Sep. 2024, [International Magazine]
  English, Scientific journal, BACKGROUND: While guidelines recommend immune checkpoint inhibitor (ICI) rechallenge as second-line therapy for unresectable hepatocellular carcinoma (HCC), data supporting this remain limited, particularly regarding a standard regimen for first- and second-line treatments. Tremelimumab/durvalumab was recently approved but data on ICI rechallenge are lacking. OBJECTIVES: The purpose of this study was to evaluate the early efficacy and safety of tremelimumab/durvalumab for HCC as an ICI rechallenge following initial ICI therapy with atezolizumab/bevacizumab. PATIENTS AND METHODS: This multicenter retrospective study included patients with HCC who underwent treatment with tremelimumab/durvalumab, with relevant available clinical information. We evaluated the safety and efficacy of tremelimumab/durvalumab as ICI rechallenge following initial treatment with atezolizumab/bevacizumab. We analyzed the outcomes in patients who underwent tremelimumab/durvalumab as an ICI rechallenge and those who received tremelimumab/durvalumab as their initial ICI therapy RESULT: A total of 45 patients treated with tremelimumab/durvalumab were included, with 55.6% (25/45) undergoing ICI rechallenge. The objective-response and disease-control rates in patients who underwent ICI rechallenge were 14.3% (3/21) and 47.6% (10/21), respectively, similar to those in patients initially treated with tremelimumab/durvalumab. All patients (n = 3) who experienced the best response to progressive disease (PD) with initial atezolizumab/bevacizumab experienced PD during ICI rechallenge. The incidence rates of adverse events were similar between patient groups treated with tremelimumab/durvalumab as ICI rechallenge and initial ICI. Among patients experiencing immune-related adverse events (irAEs) with atezolizumab/bevacizumab, 75% (3/4) encountered similar irAEs during ICI rechallenge. CONCLUSION: Early safety and efficacy profiles of durvalumab/tremelimumab as ICI rechallenge are satisfactory.
• Intracerebral transplantation of MRI-trackable autologous bone marrow stromal cells for patients with subacute ischemic stroke.
  Masahito Kawabori; Satoshi Kuroda; Hideo Shichinohe; Kaoru Kahata; Souichi Shiratori; Satoshi Ikeda; Taisuke Harada; Kenji Hirata; Khin Khin Tha; Masato Aragaki; Shunsuke Terasaka; Yoichi M Ito; Naoki Nishimoto; Shunsuke Ohnishi; Ichiro Yabe; Kohsuke Kudo; Kiyohiro Houkin; Miki Fujimura
  Med (New York, N.Y.), 5, 5, 432, 444, 10 May 2024, [International Magazine]
  English, Scientific journal, BACKGROUND: Ischemic stroke is one of the leading causes of death and neurological disability worldwide, and stem cell therapy is highly expected to reverse the sequelae. This phase 1/2, first-in-human study evaluated the safety, feasibility, and monitoring of an intracerebral-transplanted magnetic resonance imaging (MRI)-trackable autologous bone marrow stromal cell (HUNS001-01) for patients with subacute ischemic stroke. METHODS: The study included adults with severe disability due to ischemic stroke. HUNS001-01 cultured with human platelet lysates and labeled with superparamagnetic iron oxide was stereotactically transplanted into the peri-infarct area 47-64 days after ischemic stroke onset (dose: 2 or 5 × 107 cells). Neurological and radiographic evaluations were performed throughout 1 year after cell transplantation. The trial was registered at UMIN Clinical Trial Registry (number UMIN000026130). FINDINGS: All seven patients who met the inclusion criteria successfully achieved cell expansion, underwent intracerebral transplantation, and completed 1 year of follow-up. No product-related adverse events were observed. The median National Institutes of Health Stroke Scale and modified Rankin scale scores before transplantation were 13 and 4, which showed improvements of 1-8 and 0-2, respectively. Cell tracking proved that the engrafted cells migrated toward the infarction border area 1-6 months after transplantation, and the quantitative susceptibility mapping revealed that cell signals at the migrated area constantly increased throughout the follow-up period up to 34% of that of the initial transplanted site. CONCLUSIONS: Intracerebral transplantation of HUNS001-01 was safe and well tolerated. Cell tracking shed light on the therapeutic mechanisms of intracerebral transplantation. FUNDING: This work was supported by the Japan Agency for Medical Research and Development (AMED; JP17bk0104045 and JP20bk0104011).
• ブタ大腸内視鏡治療モデルを用いたESD後創部評価 新規生体吸収性素材とハイドロゲルを用いた内視鏡的絆創膏の効果
  江上 太基; 大野 正芳; 石田 啓輔; 黒川 孝幸; 早坂 秀平; 中島 早慧; 曽根 孝之; 東野 真幸; 井上 雅貴; 宮本 秀一; 山本 桂子; 小野 尚子; 大西 俊介; 坂本 直哉
  Gastroenterological Endoscopy, 66, Suppl.1, 972, 972, (一社)日本消化器内視鏡学会, Apr. 2024
  Japanese
• 消化管癌に対する新しい内視鏡治療戦略 新規生体吸収性素材とハイドロゲルを用いた内視鏡的絆創膏の開発
  大野 正芳; 石田 啓補; 黒川 孝幸; 井上 雅貴; 宮本 秀一; 山本 桂子; 小野 尚子; 大西 俊介; 坂本 直哉
  日本消化器病学会雑誌, 121, 臨増総会, A126, A126, (一財)日本消化器病学会, Mar. 2024
  Japanese
• Application of polyglycolic acid sheets and basic fibroblast growth factor to prevent esophageal stricture after endoscopic submucosal dissection in pigs.
  Yusuke Nishimura; Masayoshi Ono; Naoto Okubo; Takayuki Sone; Masayuki Higashino; Shogo Matsumoto; Marina Kubo; Keiko Yamamoto; Shoko Ono; Shunsuke Ohnishi; Naoya Sakamoto
  Journal of gastroenterology, 58, 11, 1094, 1104, Nov. 2023, [Domestic magazines]
  English, Scientific journal, BACKGROUND: Endoscopic submucosal dissection (ESD) has been the first-line treatment for early-stage esophageal cancer. However, it often causes postoperative stricture in cases requiring wide dissection. Basic fibroblast growth factor (bFGF) reportedly has anti-scarring effects during cutaneous wound healing. We hypothesized that suppressing myofibroblast activation will prevent stricture after esophageal ESD. METHODS: We resected a complete porcine esophagus circumference section by ESD. To investigate the preventive effect of bFGF on esophageal stricture formation after ESD, we endoscopically applied bFGF-soaked poly-glycolic acid (PGA) sheets onto the wound bed after ESD and fixed them by spraying fibrin glue (PGA + bFGF group), PGA sheets alone onto the wound bed and fixed them by spraying fibrin glue (PGA group), or nothing (control group). After removing the esophagus on day 22, we evaluated the mucosal constriction rate. RESULTS: Compared with those in the control group, esophageal stricture was significantly reduced in the PGA + bFGF group, and the areas stained with α-SMA and calponin-1 antibodies were significantly inhibited in the PGA + bFGF and PGA groups. The thickness of the fibrous layer in the PGA + bFGF group was uniform compared to that of the other groups. Thus, PGA + bFGF inhibited the development of unregulated fibroblasts in the acute phase, leading to uniform wound healing. CONCLUSIONS: Stenosis after esophageal ESD is related to fibrosis in the acute phase. Administration of PGA and bFGF suppresses myofibroblast activation in the acute phase, thereby preventing esophageal constriction in pigs.
• 子宮がん患者のCINVに対する六君子湯の効果 プラセボ対照無作為化二重盲検比較試験
  大西 俊介; 見延 進一郎; 野村 英司; 金野 陽輔; 永沢 崇幸; 藤本 悦子; 大原 樹; 西尾 真; 加藤 久盛; 小山田 隼佑; 有吉 恵介; 木原 康太; 渡利 英道
  日本癌治療学会学術集会抄録集, 61回, O66, 3, (一社)日本癌治療学会, Oct. 2023
  English
• Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.
  Risako Kohya; Goki Suda; Masatsugu Ohara; Takashi Sasaki; Tomoka Yoda; Naofumi Sakurai; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
  Cancers, 15, 12, 20 Jun. 2023, [International Magazine]
  English, Scientific journal, Lenvatinib, used for unresectable hepatocellular carcinoma (HCC), causes appetite loss, but the underlying mechanisms, clinical impact, and predictive factors have been unclear. The endocrine factor FGF21 modulates appetite and is involved in cachexia. We evaluated the association between FGF21 level changes during lenvatinib treatment for unresectable HCC and appetite loss. Sixty-three eligible unresectable HCC patients who started lenvatinib treatment between 2018 and 2021 were included. We analyzed FGF21 levels at baseline; 1, 2, and 4 weeks after lenvatinib initiation, and before the onset of appetite loss. Grade ≥ 2 lenvatinib-induced appetite loss led to liver functional reserve deterioration at disease progression and a poor prognosis. Baseline characteristics and serum FGF21 levels were similar between patients with and without appetite loss. However, the serum FGF21 change rate increased significantly at 4 weeks post-lenvatinib initiation in patients with grade ≥ 2 appetite loss, as compared to those without appetite loss. Similar significant increases in the serum FGF21 level change rate were observed prior to grade ≥ 2 appetite loss onset. This suggests that changes in FGF21 levels can be used to predict patients with a greater risk of marked appetite loss and provides insights into the mechanisms underlying lenvatinib-induced appetite loss in patients with HCC.
• Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
  Takashi Sasaki; Goki Suda; Masatsugu Ohara; Shunichi Hosoda; Naoki Kawagishi; Risako Kohya; Tomoka Yoda; Osamu Maehara; Shunsuke Ohnishi; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Sho Komukai; Koji Ogawa; Naoya Sakamoto
  Hepatology research : the official journal of the Japan Society of Hepatology, 53, 10, 960, 967, 18 Jun. 2023, [International Magazine]
  English, Scientific journal, AIM: Although hepatitis delta virus (HDV) coinfection with hepatitis B virus (HBV) is a global health concern, the global prevalence of HDV infections remains unknown due to insufficient data in many countries. In Japan, HDV prevalence has not been updated for over 20 years. We aimed to investigate the recent prevalence of HDV infections in Japan. METHODS: We screened 1264 consecutive patients with HBV infection at Hokkaido University Hospital between 2006 and 2022. Patients' serums were preserved and subsequently tested for HDV antibody (immunoglobulin-G). Available clinical information was collected and analyzed. We compared the changes in liver fibrosis using the Fibrosis-4 (FIB-4) index between propensity-matched patients with and without the evidence of anti-HDV antibodies and corrected for baseline FIB-4 index, nucleoside/nucleotide analog treatment, alcohol intake, sex, HIV coinfection, liver cirrhosis, and age. RESULTS: After excluding patients without properly stored serums and those lacking appropriate clinical information, 601 patients with HBV were included. Of these, 1.7% of patients had detectable anti-HDV antibodies. Patients with anti-HDV antibody serum positivity had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV coinfection than those who demonstrated serum anti-HDV antibody negativity. A propensity-matched longitudinal analysis revealed that liver fibrosis (FIB-4 index) progressed more rapidly in patients with positive results for anti-HDV antibody tests. CONCLUSIONS: The recent prevalence of HDV infections in Japanese patients with HBV was 1.7% (10/601). These patients experienced rapid liver fibrosis progression, highlighting the importance of routine HDV testing.
• Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
  Shunichi Hosoda; Goki Suda; Takuya Sho; Koji Ogawa; Megumi Kimura; Zijian Yang; Sonoe Yoshida; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Takuto Miyagishima; Naoya Sakamoto
  Liver cancer, 12, 2, 156, 170, Jun. 2023, [International Magazine]
  English, Scientific journal, INTRODUCTION: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. METHODS: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, 6 weeks after treatment initiation (early PD; n = 13). Of these, 4 patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. RESULTS: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (<333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs. 227 days; HR: 2.41, 95% CI: 1.22-4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. CONCLUSION: Baseline low serum CXCL9 (<333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
• ポリグリコール酸シートと塩基性線維芽細胞増殖因子を用いたESD後の食道狭窄に対する新規予防法の開発
  西村 友佑; 大野 正芳; 坂本 直哉; 大久保 直登; 曽根 孝之; 東野 真幸; 松本 将吾; 久保 茉理奈; 山本 桂子; 小野 尚子; 大西 俊介
  Gastroenterological Endoscopy, 65, Suppl.1, 996, 996, (一社)日本消化器内視鏡学会, Apr. 2023
  Japanese
• Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.
  Yoshimasa Tokuchi; Goki Suda; Naoki Kawagishi; Masatsugu Ohara; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Osamu Maehara; Shunsuke Ohnishi; Akinori Kubo; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Takashi Kitagataya; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
  Hepatology research : the official journal of the Japan Society of Hepatology, 53, 7, 595, 606, 21 Mar. 2023, [International Magazine]
  English, Scientific journal, AIM: Hepatitis C virus (HCV) infection has been reported to cause liver steatosis. Thus, eradicating HCV with direct-acting antivirals (DAAs) is expected to reduce liver steatosis. We aimed to clarify long-term changes in the prevalence of fatty liver and hyper-low-density lipoprotein (LDL) cholesterolemia and their associations in patients who achieve successful HCV eradication using DAAs. METHODS: This retrospective study included patients with HCV who achieved sustained virologic response after interferon-free DAA and analyzed the changes in the prevalence of fatty liver diagnosed with controlled attenuation parameter (CAP), hyper-LDL cholesterolemia, and their relationships at baseline (n = 100) and 24 weeks (SVR24, n = 100), 96 weeks (SVR96, n = 100), and 144 weeks (SVR144, n = 90) after DAA. RESULTS: In 100 participants, the prevalence of fatty liver (19% vs. 32%, p = 0.0349) and hyper-LDL cholesterolemia (6% vs. 15%, p = 0.0379) significantly increased without changes in body weight at SVR96. Median total cholesterol, low-density lipoprotein cholesterol (LDL-C), and small-dense-LDL (sdLDL) levels and CAP values were significantly greater at SVR24, SVR96, and SVR144 than at baseline. Baseline CAP values and changes in CAP values were significantly negatively correlated at every observation point: r = -0.5305, p < 0.0001 at SVR24; r = -0.3617, p = 0.0005 at SVR96; and r = -0.4735, p < 0.0001 at SVR144. A similar relationship was observed in cholesterol levels. Unlike at baseline, CAP values were significantly positively correlated with LDL-C and sdLDL-C levels at all observation points after DAAs. CONCLUSIONS: Direct-acting antivirals may cause an increased prevalence of fatty liver accompanying hyper-LDL cholesterolemia without increased body weight. As post-SVR liver steatosis could cause HCC, careful follow-up may be required.
• Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.
  Zijian Yang; Goki Suda; Osamu Maehara; Masatsugu Ohara; Tomoka Yoda; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
  Cancers, 15, 3, 18 Jan. 2023, [International Magazine]
  English, Scientific journal, The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC, and the subsequent response to these therapies, remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Patients who experienced PD after CR, PR, or SD to atezolizumab/bevacizumab were evaluated. A total of 4, 9, 19, and 14 patients showed CR, PR, SD, and PD, respectively. Of 32 patients with disease control, 28 experienced PD after CR, PR, or SD with atezolizumab/bevacizumab. Baseline growth factor levels were similar between patients with or without disease control and those with or without an objective response. Growth factor changes between the baseline and the best overall response points (BOR) for patients with disease control showed that FGF-19 significantly increased and ANG2 significantly decreased at the BOR. Growth factor changes between the BOR and the PD point in 28 patients who experienced PD after disease control showed that VEGF-D and ANG2 significantly increased at the PD point compared with that at the BOR. Summarily, increased serum VEGF-D and ANG-2 levels might contribute to developing resistance to atezolizumab/bevacizumab for unresectable HCC and might be target molecules in subsequent salvage therapies.
• Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
  Naoki Kawagishi; Goki Suda; Yoshiya Yamamoto; Masaru Baba; Ken Furuya; Osamu Maehara; Shunsuke Ohnishi; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Yoshimasa Tokuchi; Takashi Kitagataya; Masatsugu Ohara; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
  Viruses, 15, 1, 07 Jan. 2023, [International Magazine]
  English, Scientific journal, Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014-2020 were screened and evaluated for HCC occurrence or recurrence every three-six months. Multivariate Cox regression analysis revealed that age ≥ 75 years (HR: 2.92, 95% CI: 1.34-6.33; p = 0.007) and baseline Ang2 level ≥ 464 pg/mL (HR: 2.75, 95% CI: 1.18-6.37; p = 0.019) were significantly associated with HCC occurrence after DAA therapy. A high or low risk of HCC after DAA therapy could be distinguished by the combination of age and baseline Ang2 level. The cumulative incidences of de-novo HCC at two and four years were 0.8% and 3.8% in the low-risk group and 22.6% and 27.1% in the high-risk group, respectively. Baseline Ang2 level ≥ 402 pg/mL was significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs (HR: 3.68). In conclusion, serum Ang2 levels can predict HCC occurrence and recurrence after successful HCV eradication by DAAs.
• Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
  Goki Suda; Masaru Baba; Yoshiya Yamamoto; Takuya Sho; Koji Ogawa; Megumi Kimura; Shunichi Hosoda; Sonoe Yoshida; Akinori Kubo; Qingjie Fu; Zijian Yang; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Tomoe Kobayashi; Izumi Tsunematsu; Naoya Sakamoto
  Journal of medical virology, 95, 2, e28452, 04 Jan. 2023, [International Magazine]
  English, Scientific journal, BACKGROUND: No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing HBV reactivation has yet been reported. METHODS: This multicenter prospective study enrolled HBV-carriers who received TAF to prevent HBV reactivation before antitumor or immunosuppressive therapy, and patients with resolved HBV infection who experienced HBV-reactivation and received TAF to prevent HBV reactivation-related hepatitis. The efficacy of prophylactic TAF in preventing HBV reactivation and HBV reactivation-related hepatitis was evaluated at 6 and 12 months after initiating TAF. RESULTS: Overall, 110 patients were administered TAF to prevent HBV reactivation or HBV reactivation-related hepatitis. Three patients died owing to primary disease, whereas one patient was transferred to another hospital within 6 months after initiating TAF. Seven patients died due to primary disease, and five patients were transferred to another hospital within 12 months after initiating TAF. Therefore, 106 and 94 (77 patients with HBV infection, 17 with previous-HBV infection) patients were evaluated at 6 and 12 months after initiating TAF, respectively. No patient experienced HBV reactivation, HBV reactivation-related hepatitis, or treatment discontinuation due to HBV reactivation or adverse events of TAF after 6 and 12 months. CONCLUSION: TAF could effectively prevent HBV reactivation and HBV reactivation-related hepatitis. This article is protected by copyright. All rights reserved.
• Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.
  Masatsugu Ohara; Goki Suda; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
  Frontiers in nutrition, 10, 1272728, 1272728, 2023, [International Magazine]
  English, Scientific journal, INTRODUCTION: We aimed to assess the prognostic implications of muscle atrophy and high subcutaneous adipose tissue (SAT) radiodensity in patients with hepatocellular carcinoma (HCC). METHODS: In this retrospective study, muscle atrophy was assessed using the psoas muscle index (PMI) obtained from computed tomography. SAT radiodensity was evaluated based on radiodensity measurements. Survival and multivariate analyses were performed to identify factors associated with prognosis. The impact of muscle atrophy and high SAT radiodensity on prognosis was determined through survival analysis. RESULTS: A total of 201 patients (median age: 71 years; 76.6% male) with HCC were included. Liver cirrhosis was observed in 72.6% of patients, and the predominant Child-Pugh grade was A (77.1%). A total of 33.3% of patients exhibited muscle atrophy based on PMI values, whereas 12.9% had high SAT radiodensity. Kaplan-Meier survival analysis demonstrated that patients with muscle atrophy had significantly poorer prognosis than those without muscle atrophy. Patients with high SAT radiodensity had a significantly worse prognosis than those without it. Muscle atrophy, high SAT radiodensity, the Barcelona Clinic Liver Cancer class B, C, or D, and Child-Pugh score ≥ 6 were significantly associated with overall survival. Further classification of patients into four groups based on the presence or absence of muscle atrophy and high SAT radiodensity revealed that patients with both muscle atrophy and high SAT radiodensity had the poorest prognosis. CONCLUSION: Muscle atrophy and high SAT radiodensity are significantly associated with poor prognosis in patients with HCC. Identifying this high-risk subgroup may facilitate the implementation of targeted interventions, including nutritional therapy and exercise, to potentially improve clinical outcomes.
• Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy
  Naoki Kawagishi; Goki Suda; Ryotaro Sakamori; Takeshi Matsui; Masahiro Onozawa; Zijian Yang; Sonoe Yoshida; Masatsugu Ohara; Megumi Kimura; Akinori Kubo; Osamu Maehara; Qingjie Fu; Shunichi Hosoda; Yoshimasa Tokuchi; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Kenichi Morikawa; Mitsuteru Natsuizaka; Koji Ogawa; Hajime Sakai; Shunsuke Ohnishi; Masaru Baba; Tetsuo Takehara; Naoya Sakamoto
  Scientific Reports, 12, 1, Springer Science and Business Media LLC, 07 Oct. 2022
  Scientific journal, Abstract
  
  De novo hepatitis B virus (HBV) reactivation occurs during direct-acting antiviral (DAA) treatment in hepatitis C virus (HCV)-infected patients with resolved HBV infection. We evaluated the predictive factors, mechanical insight, and differences of cytokine levels during anti-cancer/immunosuppressive and DAA. Eleven, 35, and 19 HCV-infected patients with previous HBV infection with HBV reactivation during DAA treatment, previous HBV infection without HBV reactivation during DAA treatment, and without HBV infection resolution receiving DAA treatment, respectively, were enrolled. Clinical data and baseline cytokine levels were analyzed. Low baseline serum interleukin (IL)-1β levels predicted de novo HBV reactivation during DAA treatment (odds ratio: 47.6, 95% confidence interval: 6.94–333.3). HCV-infected patients with the IL-1β gene single nucleotide polymorphism rs16944 AA allele had significantly higher IL-1β levels; no HCV-infected patient with the IL-1β AA allele experienced HBV reactivation during DAA treatment. Compared to HCV-infected patients with HBV infection resolution, non-HCV infected patients with or without HBV reactivation during anti-cancer/immunosuppressive therapy or bone marrow transplantation had remarkably lower baseline IL-1β levels. Low IL-1β levels were not associated with HBV reactivation. IL-1β levels before DAA for HCV-infected patients with resolved HBV infection could predict HBV reactivation during DAA treatment.
• Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
  Takuya Sho; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Koji Ogawa; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Zijian Yang; Megumi Kimura; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Tomofumi Takagi; Jun Ito; Tomoe Kobayashi; Takuto Miyagishima; Naoya Sakamoto
  Cancers, 14, 16, 3938, 3938, MDPI AG, 15 Aug. 2022
  Scientific journal, The IMbrave150 trial demonstrated the high efficacy and safety of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma (HCC). In this multicenter study, the efficacy of this combination and its effect on liver functional reserve were evaluated in patients not meeting the eligibility criteria of IMbrave150. Of 115 patients with unresectable HCC treated with atezolizumab and bevacizumab between October 2020 and January 2022, 72 did not meet the eligibility criteria of IMbrave150, most frequently due to a history of systemic therapy (60/72), platelet counts < 75 × 109/L (7/72), Child-Pugh B (9/72), and 2+ proteinuria (8/72). Atezolizumab and bevacizumab therapy was equally effective for patients who did or did not meet the eligibility criteria (PFS, 6.5 vs. 6.9 months, p = 0.765), consistent with subgroup analyses of histories of systemic therapy, platelet counts, Child-Pugh, and proteinuria. Baseline ALBI scores were worse in patients who did not meet the criteria than in those who did and significantly worsened after treatment initiation in patients not meeting the criteria (baseline vs. 12 weeks; 2.35 ± 0.43 vs. −2.18 ± 0.54; p = 0.007). Accordingly, atezolizumab plus bevacizumab was effective for patients not meeting the eligibility criteria of IMbrave150, although careful monitoring for changes in liver functional reserve is needed.
• Small-molecule inhibitor cocktail promotes the proliferation of pre-existing liver progenitor cells.
  Qingjie Fu; Shunsuke Ohnishi; Goki Suda; Naoya Sakamoto
  Stem cell reports, 17, 7, 1589, 1603, 13 Jun. 2022, [International Magazine]
  English, Scientific journal, A recent study showed that a cocktail of three small molecules, Y-27632, A83-01, and CHIR99021 (YAC), converts mature hepatocytes (MHs) into proliferative bipotent cells that can be induced into MHs and cholangiocytes in rats. However, when we reproduced these experiments, it was found that bipotent cells may be derived from resident liver progenitor cells (LPCs), whose proliferative activity was promoted by YAC. A simple and efficient sorting scheme was also developed in this study to harvest high-purity and high-yield LPCs. The inducible bipotency of purified LPCs was verified; in addition, they were found to spontaneously differentiate into hepatocytes and cholangiocytes due to changes in proliferative status even without induction. Moreover, during the differentiation process, some hepatocytes spontaneously reconverted to LPCs under certain conditions, such as the release of contact inhibition. These findings may improve our understanding of LPCs and provide a cell source for regenerative medicine.
• The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
  Akihisa Nakamura; Koji Yamamoto; Rei Takeda; Ren Yamada; Akinori Kubo; Kenichi Morikawa; Sayaka Ando; Tomoe Shimazaki; Takaaki Izumi; Machiko Umemura; Takashi Kitagataya; Taku Shigesawa; Kazuharu Suzuki; Megumi Kimura; Masato Nakai; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Toshiro Sugiyama; Hiroshi Takeda; Naoya Sakamoto
  Hepatology research : the official journal of the Japan Society of Hepatology, 52, 6, 508, 521, Jun. 2022, [International Magazine]
  English, Scientific journal, BACKGROUND AND AIMS: Although various noninvasive markers and prediction formulas for nonalcoholic steatohepatitis (NASH) have been reported, they are of value only in the diagnosis of the advanced fibrosis stage of NASH. In this study, we evaluated soluble CD14 (sCD14) as a diagnostic marker for discriminating NASH from nonalcoholic fatty liver disease (NAFLD) using an animal model and clinical specimens. METHODS: Serum sCD14 levels were measured in samples derived from mice with diet-induced NASH and patients using an enzyme-linked immunosorbent assay. Our cohort enrolled 126 patients with liver needle biopsy-proven NAFLD. RESULTS: The intestinal defense mechanism in NASH model mice was altered as a consequence of the unique gut environment. Elevated serum levels of sCD14 were observed in mice with diet-induced NASH, and the condition of the liver was exacerbated as a result of exposure to gut-derived endotoxin. We confirmed that the serum sCD14 levels in NAFL patients significantly differed from those in NASH patients. The area under the curve for distinguishing between NAFL and NASH was 0.891. Moreover, we found that serum sCD14 levels were weakly correlated with the inflammation grade based on the NAFLD activity score (NAS), the grade of fibrosis according to the Brunt fibrosis classification, and a positive correlation with the grade of ballooning based on NAS in patients with NAFLD. CONCLUSION: sCD14 could be a useful pathophysiological marker and diagnostic adjunct distinguishing NASH from NAFLD. The use of sCD14 may allow the screening and identification of high-risk groups for NASH development and support early therapeutic interventions.
• Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis.
  Sonoe Yoshida; Goki Suda; Masatsugu Ohara; Megumi Kimura; Zijian Yang; Osamu Maehara; Qingjie Fu; Shunichi Hosoda; Kubo Akinori; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
  Hepatology research : the official journal of the Japan Society of Hepatology, 52, 7, 603, 613, 30 Mar. 2022, [International Magazine]
  English, Scientific journal, AIM: A high prevalence of overestimated renal function in patients with liver cirrhosis (LC) has been reported; nonetheless, its impact on prognosis remains unclear. We aimed to evaluate the impact of overestimated renal function on prognosis in patients with LC. METHODS: An overestimated renal function was defined as a >20% increase in the creatinine-based estimated glomerular filtration rate (eGFR), compared with cystatin C-based eGFR. LC patients with conserved serum, who were evaluated for muscle atrophy and had proper clinical information were included, and their prognostic factors were analyzed. RESULTS: A total of 215 consecutive patients with LC were included. The prevalence of overestimated renal function was 29.8% (64/215). Kaplan-Meier survival analysis revealed that patients with overestimated renal function had a poorer prognosis than those without overestimated renal function (hazard ratio [HR]: 2.217 95% confidence interval [CI]: 1.290-3.810; P=0.001). Subgroup analysis showed that overestimated renal function was a significant prognostic factor, irrespective of sex and the presence of hepatocellular carcinoma (HCC). Multivariate Cox regression analyses revealed that overestimated renal function was a significant and independent factor predictive of poor prognosis in the entire cohort (HR: 2.050; 95% CI: 1.041-4.037; P=0.038) and in subgroups classified by Child-Pugh class A (HR: 2.131; 95% CI: 1.019-4.458; P=0.044), Model for End-Stage Liver Disease score <9 (HR: 2.303; 95% CI: 1.038-5.109; P=0.04), and presence of HCC (HR: 2.290; 95% CI: 1.128-4.651; P=0.022). CONCLUSION: Overestimated renal function is a significant and independent prognostic factor in patients with LC. This article is protected by copyright. All rights reserved.
• Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.
  Zijian Yang; Goki Suda; Osamu Maehara; Masatsugu Ohara; Sonoe Yoshida; Shunichi Hosoda; Megumi Kimura; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
  Cancers, 14, 1, 04 Jan. 2022, [International Magazine]
  English, Scientific journal, Serum growth factor changes and their effect on prognosis during lenvatinib for unresectable hepatocellular carcinoma (HCC) remain underexplored. The sequential changes in serum growth factors during lenvatinib for unresectable HCC were evaluated in 58 patients using complete clinical data, and preserved serum was used to investigate changes in FGF-19, ANG-2, HGF, VEGF, and EGF. Patients with a complete response (CR), partial response (PR), and stable disease (SD) were evaluated for growth factor changes between the best response and progressive disease (PD) points, classified based on these changes, and evaluated by post progression survival (PPS). A total of 8, 24, 18, and 8 patients showed CR, PR, SD, and PD, respectively. Multivariate analysis revealed that age, relative dose intensity, and baseline ANG-2 were significantly associated with treatment response. Growth factor changes between the best response and PD points revealed that patients could be classified into four groups based on the EGF, ANG-2, and HGF changes. Although patient characteristics at baseline and PD, their response to lenvatinib, and PFS were similar among those groups, patients with an increase in all growth factors had significantly shorter PPS (median PPS was 553, 323, and 316 versus 173 days in groups 1-4 p = 0.032). We revealed that the evaluation of the changes in growth factors during lenvatinib could predict PPS.
• Intravenous transplantation of amnion-derived mesenchymal stem cells promotes functional recovery and alleviates intestinal dysfunction after spinal cord injury.
  Soichiro Takamiya; Masahito Kawabori; Kazuyoshi Yamazaki; Sho Yamaguchi; Aki Tanimori; Koji Yamamoto; Shunsuke Ohnishi; Toshitaka Seki; Kotaro Konno; Khin Khin Tha; Daigo Hashimoto; Masahiko Watanabe; Kiyohiro Houkin; Miki Fujimura
  PloS one, 17, 7, e0270606, 2022, [International Magazine]
  English, Scientific journal, Spinal cord injury (SCI) is often accompanied by gastrointestinal dysfunction due to the disconnection of the spinal autonomic nervous system. Gastrointestinal dysfunction reportedly upregulates intestinal permeability, leading to bacterial translocation of the gut microbiome to the systemic circulation, which further activates systemic inflammation, exacerbating neuronal damage. Mesenchymal stem cells (MSC) reportedly ameliorate SCI. Here, we aimed to investigate their effect on the associated gastrointestinal dysfunction. Human amnion-derived MSC (AMSCs) were intravenously transplanted one day after a rat model of midthoracic SCI. Biodistribution of transplanted cells, behavioral assessment, and histological evaluations of the spinal cord and intestine were conducted to elucidate the therapeutic effect of AMSCs. Bacterial translocation of the gut microbiome was examined by in situ hybridization and bacterial culture of the liver. Systemic inflammations were examined by blood cytokines, infiltrating immune cells in the spinal cord, and the size of the peripheral immune tissue. AMSCs released various neurotrophic factors and were mainly distributed in the liver and lung after transplantation. AMSC-transplanted animals showed smaller spinal damage and better neurological recovery with preserved neuronal tract. AMSCs transplantation ameliorated intestinal dysfunction both morphologically and functionally, which prevented translocation of the gut microbiome to the systemic circulation. Systemic inflammations were decreased in animals receiving AMSCs in the chronic phase. Intravenous AMSC administration during the acute phase of SCI rescues both spinal damage and intestinal dysfunction. Reducing bacterial translocation may contribute to decreasing systemic inflammation.
• Autograft of Demineralized Dentin Matrix Prepared Immediately after Extraction for Horizontal Bone Augmentation of the Anterior Atrophic Maxilla: A First Case of Non-Vital Tooth-Derived Dentin
  Naoto Okubo; Masahiro Ishikawa; Mamata Shakya; Hidetaka Hosono; Osamu Maehara; Tatsuya Ohkawara; Shunsuke Ohnishi; Toshiyuki Akazawa; Masaru Murata
  Journal of Hard Tissue Biology, 31, 1, 47, 54, Society for Hard Tissue Regenerative Biology, 2022
  Scientific journal
• Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
  Yoshimasa Tokuchi; Goki Suda; Megumi Kimura; Osamu Maehara; Takashi Kitagataya; Akinori Kubo; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Masatsugu Ohara; Ren Yamada; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
  Scientific Reports, 11, 1, Springer Science and Business Media LLC, Dec. 2021
  Scientific journal, We aimed to evaluate factors associated with changes in skeletal muscle mass in hepatitis C virus (HCV)-infected patients after treatment with direct-acting antivirals (DAAs). Consecutive HCV-infected patients after treatment with DAA were recruited into the study. Patients who achieved sustained virological response (SVR); and had complete clinical information, preserved serum samples at baseline and SVR48, and skeletal muscle mass evaluations based on the psoas muscle mass index (PMI) on computed tomography at baseline and ≥ 12 months were included. Altogether, 70.7% of patients (41/58) showed increased PMI after DAA therapy, and mean relative PMI was significantly higher after DAA therapy than at baseline. There were no significant associations between baseline clinical factors routinely examined in clinical practice and increased PMI. Among factors reported to be associated with skeletal muscle loss in patients with chronic liver disease, serum zinc levels and total and free carnitine levels increased significantly after DAA therapy and only changes in serum free carnitine levels were significantly associated with an increased PMI (r = 0305, P = 0.020). In conclusion, increased skeletal muscle mass after successful HCV eradication by DAAs was significantly associated with increased serum-free carnitine levels. l-carnitine supplementation may be beneficial in patients with low skeletal muscle mass after DAA.
• Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
  Takuya Sho; Goki Suda; Koji Ogawa; Megumi Kimura; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Taku Shigesawa; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Takuto Miyagishima; Naoya Sakamoto
  Hepatology research : the official journal of the Japan Society of Hepatology, 51, 9, 979, 989, Sep. 2021, [International Magazine]
  English, Scientific journal, AIM: A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma (HCC). In this study, we evaluated this therapeutic combination in a real-world setting, with a focus on patients who did not meet the IMbrave150 eligibility criteria. METHODS: In this multicenter study, patients with unresectable HCC treated with atezolizumab plus bevacizumab between October 2020 and May 2021 were screened. In patients who did not meet IMbrave150 eligibility criteria, treatment responses and safety at 6 and 12 weeks were evaluated. RESULTS: Atezolizumab plus bevacizumab was initiated in 64 patients, including 46 patients (71.9%) who did not meet IMbrave150 eligibility criteria. Most of these patients had a history of systemic therapy (44/46). The objective response rate and disease control rate observed using Response Evaluation Criteria in Solid Tumors 1.1 were 5.2% and 82.8% at 6 weeks and 10.0% and 84.0% at 12 weeks, respectively; these rates were similar between patients who met and did not meet the IMbrave150 criteria. Ten patients experienced progressive disease (PD) at 6 weeks. Portal vein tumor thrombosis was significantly associated with PD (p = 0.039); none of the 15 patients with hepatitis B virus-related HCC experienced PD (p = 0.050). The most common adverse events of grade 3 or higher were aspartate aminotransferase elevation (n = 8, 13.8%) and the safety profile was similar between patients who met and did not meet the IMbrave150 criteria. CONCLUSION: Most patients treated with atezolizumab plus bevacizumab did not meet the IMbrave150 criteria; however, the combination therapy showed good safety and efficacy at the early treatment phase.
• The TLR4–TRIF–type 1 IFN–IFN-γ pathway is crucial for gastric MALT lymphoma formation after Helicobacter suis infection
  Koji Yamamoto; Yasuyuki Kondo; Shunsuke Ohnishi; Masaru Yoshida; Toshiro Sugiyama; Naoya Sakamoto
  iScience, 24, 9, 103064, 103064, Elsevier {BV}, Sep. 2021, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Helicobacter suis, a zoonotic infection-related bacterium, can induce gastric mucosa-associated lymphoid tissue (MALT) lymphoma in humans and animals. Recently, we reported that the formation of gastric MALT lymphoma after H. suis infection is induced by interferon (IFN)-γ activation. Here, we revealed that activation of the Toll-like receptor (TLR) 4-Toll/IL-1 receptor domain-containing adapter-inducing interferon-β (TRIF) pathway after H. suis infection is associated with the production of type 1 IFNs (IFN-α, IFN-β) by gastric epithelial cells. Additionally, these type 1 IFNs interact with type 1 IFN receptors on gastric B cells, facilitating the secretion of IFN-γ and the activation of which is enhanced by positive feedback regulation in B cells. These results suggest that the TLR4-TRIF-type 1 IFN-IFN-γ pathway is crucial in the development of gastric MALT lymphoma after H. suis infection and may, therefore, represent a therapeutic target for the prevention of this condition.
• Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI
  Akinori Kubo; Goki Suda; Megumi Kimura; Osamu Maehara; Yoshimasa Tokuchi; Takashi Kitagataya; Masatsugu Ohara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
  Cancers, 13, 14, Jul. 2021, [Peer-reviewed], [International Magazine]
  English, Scientific journal, In hepatocellular carcinoma (HCC), CTNNB-1 mutations, which cause resistance to immune checkpoint inhibitors, are associated with HCC with iso-high intensity in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in resectable HCC; however, analyses on unresectable HCC are lacking. This study analyzed the prevalence, characteristics, response to lenvatinib, and CTNNB-1 mutation frequency in unresectable HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI. In 52 patients with unresectable HCC treated with lenvatinib, the prevalence of iso-high intensity in the hepatobiliary phase of EOB-MRI was 13%. All patients had multiple HCCs, and 3 patients had multiple HCCs with iso-high intensity in the hepatobiliary phase of EOB-MRI. Lenvatinib response to progression-free survival and overall survival were similar between patients with or without iso-high intensity in the hepatobiliary phase of EOB-MRI. Seven patients (three and four patients who had unresectable HCC with or without iso-high intensity in the hepatobiliary phase of EOB-MRI, respectively) underwent genetic analyses. Among these, two (67%, 2/3) who had HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI carried a CTNNB-1 mutation, while all four patients who had HCC without iso-high intensity in the hepatobiliary phase of EOB-MRI did not carry the CTNNB-1 mutation. This study's findings have clinical implications for the detection and treatment of HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI.
• Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia
  Sonoe Yoshida; Goki Suda; Masatsugu Ohara; QingJie Fu; Zijian Yang; Shunichi Hosoda; Megumi Kimura; Kubo Akinori; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Osamu Maehara; Shunsuke Ohnishi; Naoya Sakamoto
  Nutrients, 13, 7, Jul. 2021, [International Magazine]
  English, Scientific journal, Renal dysfunction and sarcopenia are important prognostic factors in patients with chronic liver disease (CLD). Muscle atrophy can cause the overestimation of renal function based on serum creatinine. However, the frequency of overestimated renal function in Japanese patients with CLD and its relationship with sarcopenia are unclear. In present study, we evaluated the frequency of overestimated renal function, defined as a >20% higher eGFR using creatinine than using cystatin C, in 307 patients with CLD as well as its relationship with indicators of sarcopenia. In total, 24.8% of patients had overestimated renal function. In a multivariate regression analysis, liver cirrhosis (p = 0.004) and psoas muscle mass index (p = 0.049) were significantly associated with overestimated renal function. Loss of skeletal muscle mass was significantly more frequent in both male and female patients with overestimated renal function than without. In males, the loss of muscle strength and rate of sarcopenia, defined as loss of muscle mass and strength, were significantly higher in patients with than without overestimated renal function. The high frequency of overestimated renal function in Japanese patients suggests that indicators of renal function should be carefully considered; furthermore, monitoring and interventions for both renal function and sarcopenia are needed in patients with CLD.
• FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma.
  Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Taku Shigesawa; Gouki Kanbe; Megumi Kimura; Masaya Sugiyama; Masashi Mizokami; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Seiji Naganuma; Naoto Okubo; Shunsuke Ohnishi; Hiroshi Takeda; Naoya Sakamoto
  Cancer biology & therapy, 22, 5-6, 372, 380, 03 Jun. 2021, [International Magazine]
  English, Scientific journal, Fibroblast growth factors (FGFs) and their receptors (FGFRs) are important for signaling to maintain cancer stem-like cells (CSCs) in esophageal squamous cell carcinoma (ESCC). However, which FGF receptor, 1, 2, 3, 4, and L1, is essential or whether FGFRs have distinct different roles in ESCC-CSCs is still in question. This study shows that FGFR2, particularly the IIIb isoform, is highly expressed in non-CSCs. Non-CSCs have an epithelial phenotype, and such cells are more differentiated in ESCC. Further, FGFR2 induces keratinocyte differentiation through AKT but not MAPK signaling and diminishes CSC populations. Conversely, knockdown of FGFR2 induces epithelial-mesenchymal transition (EMT) and enriches CSC populations in ESCC. Finally, data analysis using The Cancer Genome Atlas (TCGA) dataset shows that expression of FGFR2 significantly correlated with cancer cell differentiation in clinical ESCC samples. The present study shows that each FGFR has a distinct role and FGFR2-AKT signaling is a key driver of keratinocyte differentiation in ESCC. Activation of FGFR2-AKT signaling could be a future therapeutic option targeting CSC in ESCC.
• Topical Application of Conditioned Medium from Hypoxically Cultured Amnion-Derived Mesenchymal Stem Cells Promotes Wound Healing in Diabetic Mice.
  Hiroko Takahashi; Shunsuke Ohnishi; Yuhei Yamamoto; Toshihiko Hayashi; Naoki Murao; Masayuki Osawa; Taku Maeda; Kosuke Ishikawa; Naoya Sakamoto; Emi Funayama
  Plastic and reconstructive surgery, 147, 6, 1342, 1352, 01 Jun. 2021, [International Magazine]
  English, Scientific journal, BACKGROUND: Mesenchymal stem cells or their conditioned medium improve chronic wound healing, and their effect is enhanced by hypoxia. Diabetic foot ulcers are chronic wounds characterized by abnormal and delayed healing, which frequently require amputation. The authors evaluated the effect of topical application of conditioned medium from hypoxically cultured amnion-derived mesenchymal stem cells on wound healing in diabetic mice. METHODS: Amnion-derived mesenchymal stem cells were cultured under 21% oxygen to prepare normoxic conditioned medium and under 1% oxygen to prepare hypoxic conditioned medium. Hydrogels containing standard medium, normoxic conditioned medium, or hypoxic conditioned medium were topically applied to excisional wounds of mice with streptozotocin-induced diabetes. Ulcer tissues were harvested on day 9; immunohistochemical and quantitative polymerase chain reaction analyses were performed to analyze angiogenesis, inflammatory cell infiltration, and expression levels of inflammation-related genes. RESULTS: Hypoxic conditioned medium significantly enhanced wound closure, increased capillary density and epithelization, and reduced macrophage infiltration. It also tended to reduce the infiltration of neutrophils and enhance the infiltration of regulatory T cells; it showed a tendency to downregulate the expression of the inflammation-related genes interleukin-1β, interleukin-6, chemokine ligand 1, and chemokine ligand 2. Normoxic conditioned medium exhibited similar effects, although they were of lesser magnitude than those of hypoxic conditioned medium. CONCLUSIONS: Hydrogels containing hypoxically cultured, amnion-derived mesenchymal stem cell conditioned medium accelerated wound healing in diabetic mice by enhancing angiogenesis, accelerating epithelization, and suppressing inflammation. Therefore, topical application of amnion mesenchymal stem cell-derived hypoxic conditioned medium could be a novel treatment for diabetic foot ulcers.
• A protocol for efficacy of rikkunshito on chemotherapy-induced nausea and vomiting in patients with uterine corpus or cervical cancer treated with cisplatin-based regimen -placebo-controlled, double-blind, randomized confirmatory study (efficacy of rikkunshito on chemotherapy-induced nausea and vomiting)
  Shunsuke Ohnishi; Keisuke Ariyoshi; Shunsuke Oyamada; Kota Kihara; Yosuke Konno; Hidemichi Watari
  Medicine: Case Reports and Study Protocols, 2, 6, e0109, e0109, Ovid Technologies (Wolters Kluwer Health), Jun. 2021
  Scientific journal
• Experiment on endoscopic balloon dilation for esophageal stenosis after endoscopic submucosal dissection in pigs
  Sayoko Kinowaki; Yuichi Shimizu; Masayoshi Ono; Yang ZiJian; Ikko Tanaka; Yoshihiko Shimoda; Masaki Inoue; Marin Ishikawa; Keiko Yamamoto; Shoko Ono; Shunsuke Ohnishi; Naoya Sakamoto
  Journal of Gastroenterology, 56, 6, 527, 536, Springer Science and Business Media LLC, Jun. 2021
  Scientific journal
• Comprehensive Glycomic Approach Reveals Novel Low-Molecular-Weight Blood Group-Specific Glycans in Serum and Cerebrospinal Fluid
  Jun-ichi Furukawa; Hisatoshi Hanamatsu; Ikuko Yokota; Megumi Hirayama; Tomohiro Ando; Hiroyuki Kobayashi; Shunsuke Ohnishi; Nobuaki Miura; Kazue Okada; Shota Sakai; Kohei Yuyama; Yasuyuki Igarashi; Makoto Ito; Yasuro Shinohara; Naoya Sakamoto
  Journal of Proteome Research, American Chemical Society (ACS), 10 Mar. 2021
  Scientific journal
• Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
  Taku Shigesawa; Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Megumi Kimura; Tomoe Shimazaki; Koji Yamamoto; Ren Yamada; Takashi Kitagataya; Akihisa Nakamura; Kazuharu Suzuki; Masatsugu Ohara; Naoki Kawagishi; Machiko Umemura; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Masaya Sugiyama; Masashi Mizokami; Hiroshi Takeda; Naoya Sakamoto
  Carcinogenesis, 42, 1, 58, 69, 11 Feb. 2021, [International Magazine]
  English, Scientific journal, In hepatocellular carcinoma (HCC), a subset of cells defined by high CD44 and CD133 expression has been reported to possess cancer stem-like cell (CSC) characteristics and to be associated with a poor prognosis. Since the approval of the multikinase inhibitor, lenvatinib, for patients with unresectable HCC, two such inhibitors (sorafenib and lenvatinib) have been employed as first-line systemic chemotherapeutics for these patients. Based on differences in the kinase-affinity profiles between these two drugs, evidence has suggested that both exert different effects on HCC, although these differences are not fully characterized. In this study, using in vitro and a preclinical in vivo xenograft mouse model, we showed that lenvatinib alone (not sorafenib or the cytotoxic agent, 5-fluorouracil) diminished CD44High/CD133High CSCs in HCC. Furthermore, western blotting and reverse transcriptase-polymerase chain reaction analysis revealed that the expression of fibroblast growth factor receptor (FGFR)-1-4 differed between CD44High/CD133High CSCs and control cells. Analysis of the effects of selective FGFR inhibitors and FGFR small interfering RNAs on CSCs in HCC revealed that lenvatinib diminished CSCs in HCC by inhibiting FGFR1-3 signaling, however, FGFR4 signaling was not impacted. Finally, we showed that FGF2 and FGF19 were involved in maintaining CD44High/CD133High CSCs in HCC, potentially, via FGFR1-3. The findings provide novel mechanistic insights into the effects of lenvatinib on CSCs in HCC and provide clues for developing effective targeted therapies against CSCs in HCC.
• Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
  Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Akinobu Nakamura; Hideaki Miyoshi; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Koji Yamamoto; Taku Shigesawa; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
  Journal of gastroenterology, 56, 2, 168, 180, Feb. 2021, [Domestic magazines]
  English, Scientific journal, BACKGROUND: Entecavir and tenofovir-disoproxil-fumarate are first-line nucleos(t)ide analogs (NA) for treatment of hepatitis B virus (HBV) infections; however, their long-term administration can impact extrahepatic organs. Herein, we sought to examine the effect of NA on lipid metabolism while also characterizing the associated mechanism. METHODS: A retrospective study was performed on HBV patients administered entecavir or tenofovir-disoproxil-fumarate. Patient clinical information, as well as their preserved serum samples obtained at baseline and 6-12 months after treatment initiation, were analyzed. A 1:1 propensity score matching was applied to the assignment of tenofovir-disoproxil-fumarate or entecavir treatment. Changes in serum cholesterol, including oxidized-LDL, were analyzed. Subsequently, in vitro analysis elucidated the mechanism associated with the effect of NAs on lipid metabolism. RESULTS: Administration of tenofovir-disoproxil-fumarate, not entecavir, to chronic HBV patients, decreased serum cholesterol levels, including non-HDL and oxidized-LDL, which are strongly associated with arteriosclerosis. In vitro analysis revealed that tenofovir-disoproxil-fumarate reduced supernatant cholesterol, and upregulated the scavenger receptor, CD36, in hepatocytes. Meanwhile, silencing of hepatic CD36 increased supernatant cholesterol and negated the cholesterol-reducing effect of tenofovir-disoproxil-fumarate in HepG2-cells. Reporter, microarray, and RT-PCR analyses further revealed that tenofovir-disoproxil-fumarate treatment activates PPAR-α-mediated signaling, and upregulates PPAR-α target genes, including CPT1 and CD36. Alternatively, silencing of PPAR-α reversed the effects of tenofovir-disoproxil-fumarate on CD36. CONCLUSIONS: Tenofovir-disoproxil-fumarate modulates lipid metabolism by upregulating hepatic CD36 via PPAR-α activation. Since dyslipidemia could be associated with arteriosclerosis and hepatocarcinogenesis, these discoveries provide novel insights into anti-HBV therapies, as well as the associated extrahepatic effects of NA.
• Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
  Takashi Kitagataya; Goki Suda; Kazunori Nagashima; Takehiko Katsurada; Koji Yamamoto; Megumi Kimura; Osamu Maehara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Yoshito Komatsu; Hiroo Hata; Satoshi Takeuchi; Takashige Abe; Jun Sakakibara-Konishi; Takanori Teshima; Akihiro Homma; Naoya Sakamoto
  Journal of gastroenterology and hepatology, 35, 10, 1782, 1788, Oct. 2020, [International Magazine]
  English, Scientific journal, BACKGROUND AND AIM: Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. METHODS: In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were < 20 years old and had insufficient clinical data. RESULTS: Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade ≥ 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade ≥ 3 after ICI initiation. The clinical course of grade ≥ 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. CONCLUSIONS: Grade ≥ 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis.
• 生体ブタ全周性食道ESD施行後のバルーン拡張時の病理組織学的検討
  木脇 佐代子; 清水 勇一; 大西 俊介; 大野 正芳; 楊 子健; 霜田 佳彦; 井上 雅貴; 田中 一光; 石川 麻倫; 山本 桂子; 小野 尚子; 坂本 直哉
  Gastroenterological Endoscopy, 62, Suppl.1, 1320, 1320, (一社)日本消化器内視鏡学会, Aug. 2020
  Japanese
• Oleoylethanolamide Ameliorates Dextran Sulfate Sodium-Induced Colitis in Rats
  Shinsuke Otagiri; Shunsuke Ohnishi; Masatsugu Ohara; Qingjie Fu; Koji Yamamoto; Keiko Yamamoto; Takehiko Katsurada; Naoya Sakamoto
  FRONTIERS IN PHARMACOLOGY, 11, Aug. 2020, [Peer-reviewed]
  English, Scientific journal
• OLEOYLETHANOLAMIDE AMELIORATES DEXTRAN SULFATE SODIUM-INDUCED COLITIS IN RATS
  Shinsuke Otagiri; Shunsuke Ohnishi; Masatsugu Ohara; Qingjie Fu; Koji Yamamoto; Takehiko Katsurada; Naoya Sakamoto
  GASTROENTEROLOGY, 158, 6, S275, S275, May 2020
  English
• Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV
  Keikokw Yamamoto; Shunsuke Ohnishi; Takeshi Mizushima; Junichi Kodaira; Masayoshi Ono; Yutaka Hatanaka; Kanako C. Hatanaka; Yugo Kuriki; Mako Kamiya; Nobuyuki Ehira; Keisuke Shinada; Hiroaki Takahashi; Yuichi Shimizu; Yasuteru Urano; Naoya Sakamoto
  BMC CANCER, 20, 1, Jan. 2020, [Peer-reviewed]
  English, Scientific journal
• Gastrointestinal: Endoscopic balloon dilations for an intestinal stricture in a patient with X‐linked inhibitor of apoptosis deficiency
  S Otagiri; R Sugiura; T Katsurada; K Yamanashi; K Nagashima; J Sugita; S Ohnishi; N Sakamoto
  Journal of Gastroenterology and Hepatology, Wiley, 07 Nov. 2019, [Peer-reviewed]
  Scientific journal
• Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial
  Kenichi Yamahara; Akiko Hamada; Toshihiro Soma; Rika Okamoto; Masaya Okada; Satoshi Yoshihara; Kyoko Yoshihara; Kazuhiro Ikegame; Hiroya Tamaki; Katsuji Kaida; Takayuki Inoue; Yuko Ohsugi; Hiroki Nishikawa; Hiroshi Hayashi; Yoichi M. Ito; Hiroaki Iijima; Shunsuke Ohnishi; Daigo Hashimoto; Toshiyuki Isoe; Takanori Teshima; Hiroyasu Ogawa; Norihiro Sato; Yoshihiro Fujimori
  BMJ OPEN, 9, 7, e026403, Aug. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• FLUORESCENCE IMAGING OF EARLY ADENOCARCINOMA OF THE ESOPHAGOGASTRIC JUNCTION BY TOPICALLY SPRAYING PROBE TARGETING DIPEPTIDYLPEPTIDASE-IV
  Keiko Yamamoto; Shunsuke Ohnishi; Takeshi Mizushima; Junichi Kodaira; Masayoshi Ono; Yutaka Hatanaka; Kanako Hatanaka; Nobuyuki Ehira; Keisuke Shinada; Hiroaki Takahashi; Yugo Kuriki; Mako Kamiya; Yuichi Shimizu; Yasuteru Urano; Naoya Sakamoto
  GASTROINTESTINAL ENDOSCOPY, 89, 6, AB624, AB624, Jun. 2019, [Peer-reviewed]
  English
• Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines.
  Maehara O; Ohnishi S; Asano A; Suda G; Natsuizaka M; Nakagawa K; Kobayashi M; Sakamoto N; Takeda H
  Neoplasia (New York, N.Y.), 21, 6, 545, 556, Japanese Pharmacological Society, Jun. 2019, [Peer-reviewed]
  Japanese, CD133 is a cellular surface protein, which has been reported to be a cancer stem cell marker, and thus is considered a potential target for cancer treatment. Metformin is also known to reduce the risk of cancer development and cancer stem cells (CSCs), including the expression of CD133. However, the mechanism underlying the reduction of the expression of CD133 by metformin is not yet understood. This study shows that metformin suppressed CD133 expression mainly by affecting the CD133 P1 promoter via AMPK signaling. AMPK inhibition rescued the reduction of CD133 by metformin. Further experiments demonstrated that CEBPβ was upregulated by metformin and that two isoforms of CEBPβ reciprocally regulated the expression of CD133. Specifically, the liver-enriched activator protein (LAP) isoform increased the expression of CD133 by directly binding to the P1 promoter region, whereas the liver-enriched inhibitory protein (LIP) isoform suppressed the expression of CD133. Consistent with these findings, a 3D culture assay and drug sensitivity assay demonstrated that LAP-overexpressing cells formed large spheroids and were more resistant to 5-FU treatment, whereas LIP-overexpressing cells were more sensitive to 5-FU and showed combined effects with metformin. Our results indicated that metformin-AMPK-CEBPb signaling plays a crucial role in regulating the gene expression of CD133. Additionally, regulating the ratio of LAP/LIP may be a novel strategy for targeting CSCs for the treatment of cancer.
• Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn's disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose-response trial
  Shinsuke Otagiri; Shunsuke Ohnishi; Arisa Miura; Hiroshi Hayashi; Izumi Kumagai; Yoichi M. Ito; Takehiko Katsurada; Shiro Nakamura; Rika Okamoto; Kenichi Yamahara; Kyu Yong Cho; Toshiyuki Isoe; Norihiro Sato; Naoya Sakamoto
  BMJ OPEN GASTROENTEROLOGY, 5, 1, e000206, Dec. 2018, [Peer-reviewed]
  English, Scientific journal
• Preventive effect of mesenchymal stem cell culture supernatant on luminal stricture after endoscopic submucosal dissection in the rectum of pigs
  Momoko Tsuda; Shunsuke Ohnishi; Takeshi Mizushima; Hidetaka Hosono; Kenichi Yamahara; Marin Ishikawa; Satoshi Abiko; Takehiko Katsurada; Yuichi Shimizu; Naoya Sakamoto
  ENDOSCOPY, 50, 10, 1001, 1016, Oct. 2018, [Peer-reviewed]
  English, Scientific journal
• Rapid detection of superficial head and neck squamous cell carcinoma by topically spraying fluorescent probe targeting dipeptidyl peptidase‐IV
  Takeshi Mizushima; Shunsuke Ohnishi; Yuichi Shimizu; Yutaka Hatanaka; Kanako C. Hatanaka; Yugo Kuriki; Mako Kamiya; Akihiro Homma; Keiko Yamamoto; Shouko Ono; Yasuteru Urano; Naoya Sakamoto
  Head & Neck, 40, 7, 1466, 1475, Jul. 2018, [Peer-reviewed]
  Scientific journal
• PREVENTIVE EFFECT OF MESENCHYMAL STEM CELL-CULTURE SUPERNATANT ON LUMINAL STRICTURE AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION IN THE RECTUM OF PIGS
  Ohnishi Shunsuke; Tsuda Momoko; Mizushima Takeshi; Ishikawa Marin; Abiko Satoshi; Shimizu Yuichi; Sakamoto Naoya
  GASTROINTESTINAL ENDOSCOPY, 87, 6, AB501, Jun. 2018, [Peer-reviewed]
• Conditioned Medium Obtained from Amnion-Derived Mesenchymal Stem Cell Culture Prevents Activation of Keloid Fibroblasts
  Chigusa Sato; Yuhei Yamamoto; Emi Funayama; Hiroshi Furukawa; Akihiko Oyama; Naoki Murao; Hidetaka Hosono; Kazumichi Kawakubo; Naoya Sakamoto; Shunsuke Ohnishi
  PLASTIC AND RECONSTRUCTIVE SURGERY, 141, 2, 390, 398, Feb. 2018, [Peer-reviewed]
  English, Scientific journal
• L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
  Naoya Sakamoto; Shunsuke Ohnishi; Kenichi Morikawa; Mitsuteru Natsuizaka; Takuya Sho; Masato Nakai; Naoki Kawagishi; Takaaki Izumi; Machiko Umemura; Akihisa Nakamura; Kazuharu Suzuki; Tomoe Shimazaki; Osamu Maehara; Megumi Kimura; Goki Suda; Koji Ogawa; Masatsugu Ohara
  Hepatology Communications, 2, 8, 906, 918, 2018, [Peer-reviewed]
  Scientific journal
• Extracellular Vesicles from Amnion-Derived Mesenchymal Stem Cells Ameliorate Hepatic Inflammation and Fibrosis in Rats
  Naoya Sakamoto; Goki Suda; Osamu Maehara; Qingjie Fu; Hideki Nakamura; Kohei Yuyama; Koji Yamamoto; Hidetaka Hosono; Shunsuke Ohnishi; Masatsugu Ohara
  Stem Cells International, 2018, 3212643, 3212643, 2018, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Detection of Superficial Head and Neck Squamous Cell Carcinoma by Topically Spraying Fluorescent Probe Targeting DPP-IV
  Ohnishi Shunsuke; Mizushima Takeshi; Shimizu Yuichi; Hatanaka Yutaka; Hatanaka Kanako; Yamamoto Keiko; Homma Akihiro; Kuriki Yugo; Kamiya Mako; Urano Yasuteru; Sakamoto Naoya
  CANCER SCIENCE, 109, 730, Jan. 2018, [Peer-reviewed]
• Mesenchymal stem cell therapy for acute and chronic pancreatitis
  Sakamoto, Naoya; Kuwatani, Masaki; Ohnishi, Shunsuke; Kawakubo, Kazumichi
  Journal of Gastroenterology, 53, 1, 1, 5, 2018, [Peer-reviewed]
  English, Scientific journal
• Potential role of extracellular vesicle-mediated antigen presentation in Helicobacter pylori hypersensitivity during eradication therapy
  Riichiro Abe; Hiroshi Shimizu; Takeshi Tomonaga; Masahiro Asaka; Mototsugu Kato; Shuji Terai; Yuichi Sato; Yasuyuki Fujita; Hideyuki Ujiie; Akito Hasegawa; Katsuhiro Mabe; Shotaro Suzuki; Shunsuke Ohnishi; Takashi Shiromizu; Takamasa Ito
  Journal of Allergy and Clinical Immunology, 142, 2, 672, 676, 2018, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats
  Goki Suda; Qingjie Fu; Naoya Sakamoto; Osamu Maehara; Koji Yamamoto; Hidetaka Hosono; Shunsuke Ohnishi; Masatsugu Ohara
  Frontiers in Pharmacology, 9, 709, 709, 2018, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Effects of human amnion-derived mesenchymal stem cells and conditioned medium in rats with sclerosing cholangitis
  Ryo Sugiura; Shunsuke Ohnishi; Masatsugu Ohara; Marin Ishikawa; Shuichi Miyamoto; Reizo Onishi; Koji Yamamoto; Kazumichi Kawakubo; Masaki Kuwatani; Naoya Sakamoto
  AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 10, 7, 2102, 2114, 2018, [Peer-reviewed]
  English, Scientific journal
• Conditioned Medium from Human Amnion-Derived Mesenchymal Stem Cells Regulates Activation of Primary Hepatic Stellate Cells
  Naoya Sakamoto; Shunsuke Ohnishi; Qingjie Fu
  Stem Cells International, 2018, 4898152, 4898152, 2018, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Dipeptidylpeptidase-IVの酵素活性により蛍光を発するプローブによる頭頸部表在癌の検出
  大西 俊介; 水島 健; 清水 勇一; 畑中 豊; 畑中 佳奈子; 山本 桂子; 本間 明宏; 栗木 優五; 神谷 真子; 浦野 泰照; 坂本 直哉
  日本癌学会総会記事, 76回, P, 2320, 日本癌学会, Sep. 2017
  English
• Anti-Adipogenic and Antiviral Effects of L-Carnitine on Hepatitis C Virus Infection
  Yoko Tsukuda; Goki Suda; Seiji Tsunematsu; Jun Ito; Fumiyuki Sato; Katsumi Terashita; Masato Nakai; Takuya Sho; Osamu Maehara; Tomoe Shimazaki; Megumi Kimura; Kenichi Morikawa; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Makoto Chuma; Naoya Sakamoto
  JOURNAL OF MEDICAL VIROLOGY, 89, 5, 857, 866, May 2017, [Peer-reviewed]
  English, Scientific journal
• Rapid Detection of Superficial Head and Neck Squamous Cell Carcinoma by Topically Spraying Fluorescent Probe Targeting Dipeptidylpeptidase-Iv
  Shunsuke Ohnishi; Takeshi Mizushima; Yuichi Shimizu; Yutaka Hatanaka; Kanako Hatanaka; Keiko Yamamoto; Akihiro Homma; Yugo Kuriki; Mako Kamiya; Yasuteru Urano; Naoya Sakamoto
  GASTROINTESTINAL ENDOSCOPY, 85, 5, AB530, AB530, May 2017, [Peer-reviewed]
  English
• Fibroblast growth factor-2–mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma
  Naoya Sakamoto; Hiroshi Takeda; Hiroshi Nakagawa; Kelly A Whelan; Seiji Naganuma; Hideaki Kinugasa; Shingo Kagawa; Shinya Ohashi; Yoshiyuki Fujimoto; Ayaka Asano; Megumi Kimura; Tomoe Shimazaki; Koji Ogawa; Kenichi Morikawa; Takuya Sho; Masato Nakai; Fumiyuki Sato; Yoshito Komatsu; Shunsuke Ohnishi; Mitsuteru Natsuizaka; Goki Suda; Osamu Maehara
  Carcinogenesis, 38, 11, 1073, 1083, 2017, [Peer-reviewed]
  English, Scientific journal
• Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02)
  Satoru Iwase; Yasuhito Uezono; Takuhiro Yamaguchi; Noriaki Sakuragi; Masahiro Asaka; Toru Sugiyama; Hidenori Kato; Eiji Nomura; Shunsuke Oyamada; Tempei Miyaji; Satoshi Takeuchi; Yoko Ohba; Maki Kanno; Hidemichi Watari; Shunsuke Ohnishi
  Journal of Gynecologic Oncology, 28, 5, 2017, [Peer-reviewed]
  English, Scientific journal
• Oral administration of conditioned medium obtained from mesenchymal stem cell culture prevents subsequent stricture formation after esophageal submucosal dissection in pigs
  Naoya Sakamoto; Masahiro Asaka; Mototsugu Kato; Yuichi Shimizu; Momoko Tsuda; Kenichi Yamahara; Hidetaka Hosono; Shunsuke Ohnishi; Takeshi Mizushima
  Gastrointestinal Endoscopy, 86, 3, 542, 552.e1, 2017, [Peer-reviewed]
  English, Scientific journal
• Therapeutic effects of human amnion-derived mesenchymal stem cell transplantation and conditioned medium enema in rats with trinitrobenzene sulfonic acid-induced colitis
  Sakamoto N; Takeda H; Yamahara K; Katsurada T; Hosono H; Tsuchiya I; Onishi R; Ohnishi S; Miyamoto S
  American Journal of Translational Research, 9, 3, 940, 952, 2017, [Peer-reviewed]
  English, Scientific journal
• Prevention of Subsequent Stricture Formation After Esophageal Endoscopic Submucosal Dissection Using Conditioned Medium Obtained From Amnion-Derived Mesenchymal Stem Cell Culture
  Takeshi Mizushima; Shunsuke Ohnishi; Hidetaka Hosono; Momoko Tsuda; Masayoshi Ono; Reizo Onishi; Mototsugu Kato; Naoya Sakamoto
  GASTROINTESTINAL ENDOSCOPY, 83, 5, AB583, AB583, May 2016, [Peer-reviewed]
  English
• Rikkunshito and ghrelin
  Hiroshi Takeda; Shunsuke Ohnishi; Koji Nakagawa; Naoto Okubo; Chihiro Yamada; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Tomohisa Hattori
  Methods in Pharmacology and Toxicology, 135, 163, Humana Press Inc., 2016, [Peer-reviewed]
  English, In book
• Feasibility of Using an Enzymatically Activatable Fluorescence Probe for the Rapid Evaluation of Pancreatic Tissue Obtained Using Endoscopic Ultrasound-Guided Fine Needle Aspiration: a Pilot Study
  Sakamoto, Naoya; Urano, Yasuteru; Kawakami, Hiroshi; Kuwatani, Masaki; Kamiya, Mako; Kubota, Yoshimasa; Hosono, Hidetaka; Hatanaka, Kanako C.; Hatanaka, Yutaka; Ohnishi, Shunsuke; Kawakubo, Kazumichi
  Molecular Imaging and Biology, 18, 3, 463, 471, 2016, [Peer-reviewed]
  English, Scientific journal
• Fluorescent imaging of superficial head and neck squamous cell carcinoma using a Upsilon-glutamyltranspeptidase-activated targeting agent: a pilot study
  Urano, Yasuteru; Sakamoto, Naoya; Kato, Mototsugu; Homma, Akihiro; Ono, Shouko; Kamiya, Mako; Natsuizaka, Mitsuteru; Kubota, Yoshimasa; Hosono, Hidetaka; Hatanaka, Kanako C.; Hatanaka, Yutaka; Shimizu, Yuichi; Ohnishi, Shunsuke; Mizushima, Takeshi
  BMC Cancer, 16, 2016, [Peer-reviewed]
  English, Scientific journal
• Effect of Fetal Membrane-Derived Mesenchymal Stem Cell Transplantation in Rats With Acute and Chronic Pancreatitis
  Naoya Sakamoto; Hiroshi Takeda; Atsushi Masamune; Reizo Onishi; Masaki Kuwatani; Hirotoshi Fujita; Shunsuke Ohnishi; Kazumichi Kawakubo
  Pancreas, 45, 5, 707, 713, 2016, [Peer-reviewed]
  English, Scientific journal
• Effects of human amnion-derived mesenchymal stromal cell transplantation in rats with radiation proctitis
  Masayoshi Ono; Shunsuke Ohnishi; Minori Honda; Marin Ishikawa; Hidetaka Hosono; Reizo Onishi; Koji Nakagawa; Hiroshi Takeda; Naoya Sakamoto
  CYTOTHERAPY, 17, 11, 1545, 1559, Nov. 2015, [Peer-reviewed]
  English, Scientific journal
• Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions
  Goki Suda; Yoshiya Yamamoto; Astushi Nagasaka; Ken Furuya; Mineo Kudo; Yoshimichi Chuganji; Yoko Tsukuda; Seiji Tsunematsu; Fumiyuki Sato; Katsumi Terasita; Masato Nakai; Hiromasa Horimoto; Takuya Sho; Mitsuteru Natsuizaka; Kouji Ogawa; Shunsuke Ohnishi; Makoto Chuma; Yasuyuki Fujita; Riichiro Abe; Miki Taniguchi; Mina Nakagawa; Yasuhiro Asahina; Naoya Sakamoto
  HEPATOLOGY RESEARCH, 45, 8, 837, 845, Aug. 2015, [Peer-reviewed]
  English, Scientific journal
• EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition
  Fumiyuki Sato; Yoshimasa Kubota; Mitsuteru Natsuizaka; Osamu Maehara; Yutaka Hatanaka; Katsuji Marukawa; Katsumi Terashita; Goki Suda; Shunsuke Ohnishi; Yuichi Shimizu; Yoshito Komatsu; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Kelly A. Whelan; Hiroshi Nakagawa; Naoya Sakamoto
  CANCER BIOLOGY & THERAPY, 16, 6, 933, 940, Jun. 2015, [Peer-reviewed]
  English, Scientific journal
• Serotonin 2C receptor contributes to gender differences in stress-induced hypophagia in aged mice
  Chihiro Yamada; Chiharu Sadakane; Miwa Nahata; Yayoi Saegusa; Koji Nakagawa; Naoto Okubo; Shunsuke Ohnishi; Tomohisa Hattori; Hiroshi Takeda
  PSYCHONEUROENDOCRINOLOGY, 55, 81, 93, May 2015, [Peer-reviewed]
  English, Scientific journal
• A Novel Technique for the Detection of Endoscopic Ultrasound-Guided Fine Needle Pancreatic Tissue Acquisition by an Enzymatically Rapid-Activatable Fluorescent Probe
  Kazumichi Kawakubo; Shunsuke Ohnishi; Yasuteru Urano; Yutaka Hatanaka; Kanako C. Hatanaka; Hiroshi Kawakami; Masaki Kuwatani; Shuhei Kawahata; Yoko Abe; Yoshimasa Kubota; Kimitoshi Kubo; Naoya Sakamoto
  GASTROINTESTINAL ENDOSCOPY, 81, 5, AB536, AB537, May 2015, [Peer-reviewed]
  English
• The Hypophagia After Psychological Stress in Aged Male Mice Is Mediated by an Interaction of Activation of Estrogen Receptor a With Serotonin 2C Receptor
  Shunsuke Ohnishi; Koji Nakagawa; Naoto Okubo; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Chihiro Yamada; Tomohisa Hattori; Naoya Sakamoto; Hiroshi Takeda
  GASTROENTEROLOGY, 148, 4, S25, S26, Apr. 2015, [Peer-reviewed]
  English
• Different Response to Chronic Isolation Stress Between Young and Aged Mice
  Hiroshi Takeda; Shunsuke Ohnishi; Koji Nakagawa; Naoto Okubo; Chihiro Yamada; Yayoi Saegusa; Miwa Nahata; Tomohisa Hattori; Naoya Sakamoto
  GASTROENTEROLOGY, 148, 4, S26, S26, Apr. 2015, [Peer-reviewed]
  English
• KLF5 Promotes Tumorigenicity of Hepatocellular Carcinoma by Upregulation of Cancer Stem-Like Cells
  Fumiyuki Sato; Mitsuteru Natsuizaka; Osamu Maehara; Ayaka Asano; Yoshimasa Kubota; Jun Itoh; Seiji Tsunematsu; Yoko Tsukuda; Katsumi Terashita; Masato Nakai; Takuya Sho; Goki Suda; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
  GASTROENTEROLOGY, 148, 4, S43, S43, Apr. 2015, [Peer-reviewed]
  English
• Association of Peripheral Total and Differential Leukocyte Counts with Obesity-Related Complications in Young Adults
  Aya Yoshimura; Shunsuke Ohnishi; Chieko Orito; Yukako Kawahara; Hiroyo Takasaki; Hiroshi Takeda; Naoya Sakamoto; Satoshi Hashino
  OBESITY FACTS, 8, 1, 1, 16, Feb. 2015, [Peer-reviewed]
  English, Scientific journal
• A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma
  Naoya Sakamoto; Hiroshi Takeda; Kelly A Whelan; Yoshito Komatsu; Shunsuke Ohnishi; Koji Nakagawa; Makoto Chuma; Koji Ogawa; Kenichi Morikawa; Goki Suda; Takuya Sho; Masato Nakai; Yoko Tsukuda; Katsumi Terashita; Seiji Tsunematsu; Jun Itoh; Yoshimasa Kubota; Ayaka Asano; Mitsuteru Natsuizaka; Fumiyuki Sato; Osamu Maehara
  Cancer Biology & Therapy, 16, 10, 1453, 1461, 2015, [Peer-reviewed]
  English, Scientific journal
• Chromoendoscopy With Iodine Staining, as Well as Narrow-Band Imaging, Is Still Useful and Reliable for Screening of Early Esophageal Squamous Cell Carcinoma
  Yuichi Shimizu; Masakazu Takahashi; Takeshi Mizushima; Shouko Ono; Katsuhiro Mabe; Shunsuke Ohnishi; Mototsugu Kato; Masahiro Asaka; Naoya Sakamoto
  AMERICAN JOURNAL OF GASTROENTEROLOGY, 110, 1, 193, 194, Jan. 2015, [Peer-reviewed]
  English, Scientific journal
• Human Amnion-Derived Mesenchymal Stem Cell Transplantation Ameliorates Dextran Sulfate Sodium-Induced Severe Colitis in Rats
  Naoya Sakamoto; Hiroshi Takeda; Mitsuteru Natsuizaka; Goki Suda; Takehiko Katsurada; Koji Nakagawa; Naoto Okubo; Kenichi Yamahara; Michiko Watari; Ryosuke Higashi; Shunsuke Ohnishi; Reizo Onishi
  Cell Transplantation, 24, 12, 2601, 2614, 2015, [Peer-reviewed]
  English, Scientific journal
• Human Amnion-Derived Mesenchymal Stem Cell Transplantation Ameliorates Liver Fibrosis in Rats
  Naoya Sakamoto; Hiroshi Takeda; Kenichi Yamahara; Takahiro Yamada; Reizo Onishi; Ryosuke Higashi; Ayano Kameya; Moto Fukai; Hidetaka Hosono; Shunsuke Ohnishi; Kimitoshi Kubo
  Transplantation Direct, 1, 4, e16, 2015, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• TGF-beta in tumor microenvironment changes a switch of Notch1-mediated signaling to maintain cancer stem-like cells in esophageal squamous cell carcinoma
  Mitsuteru Natsuizaka; Shingo Kagawa; Kelly Whelan; Shinya Ohashi; Shunsuke Ohnishi; Goki Suda; Naoya Sakamoto; Anil K. Rustgi; Hiroshi Nakagawa
  CANCER RESEARCH, 75, 1, Jan. 2015, [Peer-reviewed]
  English
• Herbal medicines for the treatment of cancer chemotherapy-induced side effects
  Hiroshi Takeda; Shunsuke Ohnishi
  Frontiers in Pharmacology, 6, 2015, [Peer-reviewed]
  English, Scientific journal
• TRANSPLANTATION OF HUMAN AMNIOTIC MEMBRANE-DERIVED MESENCHYMAL STEM CELLS IMPROVES RADIATION ENTERITIS
  Minori Honda; Shunsuke Ohnishi; Masayoshi Ono; Kenichi Yamahara; Jun Yoshimatsu; Koji Nakagawa; Hiroshi Takeda; Naoya Sakamoto
  PLACENTA, 35, 10, A7, A7, Oct. 2014, [Peer-reviewed]
  English
• THE ANTI-INFLAMMATORY EFFECT OF HUMAN AMNION-DERIVED MESENCHYMAL STEM CELLS
  Reizo Onishi; Shunsuke Ohnishi; Ryosuke Higashi; Kenichi Yamahara; Jun Yoshimatsu; Takehiko Katsurada; Naoto Okubo; Koji Nakagawa; Hiroshi Takeda; Naoya Sakamoto
  PLACENTA, 35, 10, A23, A23, Oct. 2014, [Peer-reviewed]
  English
• [Sensitization to laboratory animal allergens among students and researchers exposed to laboratory rodents in Hokkaido university].
  Yoshimura A; Musashi M; Kaneko T; Ohnishi S; Orito C; Kawahara Y; Hashino S; Morimatsu M; Konno S; Arikawa J; Ishii T; Sawamura M; Ueda I
  Arerugi = [Allergy], 63, 8, 1132, 1139, Japanese Society of Allergology, Sep. 2014, [Peer-reviewed]
  Japanese, Background: Based on a case who developed anaphylaxis after mouse bite which occurred at Hokkaido University, we studied on allergic sensitization prevalence for laboratory animals among students and researchers who are exposed to laboratory rodents and rabbit, for the purpose of allergy prevention, particularly anaphylaxis. Methods: We carried out the health check-up on laboratory animal allergy (LAA) by questionnaires and specific-IgE antibody test for 555 rodents and/or rabbit handlers from whom informed consent was obtained. Result: Prevalence of positive IgE antibody higher than class 1 to mice, rats, hamsters, guinea pigs, and/or rabbits in the examinees was 14.1% (62/441), 17.9% (50/279), 18.8% (6/32), 17.4% (4/23), and 11.3% (12/106), respectively. Moreover, among users of mouse, those who had allergic symptoms during contact with animals resulted in significantly higher positive rate for anti-mouse IgE antibody test than the other (38.1% vs 8.8%, p<0.01). Conclusion: Health check-up including measurement of specific-IgE antibody against laboratory animals is useful for understanding allergic sensitization.
• Rikkunshito, a Traditional Japanese Kampo Medicine, Ameliorates the Decrease in Feeding Behavior in Aged Mice Exposed to Stress via Enhancement of Endogenous Ghrelin Production
  Shuichi Muto; Shunsuke Ohnishi; Koji Nakagawa; Chihiro Yamada; Yayoi Saegusa; Miwa Nahata; Chiharu Sadakane; Tomohisa Hattori; Naoya Sakamoto; Hiroshi Takeda
  GASTROENTEROLOGY, 146, 5, S848, S849, May 2014, [Peer-reviewed]
  English
• Gender Difference Influences Food Intake Under an Emotional Stress via 5-HT2CR Activation in Aged Mice
  Shunsuke Ohnishi; Shuichi Muto; Koji Nakagawa; Chihiro Yamada; Yayoi Saegusa; Miwa Nahata; Chiharu Sadakane; Tomohisa Hattori; Naoya Sakamoto; Hiroshi Takeda
  GASTROENTEROLOGY, 146, 5, S498, S499, May 2014, [Peer-reviewed]
  English
• The Possibility of Rikkunshito As a Treatment for Anorexia: a Proposal From a Basic Research Perspective
  Hiroshi Takeda; Shunsuke Ohnishi; Shuichi Muto; Koji Nakagawa; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Chihiro Yamada; Tomohisa Hattori; Naoya Sakamoto
  GASTROENTEROLOGY, 146, 5, S899, S899, May 2014, [Peer-reviewed]
  English
• Association of Abnormal Ghrelin Dynamics With Delayed Gastric Emptying in Acute Restraint-Stressed Mice
  Hiroshi Takeda; Shunsuke Ohnishi; Shuichi Muto; Koji Nakagawa; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Chihiro Yamada; Tomohisa Hattori; Naoya Sakamoto
  GASTROENTEROLOGY, 146, 5, S658, S658, May 2014, [Peer-reviewed]
  English
• EGFR Inhibitors Eliminate Esophageal Cancer Stem Cells by Suppressing Epithelial-Mesenchymal Transition
  Mitsuteru Natsuizaka; Bongani Kaimila; Yoshimasa Kubota; Yutaka Hatanaka; Katsuji Marukawa; Katsumi Terashita; Fumiyuki Satou; Shunsuke Ohnishi; Goki Suda; Shinya Ohashi; Shingo Kagawa; Kelly A. Whelan; Anil K. Rustgi; Hiroshi Nakagawa; Naoya Sakamoto
  GASTROENTEROLOGY, 146, 5, S821, S821, May 2014, [Peer-reviewed]
  English
• Comparison of Angiogenic, Cytoprotective, and Immunosuppressive Properties of Human Amnion- and Chorion-Derived Mesenchymal Stem Cells
  Kenichi Yamahara; Kazuhiko Harada; Makiko Ohshima; Shin Ishikane; Shunsuke Ohnishi; Hidetoshi Tsuda; Kentaro Otani; Akihiko Taguchi; Toshihiro Soma; Hiroyasu Ogawa; Shinji Katsuragi; Jun Yoshimatsu; Mariko Harada-Shiba; Kenji Kangawa; Tomoaki Ikeda
  PLOS ONE, 9, 2, Feb. 2014, [Peer-reviewed]
  English, Scientific journal
• Administration of exogenous acylated ghrelin or rikkunshito, an endogenous ghrelin enhancer, improves the decrease in postprandial gastric motility in an acute restraint stress mouse model
  H. Takeda; N. Sakamoto; T. Hattori; S. Ohnishi; N. Okubo; K. Nakagawa; C. Yamada; C. Sadakane; Y. Saegusa; M. Nahata
  Neurogastroenterology and Motility, 26, 6, 821, 831, 2014, [Peer-reviewed]
  English, Scientific journal
• Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults
  Y Igarashi; S Hashino; H Takeda; S Mitsutake; K Yuyama; S Sakai; S Ohnishi; H Hanamatsu
  Nutrition & Diabetes, 4, e141, 2014, [Peer-reviewed]
  English, Scientific journal
• A pivotal role of KLF5 in regulation of cancer stem-like cells in hepatocellular carcinoma
  Mitsuteru Natsuizaka; Osamu Maehara; Fumiyuki Sato; Yoshimasa Kubota; Goki Suda; Jun Itoh; Seiji Tsunematsu; Yoko Tsukuda; Katsumi Terashita; Masato Nakai; Takuya Sho; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
  HEPATOLOGY, 60, 825A, 825A, 2014, [Peer-reviewed]
  English
• Pathophysiologic Basis of Anorexia: Focus on the Interaction between Ghrelin Dynamics and the Serotonergic System
  Hiroshi Takeda; Koji Nakagawa; Naoto Okubo; Mie Nishimura; Shuichi Muto; Shunsuke Ohnishi; Naoya Sakamoto; Hidetaka Hosono; Masahiro Asaka
  BIOLOGICAL & PHARMACEUTICAL BULLETIN, 36, 9, 1401, 1405, Sep. 2013, [Peer-reviewed]
  English, Scientific journal
• Activation of Corticotropin-Releasing Factor 2 and Melanocortin-4 Receptors Mediates the Persistent Loss of Appetite Induced by Stress Loading in Advanced Age
  Hiroshi Takeda; Shuichi Muto; Shunsuke Ohnishi; Koji Nakagawa; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Chihiro Yamada; Tomohisa Hattori; Masahiro Asaka
  GASTROENTEROLOGY, 144, 5, S712, S713, May 2013, [Peer-reviewed]
  English
• Involvement of Ghrelin Signaling Dysfunction in Acute Restraint Stress-Induced Delayed Gastric Emptying
  Shunsuke Ohnishi; Shuichi Muto; Koji Nakagawa; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Chihiro Yamada; Tomohisa Hattori; Masahiro Asaka; Naoya Sakamoto; Hiroshi Takeda
  GASTROENTEROLOGY, 144, 5, S542, S542, May 2013, [Peer-reviewed]
  English
• Serotonin 2C Receptor Antagonism Improves Stress-Induced Anorexia in Aged Mice
  Muto Shuichi; Ohnishi Shunsuke; Nakagawa Koji; Sadakane Chiharu; Saegusa Yayoi; Nahata Miwa; Yamada Chihiro; Hattori Tomohisa; Asaka Masahiro; Takeda Hiroshi
  GASTROENTEROLOGY, 144, 5, S714, May 2013, [Peer-reviewed]
• Transplantaion of Human Fetal Membrane-Derived Mesenchymal Stem Cells Improves Severe Colitis Induced by Dextran Sulfate Sodium in Rats
  Reizo Onishi; Shunsuke Ohnishi; Ryosuke Higashi; Michiko Watari; Waka Kobayashi; Takehiko Katsurada; Hiroshi Takeda; Naoya Sakamoto
  GASTROENTEROLOGY, 144, 5, S811, S812, May 2013, [Peer-reviewed]
  English
• Gender Differences in the Action Mechanisms of Rikkunshito, a Ghrelin Signaling Enhancer, on the Improvement of Food Intake After Exposure to a Novel Environmental Stress in Aged Mice
  Chihiro Yamada; Shunsuke Ohnishi; Shuichi Muto; Koji Nakagawa; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Tomohisa Hattori; Masahiro Asaka; Hiroshi Takeda
  GASTROENTEROLOGY, 144, 5, S512, S513, May 2013, [Peer-reviewed]
  English
• Hypoxia-Inducible Factors Activate CD133 Promoter through ETS Family Transcription Factors
  Kikuko Takagi; Ryosuke Higashi; Hiroshi Takeda; Masanobu Kobayashi; Naoya Sakamoto; Masahiro Asaka; Hirotoshi Fujita; Kanako Otaki; Ayano Kameya; Koji Nakagawa; Osamu Maehara; Shunsuke Ohnishi
  Plos One, 8, 6, 2013, [Peer-reviewed]
  English, Scientific journal
• Rikkunshito, a Japanese Kampo Medicine, Ameliorates Decreased Feeding Behavior via Ghrelin and Serotonin 2B Receptor Signaling in a Novelty Stress Murine Model
  Chihiro Yamada; Yayoi Saegusa; Koji Nakagawa; Shunsuke Ohnishi; Shuichi Muto; Miwa Nahata; Chiharu Sadakane; Tomohisa Hattori; Naoya Sakamoto; Hiroshi Takeda
  BIOMED RESEARCH INTERNATIONAL, 2013, 2013, [Peer-reviewed]
  English, Scientific journal
• Serotonin 2C receptor antagonism ameliorates novelty-induced hypophagia in aged mice
  Hiroshi Takeda; Masahiro Asaka; Tomohisa Hattori; Seiichi Iizuka; Yayoi Saegusa; Chiharu Sadakane; Shunsuke Ohnishi; Koji Nakagawa; Shuichi Muto; Miwa Nahata
  Psychoneuroendocrinology, 38, 10, 2051, 2064, 2013, [Peer-reviewed]
  English, Scientific journal
• Rikkunshito and Ghrelin Secretion
  Hiroshi Takeda; Shuichi Muto; Koji Nakagawa; Shunsuke Ohnishi; Masahiro Asaka
  CURRENT PHARMACEUTICAL DESIGN, 18, 31, 4827, 4838, Oct. 2012, [Peer-reviewed]
  English, Scientific journal
• Potential New Treatment to Alleviate Stress-Induced Anorexia
  Shuichi Muto; Hiroshi Takeda; Shunsuke Ohnishi; Koji Nakagawa; Yayoi Saegusa; Miwa Nahata; Chiharu Sadakane; Tomohisa Hattori; Masahiro Asaka
  GASTROENTEROLOGY, 142, 5, S293, S293, May 2012, [Peer-reviewed]
  English
• The Ghrelin Enhancer Rikkunshito Improves Gastric Dysmotility in Restraint Stress Mice
  Hiroshi Takeda; Shuichi Muto; Shunsuke Ohnishi; Koji Nakagawa; Miwa Nahata; Yayoi Saegusa; Chiharu Sadakane; Tomohisa Hattori; Masahiro Asaka
  GASTROENTEROLOGY, 142, 5, S891, S891, May 2012, [Peer-reviewed]
  English
• A Study on Gender Differences in Feeding Behavior and Plasma Acyl Ghrelin Levels in Aged Mice Following Exposure to a Novel Environmental Stress
  Shunsuke Ohnishi; Hiroshi Takeda; Shuichi Muto; Koji Nakagawa; Chiharu Sadakane; Miwa Nahata; Yayoi Saegusa; Tomohisa Hattori; Masahiro Asaka
  GASTROENTEROLOGY, 142, 5, S559, S559, May 2012, [Peer-reviewed]
  English
• Impaired ghrelin signaling is associated with gastrointestinal dysmotility in rats with gastroesophageal reflux disease
  Hiroshi Takeda; Masahiro Asaka; Tomohisa Hattori; Yayoi Saegusa; Chiharu Sadakane; Koji Nakagawa; Nobuhiko Oridate; Shunsuke Ohnishi; Shuichi Muto; Miwa Nahata
  AJP: Gastrointestinal and Liver Physiology, 303, 1, G42, G53, 2012, [Peer-reviewed]
  English, Scientific journal
• Ghrelin Treatment of Cachectic Patients with Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
  Kenji Kangawa; Kenichi Yamahara; Masanori Yoshikawa; Nobuhiro Matsumoto; Yasuji Arimura; Yoshitaka Tateishi; Kenji Yoshimura; Seigo Kitada; Toru Hiraga; Shunsuke Ohnishi; Shinsuke Murakami; Hiroshi Kimura; Masamitsu Nakazato; Ryoji Maekura; Noritoshi Nagaya; Keisuke Miki
  Plos One, 7, 5, 2012, [Peer-reviewed]
  English, Scientific journal
• Rikkunshito as a Ghrelin Enhancer
  Hiroshi Takeda; Shuichi Muto; Koji Nakagawa; Shunsuke Ohnishi; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Tomohisa Hattori; Masahiro Asaka
  GHRELIN, 514, 333, 351, 2012, [Peer-reviewed]
  English, In book
• Decreased plasma ghrelin contributes to anorexia following novelty stress
  Yayoi Saegusa; Hiroshi Takeda; Shuichi Muto; Koji Nakagawa; Shunsuke Ohnishi; Chiharu Sadakane; Miwa Nahata; Tomohisa Hattori; Masahiro Asaka
  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 301, 4, E685, E696, Oct. 2011, [Peer-reviewed]
  English, Scientific journal
• 10-Gingerol, a component of rikkunshito, improves cisplatin-induced anorexia by inhibiting acylated ghrelin degradation
  Chiharu Sadakane; Shuichi Muto; Koji Nakagawa; Shunsuke Ohnishi; Yayoi Saegusa; Miwa Nahata; Tomohisa Hattori; Masahiro Asaka; Hiroshi Takeda
  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 412, 3, 506, 511, Sep. 2011, [Peer-reviewed]
  English, Scientific journal
• Novelty Stress-Induced Anorexia is Due to the Decrease in the Plasma Ghrelin Level via 5-HT1b/(2c)-Melanocortin4 System Activation
  Shuichi Muto; Hiroshi Takeda; Shunsuke Ohnishi; Koji Nakagawa; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Tomohisa Hattori; Masahiro Asaka
  GASTROENTEROLOGY, 140, 5, S833, S833, May 2011, [Peer-reviewed]
  English
• Potential New Treatment to Alleviate Chemotherapy Anorexia
  Shunsuke Ohnishi; Hiroshi Takeda; Shuichi Muto; Koji Nakagawa; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Tomohisa Hattori; Masahiro Asaka
  GASTROENTEROLOGY, 140, 5, S861, S861, May 2011, [Peer-reviewed]
  English
• Stress-Related Differences in Appetite-Related Genes Between Advanced-Age Male and Female Mice
  Shuichi Muto; Hiroshi Takeda; Shunsuke Ohnishi; Koji Nakagawa; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Tomohisa Hattori; Masahiro Asaka
  GASTROENTEROLOGY, 140, 5, S358, S358, May 2011, [Peer-reviewed]
  English
• Influence of Gender on Peripheral Ghrelin Secretion. -Examination in the Aging Mice-
  Shunsuke Ohnishi; Hiroshi Takeda; Shuichi Muto; Koji Nakagawa; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Tomohisa Hattori; Masahiro Asaka
  GASTROENTEROLOGY, 140, 5, S357, S357, May 2011, [Peer-reviewed]
  English
• Impaired Gastric Emptying in Gastroesophageal Reflux Disease Rat Models is Caused by a Reduced Response to Ghrelin
  Hiroshi Takeda; Shuichi Muto; Nobuhiko Oridate; Shunsuke Ohnishi; Koji Nakagawa; Chiharu Sadakane; Yayoi Saegusa; Miwa Nahata; Tomohisa Hattori; Masahiro Asaka
  GASTROENTEROLOGY, 140, 5, S481, S482, May 2011, [Peer-reviewed]
  English
• A study of the comtamination risk for the colonoscopist
  Yoshimitsu Kobayashi; Shunsuke Ohnishi; Reizo Onishi; Ryo Takemura; Mio Suzuki; Takahide Sasaki; Masayoshi Dazai; Tamotsu Hata; Junji Yamamoto; Hisashi Oda; Takuto Miyagishima
  Gastroenterological Endoscopy, 53, 3, 1117, 1121, 30 Mar. 2011
  Japanese, Scientific journal
• Gene and protein expression analysis of mesenchymal stem cells derived from rat adipose tissue and bone marrow
  Masakazu Yamagishi; Toshinari Tsubokawa; Masa-aki Kawashiri; Kenshi Hayashi; Tetsuo Konno; Shu Takabatake; Kenichi Yamahara; Shunsuke Ohnishi; Noritoshi Nagaya; Chiaki Nakanishi
  Circulation Journal: Official Journal of the Japanese Circulation Society, 75, 9, 2260, 2268, 2011, [Peer-reviewed]
  English, Scientific journal
• Macrophage migration inhibitory factor contributes to development of nonsteroidal anti-inflammatory drugs-induced gastric injury in mice
  Masahiro Asaka; Jun Nishihira; Mototsugu Kato; Shunsuke Ohnishi; Hiroshi Takeda; Tatsuya Ohkawara
  International Immunopharmacology, 11, 4, 418, 423, 2011, [Peer-reviewed]
  English, Scientific journal
• Sustained-release adrenomedullin ointment accelerates wound healing of pressure ulcers
  Tomoaki Ikeda; Noritoshi Nagaya; Kenji Kangawa; Naoto Minamino; Hatsue Ishibashi-Ueda; Hirohisa Kanoh; Kentaro Otani; Shunsuke Ohnishi; Kenichi Yamahara; Kazuhiko Harada
  Regulatory Peptides, 168, 1-3, 21, 26, 2011, [Peer-reviewed]
  English, Scientific journal
• [Repetition of Helicobacter cinaedi infections during chemotherapy for malignant lymphoma].
  Masayoshi Ono; Shunsuke Ohnishi; Reizo Onishi; Shojiro Takahashi; Yoshimitsu Kobayashi; Mio Suzuki; Kimitoshi Kubo; Masayoshi Dazai; Junji Yamamoto; Hisashi Oda; Kenji Tada; Tatsuro Takahashi; Takuto Miyagishima
  [Rinsho ketsueki] The Japanese journal of clinical hematology, 51, 12, 1781, 5, Dec. 2010, [Domestic magazines]
  Japanese, Scientific journal, A 70-year-old male, who had undergone resection of gastric malignant lymphoma in 1992, presented with cervical lymph node swelling in January 2008. Pathological examination of the lymph node biopsy demonstrated recurrence of malignant lymphoma, and he was treated with the R-CHOP regimen. Although he did not develop fever during the first through third course of R-CHOP, from the fourth course, he repeatedly demonstrated fever over 38°C for about one week after each course of chemotherapy, despite the absence of neutropenia. Helicobacter cinaedi infection was confirmed by blood culture each time. Although it is difficult to diagnose Helicobacter cinaedi infection by the standard culture method, increased numbers of recent reports especially in immunocompromised patients have emphasized the importance of diagnosing Helicobacter cinaedi infection.
• Undiagnosed collecting duct carcinoma presenting as meningeal carcinomatosis and multiple bone metastases
  Takuto Miyagishima; Tatsuro Takahashi; Kazufumi Tsuzaka; Yoshinori Iwasaki; Masayoshi Dazai; Shunsuke Ohnishi
  Internal medicine (Tokyo, Japan), 49, 15, 1541, 1544, 2010, [Peer-reviewed]
  English, Scientific journal
• Pulmonary Sequestration Diagnosed by Three-dimensional Reconstruction Computed Tomography
  Ryo Takemura; Shunsuke Ohnishi; Shojiro Takahashi; Takuto Miyagishima
  INTERNAL MEDICINE, 49, 15, 1683, 1684, 2010, [Peer-reviewed]
  English, Scientific journal
• POEMS syndrome complicated by follicular lymphoma.
  Takahide SASAKI; Shunsuke OHNISHI; Reizo ONISHI; Ryou TAKEMURA; Yoshimitsu KOBAYASHI; Mio SUZUKI; Masayoshi DAZAI; Tamotsu HATA; Junji YAMAMOTO; Hisashi ODA; Tatsuro TAKAHASHI; Kazuhiro OGASAWARA; Takuto MIYAGISHIMA
  [Rinsho ketsueki] The Japanese journal of clinical hematology, 50, 11, 1621, 5, Nov. 2009, [Domestic magazines]
  English, Scientific journal, A 59-year-old woman presented with ascites and intraperitoneal lymph node swelling. Pathological examination of the lymph node revealed follicular lymphoma. After a lymph node biopsy, she developed atypical genital bleeding, multiple endocrine disorders, polyneuropathy with a high plasma level of vascular endothelial growth factor (VEGF), and was diagnosed with POEMS syndrome. Following administration of methyl prednisolone, ascites immediately decreased and her performance status improved; however, about 18 months later, renal failure occurred, and she died despite increased steroid dosage. Lymph node swelling is often found in POEMS syndrome; however, its histological appearance is not well known, and it is very rare to be concomitant with malignant lymphoma. Therefore, it is important to perform a lymph node biopsy and investigate it in relation with VEGF.
• Selective Delivery of siRNA Nanoparticles Targeting MEK Attenuates Experimental Pulmonary Hypertension
  Hiroaki Obata; Nobuhiro Yagi; Shunsuke Ohnishi; Kenichi Yamahara; Toshihito Hosokawa; Ichiro Manabe; Makoto Kodama; Yoshifusa Aizawa; Ryozo Nagai; Noritoshi Nagaya
  CIRCULATION, 120, 18, S841, S841, Nov. 2009, [Peer-reviewed]
  English
• Involvement of tazarotene-induced gene 1 in proliferation and differentiation of human adipose tissue-derived mesenchymal stem cells
  Ohnishi, S.; Okabe, K.; Obata, H.; Otani, K.; Ishikane, S.; Ogino, H.; Kitamura, S.; Nagaya, N.
  Cell Proliferation, 42, 3, 2009, [Peer-reviewed]
  Scientific journal
• Nonviral delivery of siRNA into mesenchymal stem cells by a combination of ultrasound and microbubbles
  Kentaro Otani; Kenichi Yamahara; Shunsuke Ohnishi; Hiroaki Obata; Soichiro Kitamura; Noritoshi Nagaya
  JOURNAL OF CONTROLLED RELEASE, 133, 2, 146, 153, Jan. 2009, [Peer-reviewed]
  English, Scientific journal
• CONTRAST SONOGRAPHY ENABLES NONINVASIVE AND QUANTITATIVE ASSESSMENT OF NEOVASCULARIZATION AFTER STEM CELL TRANSPLANTATION
  Kentaro Otani; Shunsuke Ohnishi; Hiroaki Obata; Osamu Ishida; Soichiro Kitamura; Noritoshi Nagaya
  ULTRASOUND IN MEDICINE AND BIOLOGY, 34, 12, 1893, 1900, Dec. 2008, [Peer-reviewed]
  English, Scientific journal
• Adrenomedullin Induces Lymphangiogenesis and Ameriolates Secondary Lymphedema
  DongHao Jin; Kenich Yamahara; Kazuhiko Harada; Shunsuke Ohnishi; Kenji Kangawa; Noritosh Nagoya
  CIRCULATION, 118, 18, S507, S507, Oct. 2008, [Peer-reviewed]
  English
• Therapeutic Potential of Mesenchymal Stem Cells Derived from Three Different Layers of Human Fetal Membrane In Hindlimb Ischemia Model
  Kazuhiko Harada; Shunsuke Ohnishi; Kenichi Yamahara; Masaharu Sada; Shin Ishikane; Kenichi Mishima; Katsunori Iwasaki; Michihiro Fujiwara; Kenji Kangawa; Soichiro Kitamura; Noritoshl Nagaya; Tomoaki Ikeda
  CIRCULATION, 118, 18, S381, S382, Oct. 2008, [Peer-reviewed]
  English
• Novel sustained-release prostacyclin analog attenuates pulmonary hypertension in rats
  Hiroaki Obata; Yoshiki Sakai; Shunsuke Ohnishi; Makoto Kodama; Yoshifusa Aizawa; Noritoshi Nagaya
  JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 45, S26, S26, Oct. 2008, [Peer-reviewed]
  English
• Real-time intraoperative assessment of the extrahepatic bile ducts in rats and pigs using invisible near-infrared fluorescent light
  Eiichi Tanaka; Hak Soo Choi; Valerie Humblet; Shunsuke Ohnishi; Rita G. Laurence; John V. Frangioni
  SURGERY, 144, 1, 39, 48, Jul. 2008, [Peer-reviewed]
  English, Scientific journal
• Paracrine cytoprotective effects of inner chorion-derived human mesenchymal stem cells
  Kazuhiko Harada; Noritoshi Nagaya; Shunsuke Ohnishi; Shin Ishikane; Michihiro Fujiwara; Tomoaki Ikeda
  JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 51, 10, A187, A187, Mar. 2008, [Peer-reviewed]
  English
• Transplantation of Mesenchymal Stem Cells Improves Atrioventricular Conduction in a Rat Model of Complete Atrioventricular Block
  Miki Yokokawa; Shunsuke Ohnishi; Hatsue Ishibashi-Ueda; Hiroaki Obata; Kentaro Otani; Yoshinori Miyahara; Koichi Tanaka; Wataru Shimizu; Kazuo Nakazawa; Kenji Kangawa; Shiro Kamakura; Soichiro Kitamura; Noritoshi Nagaya
  CELL TRANSPLANTATION, 17, 10-11, 1145, 1155, 2008, [Peer-reviewed]
  English, Scientific journal
• Single Injection of a Sustained-release Prostacyclin Analog Improves Pulmonary Hypertension in Rats
  Noritoshi Nagaya; Yoshifusa Aizawa; Makoto Kodama; Kenji Kangawa; Hidezo Mori; Satoshi Takeshita; Shunsuke Ohnishi; Yoshiki Sakai; Hiroaki Obata
  American Journal of Respiratory and Critical Care Medicine, 177, 2, 195, 201, 2008, [Peer-reviewed]
  English, Scientific journal
• Allogeneic Injection of Fetal Membrane-Derived Mesenchymal Stem Cells Induces Therapeutic Angiogenesis in a Rat Model of Hind Limb Ischemia
  Tomoaki Ikeda; Noritoshi Nagaya; Soichiro Kitamura; Michihiro Fujiwara; Katsunori Iwasaki; Kenichi Mishima; Kazuhiko Harada; Masaharu Sada; Kenichi Yamahara; Shunsuke Ohnishi; Shin Ishikane
  Stem Cells, 26, 10, 2625, 2633, 2008, [Peer-reviewed]
  English, Scientific journal
• Adrenomedullin induces lymphangiogenesis and ameliorates secondary lymphoedema
  N. Nagaya; K. Kangawa; K. Yamahara; S. Ohnishi; K. Harada; D. Jin
  Cardiovascular Research, 80, 3, 339, 345, 2008, [Peer-reviewed]
  English, Scientific journal
• Real-time intraoperative ureteral guidance using invisible near-infrared fluorescence
  Eiichi Tanaka; Shunsuke Ohnishi; Rita G. Laurence; Hak Soo Choi; Valerie Humblet; John V. Frangioni
  JOURNAL OF UROLOGY, 178, 5, 2197, 2202, Nov. 2007, [Peer-reviewed]
  English, Scientific journal
• Clinical trial of autologous bone marrow mesenchymal stem cell transplantation for severe chronic heart failure
  Noritoshi Nagaya; Hajime Ohgushi; Wataru Shimizu; Masakazu Yamagishi; Teruo Noguchi; Takashi Noda; Kaori Doi; Yoshio Ishida; Shunsuke Ohnishi; Masafumi Kitakaze; Takeshi Nakatani; Hidezo Mori; Shiro Kamakura; Kenji Kangawa; Kunio Miyatake; Hitonobu Tomoike; Soichiro Kitamura
  CIRCULATION, 116, 16, 453, 453, Oct. 2007, [Peer-reviewed]
  English
• Infusion of adrenomedullin improves acute myocarditis via attenuation of myocardial inflammation and edema
  Bobby Yanagawa; Masaharu Kataoka; Shunsuke Ohnishi; Makoto Kodama; Koichi Tanaka; Yoshinori Miyahara; Hatsue Ishibashi-Ueda; Yoshifusa Aizawa; Kenji Kangawa; Noritoshi Nagaya
  CARDIOVASCULAR RESEARCH, 76, 1, 110, 118, Oct. 2007, [Peer-reviewed]
  English, Scientific journal
• Lymphatic drainage of the peritoneal space: A pattern dependent on bowel lymphatics
  Cherie P. Parungo; David I. Soybel; Yolonda L. Colson; Sang-Wook Kim; Shunsuke Ohnishi; Alec M. DeGrand; Rita G. Laurence; Edward G. Soltesz; Fredrick Y. Chen; Lawrence H. Cohn; Moungi G. Bawendi; John V. Frangioni
  ANNALS OF SURGICAL ONCOLOGY, 14, 2, 286, 298, Feb. 2007, [Peer-reviewed]
  English, Scientific journal
• Sentinel lymph node mapping with type-II quantum dots
  Frangioni JV; Kim SW; Ohnishi S; Kim S; Bawendi MG
  Methods Mol Biol, 374, 147, 160, 2007, [Peer-reviewed]
  Scientific journal
• Mesenchymal Stem Cells for the Treatment of Heart Failure
  Noritoshi Nagaya; Soichiro Kitamura; Hajime Ohgushi; Shunsuke Ohnishi
  International Journal of Hematology, 86, 1, 17, 21, 2007, [Peer-reviewed]
  English, Scientific journal
• CNP infusion attenuates cardiac dysfunction and inflammation in myocarditis
  Shunsuke Ohnishi
  Biochemical and Biophysical Research Communications, 356, 1, 60, 66, 2007, [Peer-reviewed]
  English, Scientific journal
• Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis
  Nagaya, Noritoshi; Kitamura, Soichiro; Kangawa, Kenji; Ishibashi-Ueda, Hatsue; Kodama, Makoto; Kataoka, Masaharu; Obata, Hiroaki; Miyahara, Yoshinori; Tanaka, Koichi; Yanagawa, Bobby; Ohnishi, Shunsuke
  Journal of Molecular and Cellular Cardiology, 42, 1, 88, 97, 2007, [Peer-reviewed]
  English, Scientific journal
• Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions
  Noritoshi Nagaya; Soichiro Kitamura; Hideaki Sumiyoshi; Shunsuke Ohnishi
  FEBS Letters, 581, 21, 3961, 3966, 2007, [Peer-reviewed]
  English, Scientific journal
• Gene expression profiles of endothelial progenitor cells by oligonucleotide microarray analysis
  Ohnami, Shumpei; Yoshida, Teruhiko; Sakamoto, Hiromi; Sasaki, Hiroki; Aoyagi, Kazuhiko; Ohnishi, Shunsuke; Aoki, Kazunori; Oki, Masayuki; Ando, Kiyoshi; Furuhata, Souichi
  Molecular and Cellular Biochemistry, 298, 1-2, 125, 138, 2007, [Peer-reviewed]
  English, Scientific journal
• Prepare cells to repair the heart: Mesenchymal stem cells for the treatment of heart failure
  Nagaya, Noritoshi; Ohnishi, Shunsuke
  American Journal of Nephrology, 27, 3, 301, 307, 2007, [Peer-reviewed]
  English, Scientific journal
• Effect of Hypoxia on Gene Expression of Bone Marrow-Derived Mesenchymal Stem Cells and Mononuclear Cells
  Noritoshi Nagaya; Soichiro Kitamura; Takeshi Yasuda; Shunsuke Ohnishi
  Stem Cells, 25, 5, 1166, 1177, 2007, [Peer-reviewed]
  English, Scientific journal
• Novel expansion/shrinkage modulation of 2D layered MOF triggered by clathrate formation with CO2 molecules
  Atsushi Kondo; Hiroshi Noguchi; Shunsuke Ohnishi; Hiroshi Kajiro; Aya Tohdoh; Yoshiyuki Hattori; Wei-Chun Xu; Hideki Tanaka; Hirofumi Kanoh; Katsumi Kaneko
  NANO LETTERS, 6, 11, 2581, 2584, Nov. 2006, [Peer-reviewed]
  English, Scientific journal
• Radiolabeled and near-infrared fluorescent fibrinogen derivatives create a system for the identification and repair of obscure gastrointestinal bleeding
  Shunsuke Ohnishi; Evan S. Garfein; Seth J. Karp; John V. Frangioni
  SURGERY, 140, 5, 785, 792, Nov. 2006, [Peer-reviewed]
  English, Scientific journal
• Transplantation of mesenchymal stem cells improves atrioventricular conduction in a rat model of complete atrioventricular block
  Miki Yokokawa; Shunsuke Ohnishi; Hatsue Ishibashi-Lieda; Masashi Inagaki; Hiroaki Obata; Yoshinori Miyahara; Koichi Tanaka; Wataru Shimizu; Kenji Kangawa; Shiro Kamakura; Soichiro Kitamura; Noritoshi Nagaya
  CIRCULATION, 114, 18, 80, 80, Oct. 2006, [Peer-reviewed]
  English, Scientific journal
• Single administration of a novel sustained-release prostacyclin analogue attenuates monocrotaline-induced pulmonary hypertension in rats
  Hiroaki Obata; Yoshiki Sakai; Shunsuke Ohnishi; Satoshi Takeshita; Hidezo Mori; Makoto Kodama; Yoshifusa Aizawa; Noritoshi Nagaya
  CIRCULATION, 114, 18, 83, 83, Oct. 2006, [Peer-reviewed]
  English
• Overexpression of the oncoprotein prothymosin α triggers a p53 response that involves p53 acetylation
  Takahiko Kobayashi; Ting Wang; Masaji Maezawa; Masanobu Kobayashi; Shunsuke Ohnishi; Kazuteru Hatanaka; Shuhei Hige; Yuichi Shimizu; Mototsugu Kato; Masahiro Asaka; Junji Tanaka; Masahiro Imamura; Kiminori Hasegawa; Yoshiyuki Tanaka; Rainer K. Brachmann
  Cancer Research, 66, 6, 3137, 3144, 15 Mar. 2006, [Peer-reviewed]
  English, Scientific journal
• Engineering InAsxP1-x/InP/ZnSe III-V alloyed core/shell quantum dots for the near infrared
  Sang-Wook Kim; John P. Zimmer; Shunsuke Ohnishi; Joseph B. Tracy; John V. Frangioni; Moungi G. Bawendi
  ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 231, Mar. 2006, [Peer-reviewed]
  English
• Tissue-like phantoms for near-infrared fluorescence imaging system assessment and the training of surgeons
  De Grand, AM; Lomnes, SJ; Lee, DS; Pietrzykowski, M.; Ohnishi, S.; Morgan, TG; Gogbashian, A.; Laurence, RG; Frangioni, JV
  Journal of Biomedical Optics, 11, 1, 2006
  Scientific journal
• Size series of small indium arsenide-zinc selenide core-shell nanocrystals and their application to in vivo imaging
  Zimmer, JP; Kim, SW; Ohnishi, S.; Tanaka, E.; Frangioni, JV; Bawendi, MG
  Journal of the American Chemical Society, 128, 8, 2006
  Scientific journal
• Intraoperative detection of cell injury and cell death with an 800 nm near-infrared fluorescent annexin V derivative
  Ohnishi, S.; Vanderheyden; J. -L.; Tanaka, E.; Patel, B.; De Grand; A. M.; Laurence, R. G.; Yamashita, K.; Frangioni, J.
  American Journal of Transplantation, 6, 10, 2006
  Scientific journal
• Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats
  Miyahara, Yoshinori; Ohnishi, Shunsuke; Obata, Hiroaki; Ishino, Kozo; Sano, Shunji; Mori, Hidezo; Kangawa, Kenji; Kitamura, Soichiro; Nagaya, Noritoshi
  Biochemical and Biophysical Research Communications, 349, 4, 1242, 1249, 2006, [Peer-reviewed]
  English, Scientific journal
• Organic Alternatives to Quantum Dots for Intraoperative Near-Infrared Fluorescent Sentinel Lymph Node Mapping
  Shunsuke Ohnishi; Stephen J. Lomnes; Rita G. Laurence; Andrew Gogbashian; Giuliano Mariani; John V. Frangioni
  MOLECULAR IMAGING, 4, 3, 172, 181, Jul. 2005, [Peer-reviewed]
  English, Scientific journal
• Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging
  Shunsuke Ohnishi
  The Journal of Thoracic and Cardiovascular Surgery, 2005
  Scientific journal
• Engineering InAs _x P _{1- x} /InP/ZnSe III−V Alloyed Core/Shell Quantum Dots for the Near-Infrared
  Shunsuke Ohnishi
  Journal of the American Chemical Society, 2005
  Scientific journal
• High-affinity Near-infrared Fluorescent Small-molecule Contrast Agents for In Vivo Imaging of Prostate-specific Membrane Antigen
  Shunsuke Ohnishi
  Molecular Imaging, 2005
  Scientific journal
• In Vivo Optical Imaging of Pleural Space Drainage to Lymph Nodes of Prognostic Significance
  Shunsuke Ohnishi
  Annals of Surgical Oncology, 2004
  Scientific journal
• Massive Invasion of Hepatocellular Carcinoma to the Duodenum:
  Shunsuke Ohnishi
  Clinical Oncology, 2004
  Scientific journal
• Hyperammonemic encephalopathy in a patient with ureterosigmoidostomy and acute hepatitis: A specific case of fulminant hepatic failure
  Shunsuke Ohnishi; Takeshi Yoshida; Hiroaki Makiyama; Katsuya Usui; Mayumi Kudo; Takahiko Kobayashi; Shuhei Hige; Masahiro Asaka
  Digestive Diseases and Sciences, 48, 4, 821, 823, 01 Apr. 2003
  English, Scientific journal
• Acute hepatitis with Salmonella paratyphi A and hepatitis E virus coinfection
  Shunsuke Ohnishi
  Journal of Clinical Gastroenterology, 2003
  Scientific journal
• Diffuse Neonatal Hemangiomatosis Without Cutaneous Lesions in an Adult
  Shunsuke Ohnishi
  Angiology, 2002
  Scientific journal
• Developmental expression of mouse Krüppel-like transcription factor KLF7 suggests a potential role in neurogenesis
  Friedrich Laub; Rafael Aldabe; Victor Friedrich Jr.; Shunsuke Ohnishi; Teruhiko Yoshida; Francesco Ramirez
  Developmental Biology, 233, 2, 305, 318, Academic Press Inc., 15 May 2001, [Peer-reviewed]
  English, Scientific journal
• Developmental expression of the mouse gene coding for the Kruppel-like transcription factor KLF5
  Shunsuke Ohnishi; Friedrich Laub; Nobuyuki Matsumoto; Masahiro Asaka; Francesco Ramirez; Teruhiko Yoshida; Masaaki Terada
  Developmental Dynamics, 217, 4, 421, 429, 2000, [Peer-reviewed]
  English, Scientific journal
• A case of G-CSF producing malignant fibrous histiocytoma of the small intestine
  Makoto Chuma; Hiroki Nakaya; Hisashi Oda; Shigeki Hatakeyama; Shunsuke Ohnishi; Kenichi Kumagai; Gong Heun Choi; Takahiko Kobayashi; Kiichiro Kamiya; Takuto Miyagishima; Tatsuro Takahashi
  Japanese Journal of Gastroenterology, 94, 5, 340, 345, The Japanese Society of Gastroenterology, May 1997, [Peer-reviewed]
  Japanese, Scientific journal
• Intraluminal tumor of the common bile duct as a metastasis of renal cell carcinoma
  Shunsuke Ohnishi
  Internal medicine (Tokyo, Japan), 1996
  Scientific journal

• THE USE OF A NOVEL BIOABSORBABLE SHEET AND HYDROGEL FACILITATES PERFORATION CLOSURE AND WOUND REGENERATION AFTER COLONIC ENDOSCOPIC SUBMUCOSAL DISSECTION IN PIGS
  Hiroki Egami; Masayoshi Ono; Keisuke Ishida; Takayuki Kurokawa; Takayuki Sone; Shoko Ono; Shunsuke Ohnishi; Naoya Sakamoto, GASTROINTESTINAL ENDOSCOPY, 101, 5, May 2025
  English, Summary international conference
• 補中益気湯の作用メカニズム ～高齢低栄養患者における体力増強～
  名畑 美和; 最上 祥子; 藤塚 直樹; 大西 俊介; 武田 宏司, 外科と代謝・栄養, 59, 2, 48, 51, 15 Apr. 2025
  低栄養は病後・術後の回復力を弱め，感染症や死亡のリスクを高める．高年齢では栄養サポートによる改善効果が低いことが臨床や実験動物で報告されており，低栄養状態に陥ったときの代償機構が働きにくい．そのため，高齢患者の栄養管理には特に注意が必要である．補給されたアミノ酸の代謝にはオートファジー活性やミトコンドリアの品質管理が重要であるが，加齢によりこれらの機能が低下し，活動・生存に必要なエネルギーが不足しやすくなると考えられる．
  
   補中益気湯は病後・術後の体力増強に処方される漢方薬であり，高齢患者において免疫状態や栄養状態の改善作用が報告されている．本稿では，加齢と栄養の観点から補中益気湯の作用機序を概説する．, 日本外科代謝栄養学会, Japanese
• 消化器内視鏡医が挑む,産学官連携によるデバイス開発の最前線~現状とそこから見える課題~
  大野正芳; 大西俊介; 坂本直哉, 肝臓, 66, Supplement 2, 2025
• TGF-β-decoy EVを用いた線維化シグナル抑制
  山之内海心; 細野秀崇; 中嶋楓; 前原経; 柘植厚志; 大久保直登; 大西俊介, 日本再生医療学会総会(Web), 24th, 2025
• クローン病に伴う痔瘻モデル作製の試み
  小松葉月; 柘植厚志; 杉浦弘周; 飯田千菜; 川村芳江; 河南雅成; 前原経; 大久保直登; 大西俊介, 日本再生医療学会総会(Web), 24th, 2025
• 羊膜間葉系幹細胞由来液性因子HSPB6の抗炎症効果についての検討
  太田友里奈; 前原経; 酒井真央; 小林美春; 武井則雄; 柘植厚志; 大久保直登; 林真広; 中石智之; 大西俊介, 日本再生医療学会総会(Web), 24th, 2025
• 羊膜MSC由来細胞外小胞の食道内視鏡的粘膜下層剥離術後狭窄に対する予防効果
  曽根孝之; 曽根孝之; 大野正芳; 江上太基; 小野尚子; 坂本直哉; 大西俊介, 日本再生医療学会総会(Web), 24th, 2025
• 羊膜間葉系幹細胞由来細胞外小胞はESD後の食道狭窄を予防する
  曽根孝之; 曽根孝之; 大野正芳; 江上太基; 早坂秀平; 小野尚子; 坂本直哉; 大西俊介, 日本消化器病学会雑誌(Web), 122, 2025
• 新規生体吸収性素材とハイドロゲルを用いた内視鏡的絆創膏の開発
  大野正芳; 石田啓補; 黒川孝幸; 井上雅貴; 宮本秀一; 山本桂子; 小野尚子; 大西俊介; 坂本直哉, 日本消化器病学会雑誌(Web), 121, 2024
• ブタ大腸内視鏡治療モデルを用いたESD後創部評価~新規生体吸収性素材とハイドロゲルを用いた内視鏡的絆創膏の効果~
  江上太基; 大野正芳; 石田啓輔; 黒川孝幸; 早坂秀平; 中島早慧; 曽根孝之; 東野真幸; 井上雅貴; 宮本秀一; 山本桂子; 小野尚子; 大西俊介; 坂本直哉, Gastroenterological Endoscopy (Web), 66, Supplement1, 2024
• ポリグリコール酸シートと塩基性線維芽細胞増殖因子を用いたESD後の食道狭窄に対する新規予防法の開発
  西村友佑; 大野正芳; 坂本直哉; 大久保直登; 曽根孝之; 東野真幸; 松本将吾; 久保茉理奈; 山本桂子; 小野尚子; 大西俊介, Gastroenterological Endoscopy (Web), 65, Supplement1, 2023
• 特集 手術に役立つ蛍光法のすべて II. 上部消化管 2.新規蛍光プローブを用いた食道癌同定の可能性
  山本 桂子; 大西 俊介, 外科, 84, 12, 1236, 1241, 01 Nov. 2022
  南江堂, Japanese
• 間葉系幹細胞を用いた消化管疾患の再生医療—Regenerative medicine for the treatment of gastrointestinal diseases using mesenchymal stem cells—再生医療の現状と展望
  大西 俊介, Bio clinica = バイオクリニカ, 37, 12, 1094, 1097, Nov. 2022
  東京 : 北隆館, Japanese
• 新規生体吸収性素材に接着機能加えた内視鏡的絆創膏の開発
  大野正芳; 大西俊介; 坂本直哉; 松本将吾; 西村友佑; 久保茉理奈; 霜田佳彦; 田中一光; 山本桂子; 小野尚子, Gastroenterological Endoscopy (Web), 64, Supplement1, 2022
• Synthesis and evaluation of ⁶⁸Ga-labeled probes based on transferrin receptor targeting linear peptides
  水野雄貴; 水野雄貴; 三浦春香; 安井博宣; 柴田悠貴; 大久保直登; 前原経; 武田宏司; 大西俊介; 久下裕司; 久下裕司, 日本薬学会年会要旨集(Web), 142nd, 2022
• SUMMING UP 消化器研究最前線 第33回
  杉山 敏郎; 久保田 英嗣; 片岡 洋望; 大西 俊介; 半田 修; 杉本 光繁; 下平 陽介; 飯島 克則, THE GI FOREFRONT, 17, 1, 56, 62, 30 Oct. 2021
  メディカルレビュー社
• 知らなきゃ損 腸管免疫学っておもしろい!(第14回)間葉系幹細胞のキホン
  大西 俊介, 消化器病学サイエンス = Science of gastroenterology / 「消化器病学サイエンス」編集委員会 編, 4, 4, 235, 239, Dec. 2020
  東京 : 先端医学社, Japanese
• 特集 分子標的時代のIBD 診療 -IBD の寛解導入,寛解維持の実践 3.IBD 治療における寛解導入と寛解維持に関するトピック(4)IBD 寛解導入療法における再生医療
  小田切 信介; 大西 俊介; 桂田 武彦; 坂本 直哉, 臨床消化器内科, 35, 10, 1263, 1266, 20 Aug. 2020
  日本メディカルセンター
• 食欲不振,嘔気,嘔吐
  大西 俊介, 臨床外科, 75, 3, 328, 333, Mar. 2020
  (株)医学書院, Japanese
• FGFR阻害剤およびMEK阻害剤は食道扁平上皮癌(ESCC)がん幹細胞を減少させる
  前原経; 夏井坂光輝; 須田剛生; 大西俊介; 坂本直哉; 武田宏司, 日本消化管学会雑誌, 4, Supplement, 2020
• 生体ブタ全周性食道ESD施行後のバルーン拡張時の病理組織学的検討
  木脇佐代子; 清水勇一; 大西俊介; 大野正芳; 楊子健; 霜田佳彦; 井上雅貴; 田中一光; 石川麻倫; 山本桂子; 小野尚子; 坂本直哉, Gastroenterological Endoscopy (Web), 62, Supplement1, 2020
• FGFR阻害剤およびMEK阻害剤は食道扁平上皮癌(ESCC)がん幹細胞を減少させる
  前原 経; 夏井坂 光輝; 須田 剛生; 大西 俊介; 坂本 直哉; 武田 宏司, 日本消化管学会雑誌, 4, Suppl., 301, 301, Jan. 2020
  (一社)日本消化管学会, Japanese
• 【肝胆膵の線維化up-to-date】肝臓の線維化 基礎研究 間葉系幹細胞による肝線維化治療
  大原 正嗣; 大西 俊介; 坂本 直哉, 肝・胆・膵, 79, 5, 853, 859, Nov. 2019
  (株)アークメディア, Japanese
• 消化器疾患と再生医療 Tissue Engineering技術を利用した臓器復元
  宮澤 光男; 合川 公康; 大西 俊介, 日本消化器病学会雑誌, 116, 臨増大会, A522, A522, Nov. 2019
  (一財)日本消化器病学会, Japanese
• 腹腔鏡下胆道再建術の工夫と治療成績 術後吻合部狭窄を招かない腹腔鏡下胆道再建法の検討 生体吸収性材料を用いた胆管再生モデルより
  宮澤 光男; 合川 公康; 大西 俊介, 胆道, 33, 3, 449, 449, Oct. 2019
  日本胆道学会, Japanese
• 消化管外科手術における縫合不全対策について考える1 生体吸収性材料を用いた新規吻合部縫合不全対策法の開発
  宮澤 光男; 合川 公康; 岡田 克也; 渡邉 幸博; 大西 俊介; 小林 宏寿; 谷口 桂三, 日本臨床外科学会雑誌, 80, 増刊, 342, 342, Oct. 2019
  日本臨床外科学会, Japanese
• 肝細胞癌細胞株においてメトホルミンはAMPK-CEBPβ経路を介してCD133の発現を制御する(Metformin regulates the expression of CD133 through the AMPK-CEBPβ pathway in hepatocellular carcinoma cell lines)
  前原 経; 大西 俊介; 夏井坂 光輝; 坂本 直哉, 日本癌学会総会記事, 78回, P, 3258, Sep. 2019
  日本癌学会, English
• 【漢方の今、これから】漢方療法のランダム化研究やビッグデータ解析 シスプラチン/パクリタキセル併用療法を受ける子宮頸癌・体癌患者における嘔気・嘔吐に対する六君子湯の効果
  大西 俊介; 渡利 英道, 産科と婦人科, 86, 8, 947, 950, Aug. 2019
  (株)診断と治療社, Japanese
• 消化器内視鏡診療におけるトランスレーショナルリサーチ DPP-IV活性により蛍光を発するプローブによる食道胃接合部腺癌の検出
  山本 桂子; 大西 俊介; 坂本 直哉, Gastroenterological Endoscopy, 61, Suppl.1, 822, 822, May 2019
  (一社)日本消化器内視鏡学会, Japanese
• ヒト羊膜由来間葉系幹細胞を用いた再生医療研究
  山本 幸司; 大西 俊介, 遺伝子医学, 9, 2, 74, 76, Apr. 2019
  (株)メディカルドゥ, Japanese
• 消化器領域における幹細胞研究とその応用 間葉系幹細胞から分泌される生理活性脂質の抗炎症・抗線維化効果
  小田切 信介; 大西 俊介; 坂本 直哉, 日本消化器病学会雑誌, 116, 臨増総会, A87, A87, Mar. 2019
  (一財)日本消化器病学会, Japanese
• 動物実験従事者におけるアレルギー健診5年分の経年的解析
  吉村 彩; 武藏 学; 折戸 智恵子; 川原 由佳子; 横田 卓; 大西 俊介; 橋野 聡, CAMPUS HEALTH, 56, 1, 239, 241, Mar. 2019
  実験動物取り扱い関係者においてみられる職業性アレルギーである実験動物アレルギーについて、本学(大学)では、平成22年度に実験中にマウスに咬まれてアナフィラキシーショックを起こした事例が発生したことを機に、23年度より毎年、動物実験従事者のうち希望者に対し取り扱い動物の特異的IgE抗体検査を含むアレルギー健診を実施しており、今回、23年度から5年間連続してアレルギー健診を受診した21名(男性10名、女性11名、平均年齢42.0±10.6歳)を対象に、経年的解析を行った。その結果、5年間連続して同種の抗体検査を実施した者は、マウスIgE抗体19名、ラットIgE抗体10名、ウサギIgE抗体3名で、マウス、ラットのIgE抗体陽性率は有意差はなく横ばい状態であった。また、個人間での抗体価の変動についても、マウス、ラットともに受診者の約60%は陰性のまま推移していた。, (公社)全国大学保健管理協会, Japanese
• DPP-IV活性により蛍光を発するプローブによる頭頸部扁平上皮表在がんの検出
  山本 桂子; 大西 俊介; 水島 健; 清水 勇一; 坂本 直哉, 耳鼻咽喉科展望, 62, 1, 42, 43, Feb. 2019
  耳鼻咽喉科展望会, Japanese
• 国産ウシ多血小板血漿由来血清「NeoSERA」を用いた各種MSCの製剤化-ウシ胎児血清との比較
  山原研一; 山原研一; 山原研一; 山原研一; 浜田彰子; 大西俊介; 高田竜治; 須藤稔太; 岡本里香; 豊嶋崇徳; 磯江敏幸; 佐藤典宏; 藤盛好啓; 藤盛好啓; 藤盛好啓, 日本再生医療学会総会(Web), 18th, 2019
• 糖尿病治療薬メトホルミンによるAMPK-CEBPβ経路を介したがん幹細胞マーカーCD133の発現制御
  大西俊介; 前原経; 浅野彩華; 須田剛生; 夏井坂光輝; 中川宏治; 小林正伸; 坂本直哉; 武田宏司, 日本分子生物学会年会プログラム・要旨集(Web), 42nd, 2019
• 羊膜間葉系幹細胞由来細胞外小胞の慢性肝障害モデルに対する抗炎症・抗線維化効果
  大原正嗣; 大西俊介; 山本幸司; 付慶傑; 前原経; 須田剛生; 坂本直哉, 日本再生医療学会総会(Web), 18th, 2019
• サイトカインリッチな成牛多血小板血漿由来血清「NeoSERA」を用いた高品質羊膜MSCの製剤化と急性GVHD・クローン病向け医師主導治験
  山原 研一; 浜田 彰子; 黒田 将子; 岡田 昌也; 吉原 哲; 大西 俊介; 相馬 俊裕; 豊嶋 崇徳; 小川 啓恭; 藤盛 好裕, 日本内分泌学会雑誌, 94, 4, 1573, 1573, Dec. 2018
  (一社)日本内分泌学会, Japanese
• ポリグリコール酸(PGA)不織布は自動縫合器の吻合部補強材として最適か?
  宮澤 光男; 合川 公康; 岡田 克也; 渡邉 幸博; 谷口 桂三; 藤野 昇三; 大西 俊介, 日本内視鏡外科学会雑誌, 23, 7, OS36, 5, Dec. 2018
  (一社)日本内視鏡外科学会, Japanese
• 創傷治癒を補助する細胞療法 炎症を標的とした細胞治療による創傷治癒戦略
  大西 俊介, 日本創傷治癒学会プログラム・抄録集, 48回, 101, 101, Nov. 2018
  (一社)日本創傷治癒学会, Japanese
• 羊膜由来間葉系幹細胞の治療応用
  大西 俊介, 日本創傷治癒学会プログラム・抄録集, 48回, 143, 143, Nov. 2018
  (一社)日本創傷治癒学会, Japanese
• 長期予後改善をめざす自己免疫性肝疾患の基礎と臨床 薬剤誘発硬化性胆管炎ラットに対するヒト羊膜由来間葉系幹細胞の治療効果
  杉浦 諒; 大西 俊介; 坂本 直哉, 日本消化器病学会雑誌, 115, 臨増大会, A606, A606, Oct. 2018
  (一財)日本消化器病学会, Japanese
• Tissue engineeringによる人工臓器作成 Tissue engineeringにより臓器復元が可能である
  宮澤 光男; 合川 公康; 岡田 克也; 渡邉 幸博; 大西 俊介, 人工臓器, 47, 2, S, 16, Oct. 2018
  (一社)日本人工臓器学会, Japanese
• 【消化器病漢方治療-理論と実践】理論 漢方薬作用機序の科学的解明 六君子湯
  武田 宏司; 大久保 直登; 中川 宏治; 大西 俊介; 藤塚 直樹; 服部 智久, 臨床消化器内科, 33, 11, 1349, 1356, Sep. 2018
  (株)日本メディカルセンター, Japanese
• 動物実験従事者におけるアレルギー健診5年分の経年的解析
  吉村 彩; 武藏 学; 折戸 智恵子; 川原 由佳子; 横田 卓; 大西 俊介; 橋野 聡, 全国大学保健管理研究集会プログラム・抄録集, 56回, 70, 70, Sep. 2018
  (公社)全国大学保健管理協会, Japanese
• 傷害肝の修復を目指す抗線維化・肝再生研究の展望 羊膜間葉系幹細胞由来細胞外小胞の慢性肝障害モデルに対する抗炎症・抗線維化効果
  大原 正嗣; 大西 俊介; 坂本 直哉, 肝臓, 59, Suppl.2, A625, A625, Sep. 2018
  (一社)日本肝臓学会, Japanese
• 酵素活性により蛍光を発するプローブの局所散布による早期胃食道接合部癌の検出(Detection of carcinoma of the esophagogastric junction by topically spraying enzymatically activatable fluorescent probe)
  大西 俊介; 山本 桂子; 清水 勇一; 水島 健; 畑中 豊; 畑中 佳奈子; 栗木 優五; 神谷 真子; 浦野 泰照; 坂本 直哉, 日本癌学会総会記事, 77回, 786, 786, Sep. 2018
  日本癌学会, English
• 急性GVHD・クローン病に対する羊膜由来間葉系幹細胞の医師主導治験 兵庫医科大学発・初認定ベンチャーによる開発をめざして
  山原 研一; 濱田 彰子; 大西 俊介; 相馬 俊裕; 岡本 里香; 中村 志郎; 岡田 昌也; 吉原 哲; 吉原 享子; 橋本 大吾; 磯江 敏幸; 豊嶋 崇徳; 佐藤 典宏; 藤盛 好啓, 兵庫医科大学医学会雑誌, 43, 1, 41, 45, Sep. 2018
  兵庫医科大学医学会, Japanese
• 術後狭窄 良性胆管狭窄治療のための必要条件 人工胆管を用いた胆管再生モデルによる検討
  宮澤 光男; 合川 公康; 大西 俊介, 胆道, 32, 3, 498, 498, Aug. 2018
  日本胆道学会, Japanese
• Cell therapy for acute GVHD using human amnion-derived MSC
  山原 研一; 濵田 彰子; 大西 俊介; 黒田 将子; 相馬 俊裕; 岡本 里香; 岡田 昌也; 吉原 哲; 吉原 享子; 橋本 大吾; 磯江 敏幸; 豊嶋 崇徳; 佐藤 典宏; 小川 啓恭; 藤盛 好啓, 臨床免疫・アレルギー科 = Clinical immunology & allergology, 70, 1, 18, 24, Jul. 2018
  科学評論社, Japanese
• DPP-IV活性により蛍光を発するプローブによる食道胃接合部腺癌の検出
  山本 桂子; 大西 俊介; 坂本 直哉, Gastroenterological Endoscopy, 60, Suppl.1, 715, 715, Apr. 2018
  (一社)日本消化器内視鏡学会, Japanese
• Palmitoylethanolamideの星細胞活性化抑制およびラット肝線維症モデルにおける抗線維化効果
  大原正嗣; 大西俊介; 須田剛生; 坂本直哉, 肝臓, 59, Suppl.1, A528, A528, Apr. 2018
  (一社)日本肝臓学会, Japanese
• 国産成牛多血小板血漿由来血清「NeoSERA」を用いた羊膜MSC製剤化と急性GVHD・クローン病向け医師主導治験
  山原研一; 山原研一; 浜田彰子; 大西俊介; 高田竜治; 須藤稔太; 岡本里香; 豊嶋崇徳; 磯江敏幸; 佐藤典宏; 藤盛好啓, 日本再生医療学会総会(Web), 17th, 2018
• 血清中のスフィンゴ糖脂質および遊離オリゴ糖鎖に特異的なABO式血液型抗原の解析
  岡田 和恵; 横田 育子; 花松 久寿; 三浦 信明; 大西 俊介; 湯山 耕平; 酒井 祥太; 伊東 信; 五十嵐 靖之; 坂本 直哉; 篠原 康郎; 古川 潤一, 生命科学系学会合同年次大会, 2017年度, [2P, 0021], Dec. 2017
  生命科学系学会合同年次大会運営事務局, Japanese
• 「それぞれの生」支持療法の工夫 嘔気対策・栄養管理 シスプラチン/パクリタキセル療法による嘔気・嘔吐・食欲不振に対する六君子湯の効果
  大西 俊介; 渡利 英道; 勘野 真紀; 大場 洋子; 竹内 聡; 宮路 天平; 小山田 隼佑; 野村 英司; 加藤 秀則; 杉山 徹; 浅香 正博; 櫻木 範明; 山口 拓洋; 上園 保仁; 岩瀬 哲, 日本癌治療学会学術集会抄録集, 55回, WS5, 5, Oct. 2017
  (一社)日本癌治療学会, Japanese
• 重症妊娠高血圧腎症術後に周産期心筋症をきたした1例
  大西 俊介; 常見 泰平; 橋口 康弘; 山尾 佳穂; 中野 和俊; 赤坂 珠理晃; 藤井 絵里子; 佐道 俊幸; 小林 浩, 産婦人科の進歩, 69, 4, 512, 512, Oct. 2017
  「産婦人科の進歩」編集室, Japanese
• 「それぞれの生」支持療法の工夫 嘔気対策・栄養管理 シスプラチン/パクリタキセル療法による嘔気・嘔吐・食欲不振に対する六君子湯の効果
  大西 俊介; 渡利 英道; 勘野 真紀; 大場 洋子; 竹内 聡; 宮路 天平; 小山田 隼佑; 野村 英司; 加藤 秀則; 杉山 徹; 浅香 正博; 櫻木 範明; 山口 拓洋; 上園 保仁; 岩瀬 哲, 日本癌治療学会学術集会抄録集, 55回, WS5, 5, Oct. 2017
  (一社)日本癌治療学会, Japanese
• 大腸ESD/EMRの課題と将来展望 ブタ大腸ESD後狭窄モデルに対する羊膜間葉系幹細胞由来培養上清の注腸投与による狭窄予防効果
  津田 桃子; 大西 俊介; 坂本 直哉, Gastroenterological Endoscopy, 59, Suppl.2, 2019, 2019, Sep. 2017
  (一社)日本消化器内視鏡学会, Japanese
• 粘膜下局注併用APCと標準的APCの生体ブタ組織に対する焼灼効果の検討
  安孫子 怜史; 清水 勇一; 大西 俊介; 水島 健; 加藤 麻倫; 松田 可奈; 宮本 秀一; 津田 桃子; 山本 桂子; 小野 尚子; 工藤 俊彦; 坂本 直哉, Gastroenterological Endoscopy, 59, Suppl.2, 2223, 2223, Sep. 2017
  (一社)日本消化器内視鏡学会, Japanese
• Dipeptidylpeptidase-IVの酵素活性により蛍光を発するプローブによる頭頸部表在癌の検出
  大西 俊介; 水島 健; 清水 勇一; 畑中 豊; 畑中 佳奈子; 山本 桂子; 本間 明宏; 栗木 優五; 神谷 真子; 浦野 泰照; 坂本 直哉, 日本癌学会総会記事, 76回, P, 2320, Sep. 2017
  日本癌学会, English
• Innovative therapeutic endoscopy 大腸ESD/EMRの課題と将来展望 ブタ大腸ESD後狭窄モデルに対する羊膜間葉系幹細胞由来培養上清の注腸投与による狭窄予防効果
  津田 桃子; 大西 俊介; 坂本 直哉, 日本消化器病学会雑誌, 114, 臨増大会, A557, A557, Sep. 2017
  (一財)日本消化器病学会, Japanese
• 大腸ESD/EMRの課題と将来展望 ブタ大腸ESD後狭窄モデルに対する羊膜間葉系幹細胞由来培養上清の注腸投与による狭窄予防効果
  津田 桃子; 大西 俊介; 坂本 直哉, Gastroenterological Endoscopy, 59, Suppl.2, 2019, 2019, Sep. 2017
  (一社)日本消化器内視鏡学会, Japanese
• 粘膜下局注併用APCと標準的APCの生体ブタ組織に対する焼灼効果の検討
  安孫子 怜史; 清水 勇一; 大西 俊介; 水島 健; 加藤 麻倫; 松田 可奈; 宮本 秀一; 津田 桃子; 山本 桂子; 小野 尚子; 工藤 俊彦; 坂本 直哉, Gastroenterological Endoscopy, 59, Suppl.2, 2223, 2223, Sep. 2017
  (一社)日本消化器内視鏡学会, Japanese
• 介護保険施設・事業所における生活環境構築のための課題と工夫 認知症介護実践研修受講者に対する自由記述回答の分析
  宮野 順子; 相良 二朗; 北川 博巳; 大森 清博; 大西 俊介; 中園 正吾; 三谷 信之, 老年社会科学, 39, 2, 255, 255, Jun. 2017
  日本老年社会科学会, Japanese
• 腰椎麻酔下帝王切開術後における高アミラーゼ血症に対する予測因子の後方視的検討
  大西 俊介; 藤本 佳克; 今中 聖悟; 丸山 祥代; 山下 健, 日本周産期・新生児医学会雑誌, 53, 1, 83, 87, May 2017
  当院で腰椎麻酔下に帝王切開術を施行した370例を対象に、術後の高アミラーゼ血症に関与する因子について検討した。その結果、術後の高アミラーゼ血症は94例で認められた。術後の高アミラーゼ血症には術中の血圧低下、嘔気・嘔吐による唾液腺の機械的刺激や胸腔内圧の上昇が関与する可能性が示唆された。, (一社)日本周産期・新生児医学会, Japanese
• 食道狭窄の内視鏡治療 羊膜由来間葉系幹細胞の培養上清を用いた内視鏡的食道粘膜下層剥離術後狭窄に対する新規治療法の開発
  水島 健; 大西 俊介; 坂本 直哉, Gastroenterological Endoscopy, 59, Suppl.1, 910, 910, Apr. 2017
  (一社)日本消化器内視鏡学会, Japanese
• DPP-IV活性により蛍光を発するプローブによる頭頸部扁平上皮表在がんの検出
  山本 桂子; 大西 俊介; 坂本 直哉, 日本消化器病学会雑誌, 114, 臨増総会, A253, A253, Mar. 2017
  (一財)日本消化器病学会, Japanese
• 大量胸・腹水を契機に診断された純粋型卵巣原発扁平上皮癌の一例
  藤本 佳克; 丸山 祥代; 大西 俊介; 山下 健, 日本産科婦人科学会雑誌, 69, 2, 813, 813, Feb. 2017
  (公社)日本産科婦人科学会, Japanese
• 粘膜下局注併用APCと標準的APCの生体ブタ組織に対する焼灼効果の検討
  安孫子怜史; 清水勇一; 大西俊介; 水島健; 加藤麻倫; 松田可奈; 宮本秀一; 津田桃子; 山本桂子; 小野尚子; 工藤俊彦; 坂本直哉, Gastroenterological Endoscopy (Web), 59, Supplement2, 2017
• シスプラチン+パクリタキセル療法による悪心・嘔吐,食欲不振に対する六君子湯の効果—特集 がんの支持療法と漢方薬
  大西 俊介, 漢方医学 = Science of kampo medicine, 41, 3, 148, 151, 2017
  東京 : 協和企画, Japanese
• 血清中のスフィンゴ糖脂質および遊離オリゴ糖鎖に特異的な血液型抗原の解析
  横田育子; 花松久寿; 大西俊介; 岡田和恵; 湯山耕平; 酒井祥太; 伊東信; 五十嵐靖之; 坂本直哉; 篠原康郎; 古川潤一, 日本糖質学会年会要旨集, 36th, 2017
• 【臨床応用を見据えた肝線維化研究の新展開】 治療 羊膜由来間葉系幹細胞投与による肝線維化治療
  大西 俊介; 久保 公利; 坂本 直哉, 肝・胆・膵, 74, 1, 95, 98, Jan. 2017
  (株)アークメディア, Japanese
• 頭頸・口腔 頭頸部がんの集学的治療 表在性頭頸部扁平上皮癌のGGT活性化標的薬を用いた蛍光イメージング(Fluorescent imaging of superficial head and neck squamous cell carcinoma using a GGT-Activated targeting agent)
  大西 俊介; 水島 健; 清水 勇一; 畑中 豊; 畑中 佳奈子; 本間 明宏; 浦野 泰照; 坂本 直哉, 日本癌治療学会学術集会抄録集, 54回, WS81, 6, Oct. 2016
  (一社)日本癌治療学会, English
• 消化器領域における再生医療・幹細胞研究の現状 羊膜由来間葉系幹細胞を用いた消化器疾患の再生医療
  大西 俊介; 水島 健; 坂本 直哉, 日本消化器病学会雑誌, 113, 臨増大会, A480, A480, Sep. 2016
  (一財)日本消化器病学会, Japanese
• 高度肥満男子学生における末梢血リンパ球サブセット解析
  吉村 彩; 大西 俊介; 川原 由佳子; 折戸 智恵子; 柏崎 晴彦; 本間 理央; 加納 崇裕; 横田 卓; 橋野 聡, 肥満研究, 22, Suppl., 229, 229, Sep. 2016
  (一社)日本肥満学会, Japanese
• 血清中に含まれる血液型特異的スフィンゴ糖脂質および遊離オリゴ糖鎖の同定
  横田 育子; 古川 潤一; 花松 久寿; 大西 俊介; 岡田 和恵; 湯山 耕平; 酒井 祥太; 伊東 信; 五十嵐 靖之; 坂本 直哉; 篠原 康郎, 日本生化学会大会プログラム・講演要旨集, 89回, [1P, 056], Sep. 2016
  (公社)日本生化学会, Japanese
• 当科における卵巣癌に対するベバシズマブの使用経験
  藤本 佳克; 丸山 祥代; 大西 俊介; 山下 健, 産婦人科の進歩, 68, 3, 298, 299, Aug. 2016
  卵巣癌・腹膜癌・卵管癌の計11例を対象に、ベバシズマブ(BEV)使用経験を報告した。11例中初発治療例は5例(卵巣癌4例、腹膜癌1例)で、年齢は51〜79歳、進行期はIIIC〜IVA期、全例術後化学療法に併用してBEVを使用し、治療効果はCR:3例、SD、PD:各1例であった。再発治療例は6例(卵巣癌4例、腹膜癌、卵巣癌各1例)で、年齢は49〜81歳、進行期は1A〜IIIc期、前治療は主にddTC療法が行われた。プラチナ感受性再発4例、抵抗性再発2例にBEVを使用し、治療効果はCR:4例、PR、PD:各1例であった。全体での奏効率は約8割に達し、奏効例の無再発生存期間は初発例で11〜12ヵ月、再発例で7〜20ヵ月であった。全11例の有害事象は高血圧6例、蛋白尿、鼻出血各3例で、重篤な合併症は認めなかった。高血圧と蛋白尿はBEV投与を重ねるにつれ悪化する傾向を認め、高血圧はやや早期に発症する傾向であった。, 「産婦人科の進歩」編集室, Japanese
• 知的・発達障害者の聴覚過敏に関する実態調査
  大西 俊介; 中園 正吾; 大森 清博, リハ工学カンファレンス講演論文集, 31回, np179, np180, Aug. 2016
  (一社)日本リハビリテーション工学協会, Japanese
• 喫煙妊婦の喫煙状況、喫煙の害についての認知度や喫煙ステージに関する調査
  山下 健; 藤本 佳克; 丸山 祥代; 大西 俊介, 日本周産期・新生児医学会雑誌, 52, 2, 584, 584, Jun. 2016
  (一社)日本周産期・新生児医学会, Japanese
• 胎内診断し得た頭蓋部の羊膜索症候群の1例
  大西 俊介; 藤本 佳克; 丸山 祥代; 山下 健; 夫 律子, 日本周産期・新生児医学会雑誌, 52, 2, 655, 655, Jun. 2016
  (一社)日本周産期・新生児医学会, Japanese
• 間葉系幹細胞を用いた細胞治療 羊膜由来間葉系幹細胞を用いた消化器疾患治療 first-in-human臨床試験へ向けて
  大西 俊介, 日本輸血細胞治療学会誌, 62, 2, 218, 218, Apr. 2016
  (一社)日本輸血・細胞治療学会, Japanese
• 上部消化管におけるAdvanced Diagnostic endscopy for treatment 頭頸部扁平上皮がん早期発見に関する蛍光イメージングの有用性の検討
  水島 健; 大西 俊介; 坂本 直哉, Gastroenterological Endoscopy, 58, Suppl.1, 458, 458, Apr. 2016
  (一社)日本消化器内視鏡学会, Japanese
• 高度肥満学生における高感度CRPの測定意義について
  吉村 彩; 大西 俊介; 川原 由佳子; 折戸 智恵子; 柏崎 晴彦; 本間 理央; 川久保 和道; 加納 崇裕; 横田 卓; 橋野 聡, CAMPUS HEALTH, 53, 1, 106, 108, Mar. 2016
  (公社)全国大学保健管理協会, Japanese
• 肥満学生における簡易型自記式食事調査票(BDHQ)の意義について
  折戸 智恵子; 大西 俊介; 川原 由佳子; 吉村 彩; 柏崎 晴彦; 本間 理央; 川久保 和道; 加納 崇裕; 横田 卓; 橋野 聡, CAMPUS HEALTH, 53, 1, 201, 203, Mar. 2016
  本学の2014年定期健診で肥満と判定された学生22名にBDHQ調査を行い、コントロール群11名と比較した。結果、「摂取エネルギー」「炭水化物」「脂質」などの栄養素に有意な群間差はなかったが、食品では「緑黄色野菜」「漬物」「アイスクリーム」「果物」「洋菓子」の摂取量が肥満群で有意に少なかった。BDHQの結果報告には、おおよその信頼度を示す数値として摂取エネルギーの推定申告誤差が表示されており、±30%の範囲であれば、ある程度信頼度が高いとされる。今回の調査では、両群ともに過少申告者が存在したが、肥満群は-30%以上の割合がコントロール群より多く、信頼度が低かった(過少申告率が高かった)。肥満群には栄養・保健指導を行い、4ヵ月後に再度BDHQ調査を行ったところ、過少申告率は更に高くなっていた。, (公社)全国大学保健管理協会, Japanese
• 消化管疾患における再生医療の最前線 羊膜由来間葉系幹細胞を用いた難治性腸炎に対する新規治療法の開発
  大野 正芳; 大西 俊介; 坂本 直哉, 日本消化器病学会雑誌, 113, 臨増総会, A117, A117, Mar. 2016
  (一財)日本消化器病学会, Japanese
• 腹壁浸潤および肝転移をきたした原発性卵管癌に対しcomplete surgeryを行った一例
  丸山 祥代; 藤本 佳克; 大西 俊介; 山下 健, 日本産科婦人科学会雑誌, 68, 2, 645, 645, Feb. 2016
  (公社)日本産科婦人科学会, Japanese
• 妊娠経過中に薬剤性味覚障害をきたした1例
  大西 俊介; 藤本 佳克; 丸山 祥代; 山下 健, 日本産科婦人科学会雑誌, 68, 2, 944, 944, Feb. 2016
  (公社)日本産科婦人科学会, Japanese
• 食道扁平上皮がん(ESCC)がん幹細胞に対するFGFR阻害剤の効果
  前原経; 夏井坂光輝; 佐藤史幸; 中川宏治; 大西俊介; 坂本直哉; 武田宏司, 再生医療, 15, 2016
• 卵膜由来間葉系幹細胞を用いた急性および慢性膵炎に対する新規治療法
  川久保和道; 大西俊介; 桑谷将城; 大西礼造; 坂本直哉, 再生医療, 15, 2016
• エタノール沈殿法による血液型特異的スフィンゴ糖脂質および遊離オリゴ糖鎖の血液型抗原の同定
  岡田和恵; 古川潤一; 横田育子; 花松久寿; 大西俊介; 湯山耕平; 酒井祥太; 伊東信; 五十嵐靖之; 坂本直哉; 篠原康郎, 日本糖質学会年会要旨集, 35th, 2016
• 【H.pylori除菌後の諸問題】 H.pylori除菌がGERD発症にどのように影響するのか
  加藤 元嗣; 小野 尚子; 中川 学; 中川 宗一; 安孫子 怜史; 宮本 秀一; 水島 健; 津田 桃子; 大野 正芳; 大西 俊介; 清水 勇一; 坂本 直哉; 間部 克裕, The GI Forefront, 11, 2, 106, 109, Jan. 2016
  (株)メディカルレビュー社, Japanese
• 【慢性胃炎を見直す】 胃炎の内視鏡診断 通常光観察
  加藤 元嗣; 小野 尚子; 中川 学; 中川 宗一; 安孫子 怜史; 宮本 秀一; 水島 健; 津田 桃子; 大野 正芳; 大西 俊介; 清水 勇一; 坂本 直哉; 間部 克裕, 胃と腸, 51, 1, 42, 51, Jan. 2016
  (株)医学書院, Japanese
• 医療イノベーション創出ネットワークの現状と展望 新しいフェーズに入ったアカデミアのシーズ開発 シーズ発表・再生医療等製品 羊膜由来間葉系幹細胞を用いた肝硬変の治療法の開発 羊膜由来間葉系幹細胞の再生医療製品化と急性GVHDに対する治療応用 重症クローン病に対する同種卵膜間葉系幹細胞による新規治療法の開発
  坂本 直哉; 山原 研一; 大西 俊介, 臨床評価, 43, Suppl.XXXV, 221, 224, Dec. 2015
  (株)臨床評価刊行会, Japanese
• 肝細胞癌におけるKLF5による癌幹細胞制御機構
  佐藤 史幸; 夏井坂 光輝; 前原 経; 浅野 彩華; 久保田 良政; 出水 孝章; 梅村 真知子; 伊藤 淳; 常松 聖司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 大西 俊介; 坂本 直哉, 肝臓, 56, Suppl.3, A1002, A1002, Nov. 2015
  (一社)日本肝臓学会, Japanese
• 喫煙妊婦のアンケート調査からわかったこと
  山下 健; 藤本 佳克; 丸山 祥代; 大西 俊介; 赤井 律子; 脇田 真紀; 吉井 瑞希, 日本禁煙学会学術総会プログラム・抄録集, 9回, 206, 206, Nov. 2015
  (一社)日本禁煙学会, Japanese
• 当科における卵巣癌に対するベバシズマブの使用経験
  藤本 佳克; 丸山 祥代; 大西 俊介; 山下 健, 産婦人科の進歩, 67, 4, 510, 510, Oct. 2015
  「産婦人科の進歩」編集室, Japanese
• γ-Glutamyltranspeptidaseにより蛍光を発するprobeによる早期頭頸部がんの検出
  大西 俊介; 清水 勇一; 水島 健; 畑中 豊; 畑中 佳奈子; 久保田 良政; 夏井坂 光輝; 神谷 真子; 本間 明宏; 加藤 元嗣; 浦野 泰照; 坂本 直哉, 日本癌学会総会記事, 74回, P, 3308, Oct. 2015
  日本癌学会, English
• 高度肥満学生に対する保健指導前後の血液学的変化および体組成変化の検討
  吉村 彩; 大西 俊介; 川原 由佳子; 折戸 智恵子; 柏崎 晴彦; 本間 理央; 川久保 和道; 加納 崇裕; 横田 卓; 橋野 聡, 肥満研究, 21, Suppl., 154, 154, Sep. 2015
  (一社)日本肥満学会, Japanese
• 当院における子宮体癌および子宮内膜異型増殖症に対する妊孕性温存療法の治療成績
  山田 有紀; 大西 俊介; 杉本 ひとみ; 森岡 佐知子; 伊東 史学; 重富 洋志; 棚瀬 康仁; 春田 祥治; 川口 龍二; 吉田 昭三; 古川 直人; 小林 浩, 産婦人科の進歩, 67, 3, 326, 328, Aug. 2015
  2009年4月〜2014年7月に類内膜腺癌G1または複雑型子宮内膜異型増殖症(AEH)に対し高用量medroxyprogesterone(MPA)療法を施行した7例(年齢中央値34歳)の奏効率、再発の有無、治療後の妊娠出産の有無を後ろ向きに検討した。MPA投与量の中央値は600mg/日であった。MPA療法の効果判定は、子宮内膜全面掻爬による病理組織診断で行い、奏効率は85.7%、再発率は83.3%であった。再発までの期間の中央値は7ヵ月であり、そのうちMPAの再投与を行った症例が4例、最終的に手術を施行した症例が4例であった。出産に至ったのは1例のみであった。AEHおよび類内膜腺癌に対する高用量MPA療法は、奏効率は高いが再発率も高く、挙児希望があれば可及的早期の妊娠を考慮することが望ましいと考えられた。, 「産婦人科の進歩」編集室, Japanese
• 高度肥満学生における高感度CRPの測定意義について
  吉村 彩; 大西 俊介; 川原 由佳子; 折戸 智恵子; 本間 理央; 川久保 和道; 加納 崇裕; 横田 卓; 橋野 聡, 全国大学保健管理研究集会プログラム・抄録集, 53回, 36, 36, Aug. 2015
  (公社)全国大学保健管理協会, Japanese
• 高度肥満学生における簡易式自記式食事歴調査票の意義について
  折戸 智恵子; 大西 俊介; 川原 由佳子; 吉村 彩; 本間 理央; 川久保 和道; 加納 崇裕; 横田 卓; 橋野 聡, 全国大学保健管理研究集会プログラム・抄録集, 53回, 58, 58, Aug. 2015
  (公社)全国大学保健管理協会, Japanese
• 帝王切開術後の高アミラーゼ血症に関与する因子の検討
  大西 俊介; 藤本 佳克; 丸山 祥代; 山下 健; 今中 聖悟, 日本周産期・新生児医学会雑誌, 51, 2, 901, 901, Jun. 2015
  (一社)日本周産期・新生児医学会, Japanese
• 広汎子宮全摘術後にクリーゼを来した重症筋無力症の1症例
  竹田 善紀; 大西 俊介; 棚瀬 康仁; 岩井 加奈; 山田 有紀; 重富 洋志; 春田 祥治; 川口 龍二; 吉田 昭三; 古川 直人; 小林 浩, 産婦人科の進歩, 67, 2, 192, 192, May 2015
  「産婦人科の進歩」編集室, Japanese
• Meckel憩室軸捻転合併妊娠の1例
  大西 俊介; 藤本 佳克; 丸山 祥代; 山下 健; 今中 聖悟, 産婦人科の進歩, 67, 2, 238, 238, May 2015
  「産婦人科の進歩」編集室, Japanese
• 前置癒着胎盤における予防的な大動脈閉塞バルン(IAB)留置効果の検討
  重光 愛子; 岩井 加奈; 山田 有紀; 赤坂 珠理晃; 常見 泰平; 杉本 ひとみ; 大西 俊介; 中野 和俊; 成瀬 勝彦; 小林 浩, 日本産婦人科・新生児血液学会誌, 25, 1, S, 29, May 2015
  日本産婦人科・新生児血液学会, Japanese
• 厚生労働省による積極的勧奨中止後に子宮頸がんワクチン接種を受けた大学生への意識調査
  川原 由佳子; 齋藤 暢一朗; 大西 俊介; 吉村 彩; 石原 可愛; 横田 卓; 橋野 聡, 日本看護学会論文集: ヘルスプロモーション, 45, 45, 89, 92, Mar. 2015
  子宮頸がんワクチン接種は、2013年4月から予防接種法改正で定期接種となったが、副反応により安全性が問われ、同年6月14日に厚労省は積極的勧奨を中止した。A大学保健センターでは、2013年6月上旬から子宮頸がんワクチン未接種の1年生を対象に自費でのワクチン接種を開始し、希望者は当初25名いたが、厚労省からの通達後、途中キャンセルが相次ぎ、ワクチン接種全3回の実施に至ったのは18名であった。今回、この18名のうち同意が得られた12名を対象としてワクチン接種に関する半構造化インタビューを行い、語られた内容をカテゴリー化した。結果、『接種行動を妨げる不安』『実施の動機づけとなった要因』という2つのコアカテゴリーが抽出された。前者を構成するカテゴリーとして【様々な情報の不確かさ】【成長過程にある思春期の影響】【実施に至るまでの葛藤】があり、後者を構成するカテゴリーとして【病気の心配から必要性を判断】【家族との話し合い】【安心できる環境が重要】【安心・安全なワクチン接種の実際】があった。, 日本看護学会, Japanese
• 本学での子宮頸がんワクチン接種実施報告 不安と疼痛の影響から考えられたこと
  川原 由佳子; 折戸 智恵子; 吉村 彩; 石原 可愛; 大西 俊介; 横田 卓; 橋野 聡, CAMPUS HEALTH, 52, 1, 231, 233, Mar. 2015
  本学保健センターでは、子宮頸がんワクチン接種を希望する新入生女子24名に対して平成25年6月上旬に1回目の接種をしていたが、同年6月14日に厚労省が積極的勧奨を差し控えたため、7名が途中キャンセルした。今回、キャンセルした学生を含む24名の接種に対する不安について、接種前後の収縮期血圧を指標に調査するとともに、接種時の疼痛についてVAS(0〜10)で調査した。結果、収縮期血圧の平均値は、1回目の接種前が114.3、接種後107、2回目の接種前103.5、接種後99、3回目の接種前105.1、接種後105.6であり、1回目の接種前が最も高く、1回目と2回目は接種前が接種後より高値であったが、3回目は接種前後で差異を認めなかった。VASは、1回目が「0」7名、「1」1名、「2」1名、「3」2名、「5」12名、「6」1名、2回目(19名)が「2」1名、「3」3名、「4」1名、「5」9名、「6」5名、3回目(18名)が「1」4名、「2」2名、「4」2名、「5」7名、「6」2名、「7」1名であった。, (公社)全国大学保健管理協会, Japanese
• 動物実験従事者におけるアレルギー健診3年分の経年的解析
  吉村 彩; 武藏 学; 折戸 智恵子; 川原 由佳子; 横田 卓; 大西 俊介; 橋野 聡, CAMPUS HEALTH, 52, 1, 443, 445, Mar. 2015
  本学では平成22年度に、実験中マウスに噛まれてアナフィラキシーショックを起こした事例があったため、平成23年度から予防対策の一環として、動物実験従事者のうち希望者に対し、取扱動物の特異的IgE抗体検査を含む健診を毎年実施している。昨年度に3回目が終了したので、3年間継続受診した者に着目して経年的な解析を行った。対象者は86名で、3年間継続して同種の抗体検査を実施したものは、マウスIgE抗体65名、ラットIgE抗体44名、ハムスターIgE抗体6名、モルモット2名、ウサギ14名であった。動物別にみた特異的IgE抗体陽性率の経年的変化は、マウスが平成23年度18.5%、24年度23.1%、25年度27.7%、ラットがそれぞれ15.9%、20.5%、22.7%であり、両者とも増加傾向にあるものの有意差はなかった。対象者に対して問診票による調査を行い、抗体陽性率との関連について検討した結果、「眼の症状」「蕁麻疹」がマウスIgE抗体陽性率と有意な関連を示したが、「ペット飼育」「親族のアレルギー歴」「喫煙」「気管支炎」「花粉症」「アトピー性皮膚炎」などはマウス・ラットとも有意な関連は示さなかった。, (公社)全国大学保健管理協会, Japanese
• ストレスと消化器疾患 ストレスによる老齢動物の摂食低下には性差が存在する
  大西 俊介; 武藤 修一; 武田 宏司, 日本消化器病学会雑誌, 112, 臨増総会, A93, A93, Mar. 2015
  (一財)日本消化器病学会, Japanese
• 消化管ホルモンの役割を見直す 摂食行動と栄養代謝調節 セロトニンによるグレリン分泌の調節機構
  武藤 修一; 大西 俊介; 武田 宏司, 日本消化器病学会雑誌, 112, 臨増総会, A98, A98, Mar. 2015
  (一財)日本消化器病学会, Japanese
• シスプラチンの副作用に対するKampoのメカニズム (特集 臨床"Kampo" : 各科領域におけるエビデンス)
  武田 宏司; 武藤 修一; 大西 俊介, 医薬ジャーナル, 51, 2, 75, 80, Feb. 2015
  医薬ジャーナル社, Japanese
• 【臨床"Kampo"〜各科領域におけるエビデンス〜】 シスプラチンの副作用に対するKampoのメカニズム
  武田 宏司; 武藤 修一; 大西 俊介, 医薬ジャーナル, 51, 2, 705, 710, Feb. 2015
  (株)医薬ジャーナル社, Japanese
• 重篤なヒトパルボB19ウイルス胎内感染を起こすも後遺症なく出生発達した一例
  河原 直紀; 成瀬 勝彦; 大西 俊介; 岩井 加奈; 重光 愛子; 常見 泰平; 小林 浩, 日本産科婦人科学会雑誌, 67, 2, 606, 606, Feb. 2015
  (公社)日本産科婦人科学会, Japanese
• 高度救命救急センターとの連携により救命しえた産科危機的出血の4例と文献的考察
  森岡 佐知子; 大西 俊介; 河原 直紀; 岩井 加奈; 重光 愛子; 常見 泰平; 成瀬 勝彦; 小林 浩, 日本産科婦人科学会雑誌, 67, 2, 782, 782, Feb. 2015
  (公社)日本産科婦人科学会, Japanese
• 自動データ送信可能な血圧計による産後家庭血圧の新たな遠隔管理
  大西 俊介; 成瀬 勝彦; 小池 奈月; 赤坂 珠理晃; 重光 愛子; 岩井 加奈; 常見 泰平; 小林 浩, 日本産科婦人科学会雑誌, 67, 2, 924, 924, Feb. 2015
  (公社)日本産科婦人科学会, Japanese
• 統合失調症合併妊娠の転帰と周産期予後に関する検討
  重光 愛子; 成瀬 勝彦; 大西 俊介; 河原 直紀; 岩井 加奈; 森岡 佐知子; 常見 泰平; 小林 浩, 日本産科婦人科学会雑誌, 67, 2, 928, 928, Feb. 2015
  (公社)日本産科婦人科学会, Japanese
• 帝王切開術後肺血栓塞栓症撲滅をめざした抗凝固薬による血栓症予防
  春田 祥治; 川口 龍二; 大西 俊介; 河原 直紀; 森岡 佐知子; 岩井 加奈; 重光 愛子; 常見 泰平; 成瀬 勝彦; 小林 浩, 日本産科婦人科学会雑誌, 67, 2, 935, 935, Feb. 2015
  (公社)日本産科婦人科学会, Japanese
• 羊膜由来間葉系幹細胞を用いた放射線性腸炎に対する新規治療法の開発
  大野正芳; 本田みのり; 大西俊介; 大西礼造; 山原研一; 武田宏司; 坂本直哉, 再生医療, 14, 2015
• 脳腸相関の新展開 脳腸相関からみた六君子湯の食欲改善作用
  武田 宏司; 大西 俊介; 武藤 修一, 日本東洋心身医学研究, 29, 1-2, 16,103, 20,103, Dec. 2014
  日本東洋心身医学研究会, Japanese
• 当院における子宮体癌および子宮内膜異型増殖症に対する妊孕性温存療法の治療成績
  山田 有紀; 大西 俊介; 杉本 ひとみ; 森岡 佐知子; 伊東 史学; 重富 洋志; 棚瀬 康仁; 春田 祥治; 川口 龍二; 吉田 昭三; 古川 直人; 小林 浩, 産婦人科の進歩, 66, 4, 476, 476, Oct. 2014
  「産婦人科の進歩」編集室, Japanese
• 大学生における末梢血白血球数および白血球分画と肥満関連合併症との関連についての検討
  吉村 彩; 大西 俊介; 川原 由佳子; 折戸 智恵子; 橋野 聡, 肥満研究, 20, Suppl., 160, 160, Oct. 2014
  (一社)日本肥満学会, Japanese
• 若年性肥満群血清におけるセラミド及びスフィンゴミエリン分子種の解析
  花松 久寿; 大西 俊介; 酒井 祥太; 湯山 耕平; 光武 進; 五十嵐 靖之, 日本生化学会大会プログラム・講演要旨集, 87回, [2P, 487], Oct. 2014
  (公社)日本生化学会, Japanese
• 北海道大学における動物実験実施者等の実験動物への感作状況
  吉村 彩; 武藏 学; 金子 壮朗; 大西 俊介; 折戸 智恵子; 川原 由佳子; 橋野 聡; 森松 正美; 今野 哲; 有川 二郎; 石井 哲也; 澤村 正也; 上田 一郎, アレルギー, 63, 8, 1132, 1139, Sep. 2014
  (一社)日本アレルギー学会, Japanese
• EGFR阻害剤を用いた食道扁平上皮癌幹細胞を標的とした新規治療法の開発(EGFR inhibitors suppress EMT and diminish cancer stem-like cells in esophageal squamous cell carcinoma)
  佐藤 史幸; 夏井坂 光輝; 大橋 真也; 賀川 真吾; 桑谷 将城; 河上 洋; 大西 俊介; 小松 嘉人; 加藤 元嗣; 坂本 直哉, 日本癌学会総会記事, 73回, J, 1034, Sep. 2014
  日本癌学会, English
• 本学での子宮頸がんワクチン接種実施報告 不安と疼痛の影響から考えられたこと
  川原 由佳子; 折戸 智恵子; 吉村 彩; 石原 可愛; 大西 俊介; 横田 卓; 橋野 聡, 全国大学保健管理研究集会プログラム・抄録集, 52回, 58, 58, Aug. 2014
  (公社)全国大学保健管理協会, Japanese
• 動物実験従事者におけるアレルギー健診3年分の経年的解析
  吉村 彩; 折戸 智恵子; 川原 由佳子; 横田 卓; 大西 俊介; 橋野 聡, 全国大学保健管理研究集会プログラム・抄録集, 52回, 103, 103, Aug. 2014
  (公社)全国大学保健管理協会, Japanese
• マルチディスプレイによるオンスクリーンキーボードの課題解消に向けた取り組み
  大西 俊介; 中園 正吾; 原 良昭; 杉本 義己, リハ工学カンファレンス講演論文集, 29回, np51, np52, Aug. 2014
  (一社)日本リハビリテーション工学協会, Japanese
• NAFLDおよびインスリン抵抗性の発症におけるスフィンゴミエリン代謝系の関与
  大西 俊介; 光武 進; 湯山 耕平; 酒井 祥太; 花松 久寿; 折戸 智恵子; 川原 由佳子; 吉村 彩; 高崎 裕代; 武田 宏司; 五十嵐 靖之; 橋野 聡; 坂本 直哉, 肝臓, 55, Suppl.1, A320, A320, Apr. 2014
  (一社)日本肝臓学会, Japanese
• 保健センターでの子宮頸がんワクチン接種実施報告 接種勧奨中止に伴う影響
  折戸 智恵子; 大西 俊介; 川原 由佳子; 吉村 彩; 小西 剛; 今野 康二; 渡邉 昌也; 橋野 聡, CAMPUS HEALTH, 51, 1, 237, 239, Mar. 2014
  子宮頸がんワクチン定期接種導入前の新入生のワクチン接種率を把握し、どのようなニーズがあるか検討した。入学前接種率は57.1%で、今後接種を考えていると答えた未接種者は71.8%であった。接種を考えない理由では「価格」が一番多く(34%)、「副反応」を理由に挙げたのは11%であった。ワクチンについての情報源は、女子は学校と家族が多く、男子は学校の他にTVが多かった。1回目の接種直後に「積極的勧奨の中止」の報道があり、25例の申込みのうち、最終の1例が未接種で辞退、5例が2回目以降の接種を辞退した。ワクチンを接種する際、保護者特に母親の理解が必要で、今回の調査でも中止という選択も母親の意向が強かったことが窺えた。, (公社)全国大学保健管理協会, Japanese
• 定期健康診断の血圧測定における本学の取り組み 高血圧の偽陽性の学生を少なくするために
  川原 由佳子; 谷 忍; 小西 剛; 折戸 智恵子; 吉村 彩; 横田 卓; 渡辺 昌也; 大西 俊介; 橋野 聡, CAMPUS HEALTH, 51, 1, 268, 270, Mar. 2014
  (公社)全国大学保健管理協会, Japanese
• 留学生の尿検査有所見の傾向 陽性率からみる健診対策
  吉村 彩; 折戸 智恵子; 川原 由佳子; 小西 剛; 谷 忍; 前野 由紀子; 渡邉 昌也; 横田 卓; 大西 俊介; 橋野 聡, CAMPUS HEALTH, 51, 1, 297, 299, Mar. 2014
  定期健康診断時(定健)の尿検査や再検査の結果について、一般学生(日本国籍)と比較し、留学生における尿検査有所見の傾向について検討した。定健尿検査を受診した学生31555例を一般学生と留学生に分けて検討した。定健尿検査(1回目)の再検該当者は、一般学生は平均3.2%であったが、留学生平均7.7%と高かった。さらに、男女別では、女性の留学生に高い傾向が見られた。再検該当項目別の陽性率は、尿潜血賜性は留学生及び男女、特に女性で高かった。再検受診者のうち、他医療機関へ紹介した紹介率は、留学生が平均5割と高いが、医療機閣からの返信が来た返信率は、一般学生の方が高かった。医療機関からの返信内容では、異常なしと血尿が多い傾向にあった。留学生の受診者数でもっとも多いのがアジアで、再検該当率、受診率最多は中国で次いで韓国、インドネシアに多く多かった。, (公社)全国大学保健管理協会, Japanese
• FGIDの病態生理学と脳腸相関研究の進歩 ストレスによる胃機能異常にはグレリンシグナルの異常が関与する
  武藤 修一; 大西 俊介; 武田 宏司, 日本消化器病学会雑誌, 111, 臨増総会, A164, A164, Mar. 2014
  (一財)日本消化器病学会, Japanese
• 羊膜由来間葉系幹細胞を用いた放射線腸炎に対する新規治療法の開発
  本田みのり; 大西俊介; 大野正芳; 山原研一; 吉松淳; 中川宏治; 武田宏司; 坂本直哉, 日本絨毛性疾患研究会・日本胎盤学会学術集会プログラム・抄録集, 32nd-22nd, 2014
• 肝炎ウイルスの複製増殖および病原性発現機構と薬剤感受性の解析 LカルニチンによるHCV増殖抑制,脂肪化抑制,酸化ストレス抑制効果の検討
  大西俊介; 須田剛生, 肝炎ウイルスの複製増殖および病原性発現機構と薬剤感受性の解析 平成25年度 総括・分担研究報告書, 48‐49, 2014
  Japanese
• 卵膜由来間葉系幹細胞を用いた急性膵炎の新規治療法の開発
  大西 俊介, 日本膵臓病研究財団研究報告書, 20回, 101, 105, Dec. 2013
  (公財)日本膵臓病研究財団, Japanese
• 【Cachexiaと栄養管理】 抗癌剤に伴うcachexiaとその治療
  武田 宏司; 武藤 修一; 大西 俊介; 河野 透, 栄養-評価と治療, 30, 4, 283, 286, Nov. 2013
  (株)メディカルレビュー社, Japanese
• 消化管の新たな映像(第11回) 術中近赤外蛍光イメージング
  大西 俊介; 田中 栄一; 芦立 嘉智; Frangioni John V, Frontiers in Gastroenterology, 18, 4, 334, 339, Oct. 2013
  (株)メディカルレビュー社, Japanese
• 保健センターでの子宮頸がんワクチン接種実施報告 接種勧奨中止に伴う影響
  折戸 智恵子; 大西 俊介; 川原 由佳子; 吉村 彩; 小西 剛; 今野 康二; 渡邉 昌也; 橋野 聡, 全国大学保健管理研究集会プログラム・抄録集, 51回, 82, 82, Oct. 2013
  (公社)全国大学保健管理協会, Japanese
• 定期健康診断における高血圧の偽陽性率を低下させるための取り組み
  川原 由佳子; 谷 忍; 小西 剛; 折戸 智恵子; 吉村 彩; 渡邉 昌也; 大西 俊介; 橋野 聡, 全国大学保健管理研究集会プログラム・抄録集, 51回, 85, 85, Oct. 2013
  (公社)全国大学保健管理協会, Japanese
• 留学生の尿検査有所見の傾向 陽性率からみる健診対策
  吉村 彩; 折戸 智恵子; 川原 由佳子; 小西 剛; 谷 忍; 前野 由紀子; 渡邉 昌也; 大西 俊介; 橋野 聡, 全国大学保健管理研究集会プログラム・抄録集, 51回, 88, 88, Oct. 2013
  (公社)全国大学保健管理協会, Japanese
• 食道扁平上皮癌におけるTGF-βおよびNotch1による癌幹細胞維持機構(TGF-β changes a switch of Notch1-mediated signaling to maintain tumor-initiating cells in esophageal SCC(ESCC))
  夏井坂 光輝; 大橋 真也; 長沼 誠二; 大西 俊介; 桑谷 将城; 河上 洋; 中馬 誠; 小松 嘉人; 加藤 元嗣; 坂本 直哉, 日本癌学会総会記事, 72回, 137, 137, Oct. 2013
  日本癌学会, English
• HIFによる低酸素非依存的なCD133プロモーター活性の制御(Hypoxia-inducible factors regulate CD133 promoter activity independently of hypoxia)
  大西 俊介; 中川 宏治; 坂本 直哉; 小林 正伸; 武田 宏司, 日本癌学会総会記事, 72回, 334, 334, Oct. 2013
  日本癌学会, English
• 消化器疾患と栄養代謝ネットワーク 基礎から臨床まで ストレスによる老齢動物の摂食低下には5-HT2C受容体の機能亢進が関与する
  大西 俊介; 武藤 修一; 武田 宏司, 日本消化器病学会雑誌, 110, 臨増大会, A582, A582, Sep. 2013
  (一財)日本消化器病学会, Japanese
• 携帯型情報端末を用いた知的障害児の二者択一場面を支援するアプリケーションの開発
  杉本 義己; 大森 清博; 大西 俊介, リハ工学カンファレンス講演論文集, 28回, 177, 178, Aug. 2013
  (一社)日本リハビリテーション工学協会, Japanese
• 社会的ストレスと消化器症状
  武田 宏司; 武藤 修一; 大西 俊介, 消化器心身医学, 20, 1, 6, 9, Aug. 2013
  消化器心身医学研究会, Japanese
• 光の臨床応用 近赤外蛍光イメージングとBlue LASER Imaging
  大西 俊介; 田中 栄一; 小野 尚子; 加藤 元嗣, JSMI Report, 6, 2, 59, 59, May 2013
  日本分子イメージング学会, Japanese
• 動物実験従事者の動物アレルギー
  吉村 彩; 武藏 学; 金子 壮朗; 大西 俊介; 折戸 智恵子; 川原 由佳子; 森松 正美; 今野 哲; 有川 二郎, CAMPUS HEALTH, 50, 1, 316, 316, Mar. 2013
  (公社)全国大学保健管理協会, Japanese
• 【摂食制御と消化管】 六君子湯による摂食不振・悪液質の改善
  武田 宏司; 中川 宏治; 西村 三恵; 大久保 直登; 細野 秀崇; 浅香 正博; 武藤 修一; 大西 俊介; 坂本 直哉, G.I.Research, 21, 1, 48, 58, Feb. 2013
  (株)先端医学社, Japanese
• 消化器領域における幹細胞研究の進歩 食道がん幹細胞におけるTGF-β/Notchシグナルを標的とした新規治療法の創出
  夏井坂 光輝; 大西 俊介; 坂本 直哉, 日本消化器病学会雑誌, 110, 臨増総会, A82, A82, Feb. 2013
  (一財)日本消化器病学会, Japanese
• 当科における虚血性大腸炎診断の取り組み
  武藤 修一; 武田 宏司; 大西 俊介; 小西 康平; 江藤 和範; 宮本 秀一, 日本消化器病学会雑誌, 110, 臨増総会, A309, A309, Feb. 2013
  (一財)日本消化器病学会, Japanese
• 【消化管疾患に対する漢方医学からのアプローチ-現状と展望】 消化管疾患に対する漢方医療の実際 消化器癌に対する補助療法 食欲不振
  武田 宏司; 武藤 修一; 大西 俊介, 臨床消化器内科, 28, 2, 209, 214, Jan. 2013
  (株)日本メディカルセンター, Japanese
• 健康診断の血液検査で発見されたサラセミアの9例
  吉村 彩; 武藏 学; 大西 俊介; 奈良部 正子; 折戸 智恵子; 山城 安啓; 服部 幸夫, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 87, 6, 259, 259, 01 Nov. 2012
  Japanese
• 【有効性・安全性・経済性を考慮した「漢方薬」提案のヒント】 こんな時には漢方薬 方剤単位で学ぶ「漢方薬」提案のヒント 六君子湯
  武田 宏司; 武藤 修一; 大西 俊介, 薬局, 63, 11, 3290, 3299, Oct. 2012
  (株)南山堂, Japanese
• 大腸癌における造影超音波検査と再発予測について
  武藤 修一; 大西 俊介; 小西 康平; 江藤 和範; 宮本 秀一; 高橋 亜希; 福島 拓; 高橋 一宏; 石津 明洋; 武田 宏司, 日本癌治療学会誌, 47, 3, 2250, 2250, Oct. 2012
  (一社)日本癌治療学会, Japanese
• 機能性消化管障害の病態と治療 グレリンシグナルの低下がGERDにおける胃排出低下に関与する
  武田 宏司; 武藤 修一; 大西 俊介, 日本消化器病学会雑誌, 109, 臨増大会, A433, A433, Sep. 2012
  (一財)日本消化器病学会, Japanese
• 大腸癌における術前超音波検査結果とその後の予後の検討
  武藤 修一; 武田 宏司; 大西 俊介; 福島 拓; 高橋 一宏; 宮本 秀一; 石津 明洋; 浅香 正博, 日本消化器病学会雑誌, 109, 臨増大会, A822, A822, Sep. 2012
  (一財)日本消化器病学会, Japanese
• 動物実験従事者の動物アレルギー
  吉村 彩; 武藏 学; 金子 壮朗; 大西 俊介; 折戸 智恵子; 川原 由佳子; 森松 正美; 今野 哲; 有川 二郎, CAMPUS HEALTH, 49, 4, 89, 89, Sep. 2012
  (公社)全国大学保健管理協会, Japanese
• 新奇環境ストレスによる食欲低下に対する六君子湯の効果
  三枝 弥生; 武藤 修一; 中川 宏治; 大西 俊介; 定金 千春; 名畑 美和; 服部 智久; 浅香 正博; 武田 宏司, Journal of Traditional Medicines, 29, Suppl., 94, 94, Aug. 2012
  (一社)和漢医薬学会, Japanese
• HIFによるEts結合部位を介したCD133プロモーター活性の制御(Hypoxia-inducible factors activate CD133 promoter through Ets-binding sites)
  大西 俊介; 中川 宏治; 坂本 直哉; 小林 正伸, 日本癌学会総会記事, 71回, 245, 245, Aug. 2012
  日本癌学会, English
• 健康診断の血液検査で発見されたサラセミアの9例
  吉村 彩; 武藏 学; 大西 俊介; 奈良部 正子; 折戸 智恵子; 山城 安啓; 服部 幸夫, CAMPUS HEALTH, 49, 3, 9, 14, May 2012
  (公社)全国大学保健管理協会, Japanese
• 栄養代謝制御における消化管生理活性ペプチドの役割 性差が末梢グレリン分泌に与える影響 老化マウスにおける検討
  大西 俊介; 武藤 修一; 武田 宏司, 日本消化器病学会雑誌, 109, 臨増総会, A142, A142, Mar. 2012
  (一財)日本消化器病学会, Japanese
• 虚血性腸炎の診断における腹部エコー検査の有用性についての検討
  武藤 修一; 福島 拓; 高橋 一宏; 宮本 秀一; 大西 俊介; 武田 宏司, 日本消化器病学会雑誌, 109, 臨増総会, A323, A323, Mar. 2012
  (一財)日本消化器病学会, Japanese
• 本学における学生生活実態調査30年のまとめ 経済状況、食生活および健康状況の変化について
  折戸 智恵子; 大西 俊介; 武藏 学, CAMPUS HEALTH, 49, 1, 111, 112, Feb. 2012
  (公社)全国大学保健管理協会, Japanese
• 健康診断の血液検査で発見されたサラセミアの9例
  吉村 彩; 武藏 学; 大西 俊介; 奈良部 正子; 折戸 智恵子; 山城 安啓; 服部 幸夫, CAMPUS HEALTH, 49, 1, 181, 181, Feb. 2012
  (公社)全国大学保健管理協会, Japanese
• 急性上気道炎に対する抗生剤投与は学生の再診率低下に寄与するのか?
  大西 俊介; 金子 壮朗; 小西 剛; 吉田 和絵; 折戸 智恵子; 武藏 学, CAMPUS HEALTH, 49, 1, 394, 396, Feb. 2012
  (公社)全国大学保健管理協会, Japanese
• Stage4消化器癌患者の入院時Alb値とCRP値の評価
  武藤 修一; 武田 宏司; 大西 俊介; 福島 拓; 高橋 一宏; 宮本 秀一, 日本内科学会雑誌, 101, Suppl., 159, 159, Feb. 2012
  (一社)日本内科学会, Japanese
• 本学における学生生活実態調査30年のまとめ 経済状況、食生活および健康状況の変化
  折戸 智恵子; 大西 俊介; 武藏 学, CAMPUS HEALTH, 48, 3, 61, 61, Oct. 2011
  (公社)全国大学保健管理協会, Japanese
• 急性上気道炎に対する抗生剤投与は学生の再診率低下に寄与するのか?
  大西 俊介; 金子 壮朗; 小西 剛; 吉田 和絵; 折戸 智恵子; 武蔵 学, CAMPUS HEALTH, 48, 3, 91, 91, Oct. 2011
  (公社)全国大学保健管理協会, Japanese
• 【神経消化器病学の進歩】 内分泌ペプチドと消化器の生理 神経内分泌ペプチドを介した悪心・嘔吐の制御機構
  武田 宏司; 中川 宏治; 大西 俊介, 医学のあゆみ, 238, 10, 997, 1001, Sep. 2011
  医歯薬出版(株), Japanese
• 大腸癌に対するFDG-PET/CT検査の有用性
  武藤 修一; 大西 俊介; 福島 拓; 高橋 一宏; 宮本 秀一; 武田 宏司, 日本消化器病学会雑誌, 108, 臨増大会, A868, A868, Sep. 2011
  (一財)日本消化器病学会, Japanese
• 【高齢者の消化と吸収と老化制御】 加齢による食欲不振のメカニズムとその対策 六君子湯の効果とその作用機序
  武藤 修一; 大西 俊介; 浅香 正博; 武田 宏司, 消化器内科, 53, 3, 247, 251, Sep. 2011
  (有)科学評論社, Japanese
• 成分栄養剤エレンタールにより、消化管粘膜障害が軽快した大腸癌化学療法の1症例
  武藤 修一; 福島 拓; 高橋 一宏; 宮本 秀一; 大西 俊介; 武田 宏司, 日本癌治療学会誌, 46, 2, 842, 842, Sep. 2011
  (一社)日本癌治療学会, Japanese
• 【実践!!薬効モニタリング】 薬効モニタリングの実践 過敏性腸症候群
  武田 宏司; 中川 宏治; 桂田 武彦; 平山 剛; 大西 俊介; 細野 秀崇; 浅香 正博, 薬局, 62, 9, 3191, 3197, Aug. 2011
  (株)南山堂, Japanese
• Helicobacterと内視鏡技術(第23回) 近赤外2波長蛍光イメージング装置の開発
  大西 俊介; 田中 栄一; 楢崎 肇; 加藤 元嗣; Frangioni John V, Helicobacter Research, 15, 3, 194, 198, Jun. 2011
  (株)先端医学社, Japanese
• 【消化器癌をめぐる栄養療法】 消化器癌化学療法に伴う食欲不振のメカニズムとその対策
  武藤 修一; 大西 俊介; 浅香 正博; 武田 宏司, 消化器内科, 52, 6, 559, 565, Jun. 2011
  (有)科学評論社, Japanese
• 【明日の診療に漢方をいかす 西洋医学と漢方医学の融合】 日常診療でまず使ってみたい漢方ベストチョイス15 IBS(便秘型) 大建中湯
  武田 宏司; 中川 宏治; 武藤 修一; 大西 俊介; 浅香 正博; 細野 秀崇, 診断と治療, 99, 5, 817, 822, May 2011
  (株)診断と治療社, Japanese
• 大腸癌における術前の超音波検査の意義
  武藤 修一; 高橋 亜希; 大西 俊介; 武田 宏司, 超音波医学, 38, Suppl., S414, S414, Apr. 2011
  (一社)日本超音波医学会, Japanese
• 下部消化管内視鏡検査手技に伴う術者顔面の汚染リスクについての検討
  小林 良充; 大西 俊介; 大西 礼造; 竹村 龍; 鈴木 美櫻; 佐々木 尚英; 太宰 昌佳; 幡 有; 山本 純司; 小田 寿; 宮城島 拓人, Gastroenterological Endoscopy, 53, 3, 1117, 1121, Mar. 2011
  下部消化管内視鏡検査に伴う術者の汚染リスクについて検討するため、術者11名にフェースガード付マスクを着用させ、内視鏡検査102例実施後の水滴付着の有無および面積、個数を調べた。その結果、18例で水滴付着を認め、うち17例は検査経験3年以下の術者によるものであった。検査状況でみると、鉗子口の操作回数に伴って水滴付着陽性率は増加し、水滴面積も増大する傾向にあった。鉗子口の操作数を、鉗子を入れた回数と注射器を用いた水の注入回数の和とし、4回以下の群と5回以上の群で比較したところ、5回以上群で有意に水滴数が多く、水滴面積も大きかった。水滴は全30滴中、20滴がフェースガードの左側に付着していた。検査時間(30分未満/以上)、検査形態(通常検査/緊急検査/EMR・ポリペクトミー)、液体吸引量(200ml未満/以上)と水滴数、水滴面積に有意差はなく関係は認めなかった。また、術者の身長(170cm未満/以上)とも関係は認めなかった。, (一社)日本消化器内視鏡学会, Japanese
• 消化器病における漢方治療のエビデンスを目指して 六君子湯は社会的隔離による食欲不振を改善する
  武田 宏司; 武藤 修一; 大西 俊介, 日本消化器病学会雑誌, 108, 臨増総会, A142, A142, Mar. 2011
  (一財)日本消化器病学会, Japanese
• 遺伝性血管性浮腫(HAE)症例の診断と経過、治療について
  武藤 修一; 武田 宏司; 大西 俊介; 大西 礼造; 上畠 寧子; 小原 俊央, 日本消化器病学会雑誌, 108, 臨増総会, A337, A337, Mar. 2011
  (一財)日本消化器病学会, Japanese
• 急速に進行した低酸素血症と肺高血圧症を呈し、Pulmonary Tumor Thrombotic Microangiopathy(PTTM)が疑われた胆管癌の1症例
  武藤 修一; 武田 宏司; 大西 俊介; 大西 礼造; 上畠 寧子; 小原 俊央, 日本消化器病学会雑誌, 108, 臨増総会, A377, A377, Mar. 2011
  (一財)日本消化器病学会, Japanese
• 胸膜中皮腫と酷似した肺腺癌の1剖検例
  大西 礼造; 大西 俊介; 佐々木 尚英; 大野 正芳; 鈴木 美櫻; 久保 公利; 山本 純司; 小田 寿; 宮城島 拓人; 高橋 達郎; 岡本 賢三, 日本職業・災害医学会会誌, 59, 2, 90, 95, Mar. 2011
  (一社)日本職業・災害医学会, Japanese
• 脳腸相関 消化器内科領域における漢方
  武田 宏司; 中川 宏治; 武藤 修一; 大西 俊介; 浅香 正博, 日本東洋心身医学研究, 25, 1-2, 37, 41, Mar. 2011
  日本東洋心身医学研究会, Japanese
• 食道平滑筋腫上に発生した食道癌に対し内視鏡的粘膜下層剥離術を施行した1例
  鈴木 美櫻; 大西 俊介; 大野 正芳; 大西 礼造; 小林 良充; 久保 公利; 太宰 昌佳; 山本 純司; 小田 寿; 宮城島 拓人; 高橋 達郎, Gastroenterological Endoscopy, 53, 1, 22, 27, Jan. 2011
  50歳代男。主訴は食道腫瘍の増大で、腫瘍は20年前の検診で指摘され、15年前の生検にて食道平滑筋腫と診断され経過観察中であった。食道バリウム造影および上部消化管内視鏡検査では胸部中部食道後壁になだらかな隆起性病変を認め、隆起部のヨード不染帯からの生検では強い異型を認めた。超音波内視鏡では第二層由来の内部均一な低エコー腫瘤を認めたため、食道癌と食道平滑筋腫の合併と考え内視鏡的粘膜下層剥離術により一括切除した。病理組織学的に平滑筋腫の直上上皮粘膜にcarcinoma in situを認めT1a-EP食道癌と診断した。, (一社)日本消化器内視鏡学会, Japanese
• 悪性リンパ腫の化学療法中に繰り返し発症したHelicobacter cinaedi感染症
  大野 正芳; 大西 俊介; 大西 礼造; 高橋 正二郎; 小林 良充; 鈴木 美櫻; 久保 公利; 太宰 昌佳; 山本 純司; 小田 寿; 多田 憲司; 高橋 達郎; 宮城島 拓人, 臨床血液, 51, 12, 1781, 1785, Dec. 2010
  (一社)日本血液学会-東京事務局, Japanese
• 【消化器の生理と漢方】 機能性ディスペプシアおよび食欲不振に対する漢方治療
  武田 宏司; 武藤 修一; 大西 俊介; 浅香 正博, 日本消化器病学会雑誌, 107, 10, 1586, 1591, Oct. 2010
  (一財)日本消化器病学会, Japanese
• Role of Kampo medicine in the treatment of dyspepsia and anorexia
  Hiroshi Takeda; Shuichi Muto; Shunsuke Ohnishi; Masahiro Asaka, Journal of Japanese Society of Gastroenterology, 107, 10, 1586, 1591, Oct. 2010
  The Japanese Society of Gastroenterology, Japanese
• 濾胞性リンパ腫を合併したPOEMS症候群
  佐々木 尚英; 大西 俊介; 大西 礼造; 竹村 龍; 小林 良充; 鈴木 美櫻; 太宰 昌佳; 幡 有; 山本 純司; 小田 寿; 高橋 達郎; 小笠原 和宏; 宮城島 拓人, 臨床血液, 50, 11, 1621, 1625, Nov. 2009
  (一社)日本血液学会-東京事務局, Japanese
• ESD症例に対するアルギン酸ナトリウムパウダーの改良撒布法とその治療成績
  山本 純司; 小田 寿; 大西 俊介; 幡 有; 太宰 昌佳; 佐々木 尚英; 小林 良充; 鈴木 美櫻; 竹村 龍; 大西 礼造; 大野 正芳; 廣瀬 孝則; 五明 秀能, Gastroenterological Endoscopy, 51, Suppl.2, 2200, 2200, Sep. 2009
  (一社)日本消化器内視鏡学会, Japanese
• 組織学的に分枝型膵管内乳頭粘液性腫瘍(IPMN)からの進展と考えられた膵管内腫瘍由来の浸潤癌の一例
  大野 正芳; 大西 礼造; 竹村 龍; 鈴木 美櫻; 小林 良充; 佐々木 尚英; 太宰 昌佳; 幡 有; 山本 純司; 大西 俊介; 小田 寿; 宮城島 拓人; 河合 朋昭; 高橋 達郎, 日本消化器病学会雑誌, 106, 臨増大会, A945, A945, Sep. 2009
  (一財)日本消化器病学会, Japanese
• Bevacizumabの有用性を検討するレトロスペクティブ調査(HGCSG0801) 年齢別の解析
  小松 嘉人; 結城 敏志; 曽我部 進; 大西 俊介; 宮城島 拓人; 畑中 一映; 成瀬 宏仁; 加藤 貴司; 目黒 高志; 鎌田 豪; 上林 実; 中村 路夫; 細川 歩; 久須美 貴哉; 浅香 正博, 日本癌治療学会誌, 44, 2, 422, 422, Sep. 2009
  (一社)日本癌治療学会, Japanese
• 【色素内視鏡を見直す 画像強調観察法との比較】 分子イメージングを目的とした近赤外蛍光プローブの開発
  大西 俊介; 浅香 正博; Frangioni John V, 臨床消化器内科, 24, 10, 1411, 1417, Aug. 2009
  (株)日本メディカルセンター, Japanese
• 遺伝子修飾幹細胞療法としての間葉系幹細胞に対する新規siRNA導入法の開発(Development of a novel siRNA delivery system into stem cells for genetically modified stem cell therapy)
  大西 俊介; 大谷 健太郎, 日本癌学会総会記事, 68回, 412, 412, Aug. 2009
  日本癌学会, English
• 【がん転移・浸潤に対する新たな治療戦略】 がんの転移・浸潤を見極める新しい臨床診断ツール
  大西 俊介; ジョン・V・フランジオーニ, Medical Bio, 6, 3, 22, 25, May 2009
  (株)オーム社, Japanese
• 下部消化管内視鏡検査における糞口感染リスクの検討
  小林 良充; 大西 礼造; 竹村 龍; 鈴木 美櫻; 佐々木 尚英; 太宰 昌佳; 幡 有; 山本 純司; 小田 寿; 大西 俊介; 宮城島 拓人, Gastroenterological Endoscopy, 51, Suppl.1, 817, 817, Apr. 2009
  (一社)日本消化器内視鏡学会, Japanese
• 腹膜中皮腫の2例
  大西 礼造; 大西 俊介; 竹村 龍; 小林 良充; 鈴木 美櫻; 佐々木 尚英; 太宰 昌佳; 幡 有; 山本 純司; 小田 寿; 宮城嶋 拓人; 高橋 達郎, 日本消化器病学会雑誌, 106, 臨増総会, A423, A423, Mar. 2009
  (一財)日本消化器病学会, Japanese
• 【内視鏡イメージングの進化】 近赤外光を用いた蛍光分子イメージング法の開発
  大西 俊介; 浅香 正博; Frangioni John V, 消化器内視鏡, 21, 2, 303, 309, Feb. 2009
  (株)東京医学社, Japanese
• 肝再生 基礎と臨床のBridge研究 胎児付属物由来間葉系幹細胞の新しい再生医療材料としての可能性
  大西 俊介; 原田 和彦; 池田 智明, 肝臓, 49, Suppl.2, A490, A490, Sep. 2008
  (一社)日本肝臓学会, Japanese
• 分子イメージングを目的とした近赤外蛍光プローブの開発
  大西 俊介; 田中 栄一; 清水 勇一; 宮城島 拓人; 加藤 元嗣; 浅香 正博; Frangioni J, Gastroenterological Endoscopy, 50, Suppl.2, 2293, 2293, Sep. 2008
  (一社)日本消化器内視鏡学会, Japanese
• 内視鏡観察の新展開(特殊光、拡大、超拡大観察) 近赤外光を応用した"Image-Guided Surgery"の開発
  田中 栄一; 大西 俊介; 近藤 哲, 日本消化器病学会雑誌, 105, 臨増大会, A718, A718, Sep. 2008
  (一財)日本消化器病学会, Japanese
• ヒト卵膜由来間葉系幹細胞による心血管再生保護効果の検討
  原田 和彦; 山原 研一; 大西 俊介; 佐田 正晴; 石兼 真; 藤原 道弘; 寒川 賢治; 北村 惣一郎; 永谷 憲歳; 池田 智明, 日本内分泌学会雑誌, 84, 2, 687, 687, Sep. 2008
  (一社)日本内分泌学会, Japanese
• 超音波と微小気泡の併用による間葉系幹細胞への核酸導入法の開発
  大谷 健太郎; 山原 研一; 大西 俊介; 小幡 裕明; 北村 惣一郎; 永谷 憲歳, 日本内分泌学会雑誌, 84, 2, 689, 689, Sep. 2008
  (一社)日本内分泌学会, Japanese
• 近赤外光を用いた術中リアルタイム蛍光分子イメージング法の開発(Intra-Operative Real-Time Molecular Imaging using Near-Infrared Fluorescent Contrast Agents)
  大西 俊介; 田中 栄一; 藤井 博史; フランジオーニ・ジョン, 日本癌学会総会記事, 67回, 485, 485, Sep. 2008
  日本癌学会, English
• 超音波と微小気泡を併用した間葉系幹細胞への核酸導入法の開発
  大谷 健太郎; 山原 研一; 大西 俊介; 小幡 裕明; 北村 惣一郎; 永谷 憲歳, 超音波医学, 35, Suppl., S290, S290, Apr. 2008
  (一社)日本超音波医学会, Japanese
• OJ-033 Capability of Contrast-enhanced Sonography in the Assessment of Neovascularization after Mesenchymal Stem Cell Transplantation in Rat Model of Hindlimb Ischemia(Echo/Doppler(03)(I),Oral Presentation(Japanese),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)
  Otani Kentaro; Ohnishi Shunsuke; Obata Hiroaki; Ishida Osamu; Kitamura Soichiro; Nagaya Noritoshi, Circulation journal : official journal of the Japanese Circulation Society, 72, 296, 296, 01 Mar. 2008
  Japanese Circulation Society, English
• Tissue regeneration as next-generation therapy for COPD--potential applications
  Ohnishi, S.; Nagaya, N., Int J Chron Obstruct Pulmon Dis, 3, 4, 509, 514, 2008, [Peer-reviewed]
  English
• グレリンと心血管疾患
  大西 俊介; 寒川 賢治; 永谷 憲歳, 血管, 30, 3, 77, 80, Oct. 2007
  日本心脈管作動物質学会, Japanese
• メタボリックシンドロームにおける脂肪組織血管内皮機能障害 共培養系における検討
  山原 研一; 大西 俊介; 永谷 憲歳, 日本内分泌学会雑誌, 83, 2, 587, 587, Sep. 2007
  (一社)日本内分泌学会, Japanese
• 脂肪組織由来と骨髄由来間葉系幹細胞の遺伝子発現、分泌タンパク質の差異の検討
  中西 千明; 山岸 正和; 大西 俊介; 北村 惣一郎; 永谷 憲歳, 日本内分泌学会雑誌, 83, 2, 602, 602, Sep. 2007
  (一社)日本内分泌学会, Japanese
• 内側絨毛膜由来間葉系幹細胞による心血管細胞の保護と血管再生効果の検討
  原田 和彦; 永谷 憲歳; 大西 俊介; 佐田 正晴; 藤原 道弘; 北村 惣一郎; 池田 智明, 日本内分泌学会雑誌, 83, 2, 602, 602, Sep. 2007
  (一社)日本内分泌学会, Japanese
• ラット下肢虚血モデルにおける微細針刺入刺激による血管新生療法の検討
  石田 治; 大西 俊介; 大谷 健太郎; 北村 惣一郎; 永谷 憲歳, 日本内分泌学会雑誌, 83, 2, 602, 602, Sep. 2007
  (一社)日本内分泌学会, Japanese
• 間葉系細胞の心線維芽細胞に対するパラクライン効果
  大西 俊介; 北村 惣一郎; 永谷 憲歳, 日本内分泌学会雑誌, 83, 2, 603, 603, Sep. 2007
  (一社)日本内分泌学会, Japanese
• 褥瘡に対するアドレノメデュリンの効果
  原田 和彦; 大西 俊介; 山原 研一; 池田 智明; 藤原 道弘; 北村 惣一郎; 寒川 賢治; 永谷 憲歳, 日本内分泌学会雑誌, 83, 2, 603, 603, Sep. 2007
  (一社)日本内分泌学会, Japanese
• 【ペプチドと創薬】 新規機能と創薬ターゲット カヘキシアとグレリン
  大西 俊介; 永谷 憲歳; 寒川 賢治, 遺伝子医学MOOK, 8, 132, 136, Jul. 2007
  (株)メディカルドゥ, Japanese
• 【心不全 最新の基礎・臨床研究の進歩】 成因・病態に関する基礎的研究 不全心の分子機構に関する最新の基礎研究 神経体液性因子の活性化の分子機構と作用 グレリン
  大西 俊介; 永谷 憲歳; 寒川 賢治, 日本臨床, 65, 増刊4 心不全(上), 186, 190, Apr. 2007
  (株)日本臨床社, Japanese
• FRS-055 Transplantation of Mesenchymal Stem Cells Improves Atrioventricular Conduction in Rat Model of Complete Atrioventricular Block(Regeneration, The 71st Annual Scientific Meeting of the Japanese Circulation Society)
  Yokokawa Miki; Ohnishi Shunsuke; Ueda Hatsue; Obata Hiroaki; Miyahara Yoshinori; Tanaka Koichi; Shimizu Wataru; Kamakura Shiro; Nagaya Noritoshi, Circulation journal : official journal of the Japanese Circulation Society, 71, 132, 132, 01 Mar. 2007
  Japanese Circulation Society, English
• 病因と病態 グレリンの心血管系への作用
  大西 俊介; 永谷 憲歳; 寒川 賢治, Annual Review循環器, 2007, 55, 59, Jan. 2007
  (株)中外医学社, Japanese
• 長期作用型プロスタサイクリンアゴニストの開発と肺高血圧モデルに対する効果の検討
  小幡 裕明; 酒井 芳紀; 大西 俊介; 竹下 聡; 盛 英三; 小玉 誠; 相澤 義房; 永谷 憲歳, 日本内分泌学会雑誌, 82, 2, 511, 511, Sep. 2006
  (一社)日本内分泌学会, Japanese
• 胎児付属物由来間葉系幹細胞の分離・培養法の確立とパラクライン効果の検討
  原田 和彦; 永谷 憲歳; 大西 俊介; 白石 修一; 小幡 裕明; 中西 千明; 三島 健一; 江頭 伸昭; 岩崎 克典; 藤原 道弘; 北村 惣一郎; 池田 智明, 日本内分泌学会雑誌, 82, 2, 512, 512, Sep. 2006
  (一社)日本内分泌学会, Japanese
• 急性心筋炎に対するアドレノメデュリンの効果
  大西 俊介; Yanagawa Bobby; 片岡 雅晴; 小玉 誠; 寒川 賢治; 永谷 憲歳, 日本内分泌学会雑誌, 82, 2, 514, 514, Sep. 2006
  (一社)日本内分泌学会, Japanese
• 骨髄間葉系細胞と骨髄単核球の遺伝子発現の差異の検討
  大西 俊介; 永谷 憲歳; 安田 剛; 北村 総一郎, 日本内分泌学会雑誌, 82, 2, 514, 514, Sep. 2006
  (一社)日本内分泌学会, Japanese
• コントラストエコー法を用いた新生血管評価 ラット下肢虚血モデルによる検討
  大谷 健太郎; 永谷 憲歳; 石田 治; 小幡 裕明; 大西 俊介; 北村 惣一郎, 日本内分泌学会雑誌, 82, 2, 515, 515, Sep. 2006
  (一社)日本内分泌学会, Japanese
• 【高血圧 最新の研究動向】 基礎編 血圧調節因子 循環生理活性物質 グレリン
  大西 俊介; 永谷 憲歳; 寒川 賢治, 日本臨床, 64, 増刊5 高血圧(上), 151, 155, Jul. 2006
  (株)日本臨床社, Japanese
• Ghrelin
  Shunsuke Ohnishi; Noritoshi Nagaya; Kenji Kangawa, Nippon rinsho. Japanese journal of clinical medicine, 64, 151, 155, 2006
  Japanese, Book review
• Downregulation and growth inhibitory effect of epithelial-type Krüppel-like transcription factor KLF4, but not KLF5, in bladder cancer.
  Shunsuke Ohnishi; Sumiko Ohnami; Friedrich Laub; Kazunori Aoki; Koichi Suzuki; Yae Kanai; Kazunori Haga; Masahiro Asaka; Francesco Ramirez; Teruhiko Yoshida, Biochemical and biophysical research communications, 308, 2, 251, 6, 22 Aug. 2003, [International Magazine]
  Krüppel-like factors (KLFs) are key transcriptional regulators of cell differentiation and proliferation. Among the KLF family, the expression of KLF4 (GKLF) and KLF5 (IKLF) is highly restricted in the epithelial cells of several organs such as the gut and skin, and it has been reported that these epithelial-type KLF genes may be involved in colon carcinogenesis. Recently we found that Klf4 and Klf5 genes were significantly expressed in the developmental bladder epithelium of mice as well. Therefore, in this report we studied the involvement of the KLF4 and KLF5 genes in bladder carcinogenesis. First, we analyzed the expression of KLF4 and KLF5 in a variety of human bladder cancer cell lines and surgical specimens by RNA blot and in situ hybridization analyses. Both genes were highly expressed in the normal bladder epithelium, whereas KLF4, but not KLF5, was frequently downregulated in bladder cancer cell lines and cancer tissues. We then transduced the KLF4 and KLF5 genes into the bladder cancer cell lines using adenoviral vectors to examine the biological activities of the genes on those cells. The transduction of KLF4, but not KLF5, suppressed cell growth and induced apoptosis. Our study suggests that inactivation of KLF4 is one of the frequent steps towards bladder carcinogenesis., English
• CTHAで低吸収域を示す肝結節性病変
  髭 修平; 関口 真弓; 大西 俊介; 小林 隆彦; 浅香 正博, 北海道医学雑誌, 77, 6, 588, 588, Nov. 2002
  北海道医学会, Japanese
• ラミブジン投与の効果と問題点 B型慢性肝炎ラミブジン治療例の投与中止後の検討
  中西 満; 髭 修平; 畑中 一映; 大西 俊介; 中馬 誠; 小林 隆彦; 浅香 正博; 松嶋 喬, 肝臓, 43, Suppl.3, A451, A451, Nov. 2002
  (一社)日本肝臓学会, Japanese
• prothymosin-αによるp53の転写活性制御
  小林 隆彦; 大西 俊介; 浅香 正博, 日本癌学会総会記事, 61回, 234, 234, Oct. 2002
  日本癌学会, Japanese
• ラミブジン耐性株が出現したB型肝炎症例の検討
  髭 修平; 中西 満; 中馬 誠; 大西 俊介; 小林 隆彦; 浅香 正博, 肝臓, 43, Suppl.1, A53, A53, May 2002
  (一社)日本肝臓学会, Japanese
• ラミブジン投与例に対するIFNあるいはHBワクチン併用の検討
  髭 修平; 関口 真弓; 大西 俊介; 中馬 誠; 小林 隆彦; 浅香 正博, 日本消化器病学会雑誌, 99, 臨増総会, A276, A276, Mar. 2002
  (一財)日本消化器病学会, Japanese
• B型肝炎におけるラミブジン耐性株出現例の検討
  関口 真弓; 髭 修平; 大西 俊介; 小林 隆彦; 浅香 正博, 肝臓, 42, Suppl.2, A412, A412, Sep. 2001
  (一社)日本肝臓学会, Japanese
• Cyclophosphamide大量間欠投与が奏効した特発性寒冷凝集素症
  中川 雅夫; 宮城島 拓人; 鎌田 崇宏; 新井 尚子; 三浦 慶昭; 大西 俊介; 岸本 篤人; 神島 雄一郎; 崔 公賢; 工藤 峰生; 岡部 實裕, 臨床血液, 42, 9, 713, 715, Sep. 2001
  55歳女.貧血を指摘されたが放置,感冒様症状および全身倦怠感が出現したため受診し,特発性寒冷凝集素症と診断され,プレドニゾロン(PSL)療法,シクロスポリン療法を施行されたが治療抵抗性であった.眼瞼結膜には貧血がみられ,眼球結膜にも黄染が認められ,白血球と好中球は高値で,PSL投与の影響と思われた.さらに末梢血は大小不同があり,赤芽球も出現し,末梢血塗抹標本においては赤血球の著明な凝集が認められ,また網状赤血球とビリルビンは上昇,LDHは高値であったが,アイソザイムには異常が認められなかった.血清学的検査では寒冷凝集素512倍,エリスロポイエチン上昇,ハプトグロビン低下,直接・間接クームス試験陽性も認められた.以上の経過から,シクロフォスファミド大量間欠療法を4週間隔で行ったが,患者のHbは速やかな上昇をし,自覚症状も著明に改善していった, (一社)日本血液学会-東京事務局, Japanese
• 【血管新生】 抗血管新生薬の開発
  大西 俊介, 臨床検査, 44, 13, 1643, 1645, Dec. 2000
  (株)医学書院, Japanese
• Kruppel型転写因子KLF4/GKLFのがんにおける発現と機能解析
  大西 俊介; 青木 一教; Ramirez Francesco; 金井 弥栄; 芳賀 一徳; 小柳 知彦; 浅香 正博; 寺田 雅昭; 吉田 輝彦, 日本癌学会総会記事, 59回, 513, 513, Sep. 2000
  日本癌学会, Japanese
• Kruppel型転写因子BTEB2の各種がん細胞における発現の検討
  大西 俊介; 松本 伸行; Francesco Ramirez; 寺田 雅昭; 吉田 輝彦, 日本癌学会総会記事, 58回, 485, 485, Aug. 1999
  日本癌学会, Japanese
• がん細胞におけるKruppel型転写因子UKLF及びCPBPの発現
  松本 伸行; 大西 俊介; 佐々木 一樹; Ramirez Frencesco; 寺田 雅昭; 吉田 輝彦, 日本癌学会総会記事, 58回, 535, 535, Aug. 1999
  日本癌学会, Japanese
• 強化療法として自己造血幹細胞移植併用大量化学療法を施行した予後不良ユーイング肉腫の2例
  大西 俊介; 中川 学; 小林 直樹; 小笠原 正浩; 木山 善雄; 直原 徹; 比嘉 敏夫; 佐藤 利宏; 笠井 正晴; 武田 直樹, 癌の臨床, 44, 9, 925, 929, Sep. 1998
  症例1は23歳女,左大腿骨原発であり,症例2は12歳男,Th5〜7の硬膜外原発であった.大量化学療法はIfosphamide 10g/m2,Carboplatin 1,000mg/m2,Etoposide 1,250mg/m2(ICE療法)を行い,ASCTを施行した.2例とも重篤な非血液毒性を認めず,安全に施行可能であった.ASCT施行後,1年以上の無病生存を得ている, (株)篠原出版新社, Japanese
• 再生不良性貧血に対するcyclosporine併用anti-thymocyte globulin療法の検討
  大西 俊介; 中川 学; 小林 直樹; 小笠原 正浩; 木山 善雄; 直原 徹; 比嘉 敏夫; 笠井 正晴, 臨床血液, 39, 9, 640, 644, Sep. 1998
  再生不良性貧血に対してシクロスポリンを併用した抗ヒト胸腺細胞グロブリン(ATG)療法を試みた9例を対象とし,その有効性,Tリンパ球の変動,合併症について検討した.対象は男4例,女5例で年齢中央値は55歳.重症が8例,中等症が1例.初回治療例が3例,治療抵抗例が6例.投与直後から急速に著明なTリンパ球の減少,消失がみられ,CD4,CD8陽性細胞共に減少した.1例は肺出血で死亡,6ヵ月以上の観察期間で著効は3例,やや有効は2例,無効は3例.ATGによる薬物有害反応としては,一過性の発熱,掻痒感,皮疹等がみられたが,重篤な症状は認められなかった.シクロスポリンを併用したATG療法は有用であり,安全に施行しうる, (一社)日本血液学会-東京事務局, Japanese
• 慢性骨髄性白血病の同種末梢血幹細胞移植後の細胞遺伝学的再発に対するドナーリンパ球輸血の試み
  大西 俊介; 中川 学; 大川原 辰也; 中川 宗一; 依田 有生; 大泉 弘子; 小林 直樹; 小笠原 正浩; 木山 善雄; 直原 徹, 日本輸血学会雑誌, 44, 4, 586, 586, Aug. 1998
  (一社)日本輸血・細胞治療学会, Japanese
• 縦隔原発NK細胞性リンパ腫/白血病の一例
  大西 俊介, International Journal of Hematology, 67, Suppl.1, 161, 161, Apr. 1998
  (一社)日本血液学会, Japanese
• 透析患者におけるHelicobacter pyloli感染の検討
  大泉 弘子; 斎藤 雅雄; 中川 宗一; 大川原 辰也; 依田 有生; 中川 学; 大西 俊介; 小林 直樹; 木山 善雄; 小笠原 正浩, 日本消化器病学会雑誌, 95, 臨増, 181, 181, Mar. 1998
  (一財)日本消化器病学会, Japanese
• 自家末梢血造血幹細胞移植症例の検討 : 日本アフェレシス学会第17回北海道地方会
  直原 徹; 中川 学; 大西 俊介; 小林 直樹; 小笠原 正浩; 木山 善雄; 比嘉 敏夫; 笠井 正晴, 日本アフェレシス学会雑誌, 17, 2, 154, 154, 1998
  日本アフェレシス学会, Japanese
• 再生不良性貧血に対するシクロスポリン併用ATG療法の検討
  大西 俊介, 臨床血液, 38, 10, 1039, 1039, Oct. 1997
  (一社)日本血液学会-東京事務局, Japanese
• 強化療法として自己末梢血幹細胞移植(PBSCT)併用大量化学療法を施行したユーイング肉腫の2症例
  大西 俊介, 日本癌治療学会誌, 32, 5, 688, 688, Aug. 1997
  (一社)日本癌治療学会, Japanese
• 多発性筋炎に併発した非Hodgkinリンパ腫
  大西 俊介; 小田 寿; 仲屋 裕樹, 臨床血液, 38, 7, 582, 586, Jul. 1997
  67歳男多発性筋炎(PM)と診断され,プレドニンを投与されていた.その後鼻閉が出現し,CTにて上咽頭に充実性の腫瘍を認めた.同部の生検にて非Hodgkin悪性リンパ腫(diffuse medium,B cell type)と診断された.骨髄浸潤を認め臨床病期IVであった.CHOP療法を6コース施行し,完全寛解を得たが,1ヵ月後に中枢神経浸潤を認め,嚥下性肺炎を併発し死亡した, (一社)日本血液学会-東京事務局, Japanese
• Hodgkin病とT cell lymphomaのcomposite lymphomaが疑われた1例
  大西 俊介, 日本リンパ網内系学会会誌, 37, 2, 67, 67, May 1997
  (一社)日本リンパ網内系学会, Japanese
• 多発性筋炎に併発し,中枢神経浸潤を認め死亡した悪性リンパ腫の1例
  大西 俊介, 臨床血液, 37, 2, 186, 186, Feb. 1996
  (一社)日本血液学会-東京事務局, Japanese
• A Case of Early Non-Hodgkin's Lymphoma of the Duodenum
  Takuto Miyagishima; Shunsuke Ohnishi; Makoto Chuma; Atuhito Kishimoto; Kenichi Kumagai; Masaru Aoshima; Jun Ishizuka; Takahiko Kobayashi; Nozomu Fujimoto; Yoshinobu Hata; Tetuo Oku; Kazuhiro Ogasawara; Taturo Takahashi; Takumi Ohmura, GASTROENTEROLOGICAL ENDOSCOPY, 37, 12, 2761, 2767,2781, 1995
  (一社)日本消化器内視鏡学会, English
• 精索原発悪性リンパ腫の1例
  大西 俊介, 臨床血液, 35, 12, 1392, 1392, Dec. 1994
  (一社)日本血液学会-東京事務局, Japanese

• 卒業研究準備実習Ⅰ, 2024年, 学士課程, 薬学部
• 生命医薬科学概論, 2024年, 修士課程, 生命科学院
• 卒業研究準備実習Ⅱ, 2024年, 学士課程, 薬学部
• 薬物治療学特論, 2024年, 博士後期課程, 生命科学院
• 薬学論文講読演習Ⅰ, 2024年, 学士課程, 薬学部
• 健康と社会, 2024年, 学士課程, 全学教育
• 薬学論文講読演習Ⅱ, 2024年, 学士課程, 薬学部
• 病態生理学Ⅰ, 2024年, 学士課程, 薬学部
• 薬学論文講読演習Ⅲ, 2024年, 学士課程, 薬学部
• 病態生理学Ⅱ, 2024年, 学士課程, 薬学部
• 薬学総合演習, 2024年, 学士課程, 薬学部
• 病態生理学Ⅲ, 2024年, 学士課程, 薬学部
• 薬学卒業研究, 2024年, 学士課程, 薬学部
• 漢方医学, 2024年, 学士課程, 医学部
• 薬科学演習, 2024年, 学士課程, 薬学部
• 生薬学・漢方医学, 2024年, 学士課程, 薬学部
• 薬科学論文講読演習, 2024年, 学士課程, 薬学部
• 薬科学卒業研究, 2024年, 学士課程, 薬学部
• 生命科学研究, 2024年, 修士課程, 生命科学院
• 生命科学実習, 2024年, 修士課程, 生命科学院
• 生命科学論文講読Ⅰ, 2024年, 修士課程, 生命科学院
• 生命科学論文講読Ⅱ, 2024年, 修士課程, 生命科学院
• 医学総論, 2024年, 博士後期課程, 医学研究科
• 生命科学特別研究, 2024年, 博士後期課程, 生命科学院
• 生命科学文献講読, 2024年, 博士後期課程, 生命科学院

• Identification of anti-fibrotic humoral factors from mesenchymal stromal cells
  Grants-in-Aid for Scientific Research
  01 Apr. 2026 - 31 Mar. 2029
  大西 俊介; 柘植 厚志
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 26K10918
• Development of a new endoscopic treatment method for bile duct damage/defect using bioabsorbable bile duct substitutes
  Grants-in-Aid for Scientific Research
  01 Apr. 2024 - 31 Mar. 2027
  宮澤 光男; 大西 俊介; 高島 順平
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), International University of Health and Welfare, 24K11074
• Therapeutic effect of gene-modified MSC-derived exosomes in liver fibrosis
  Grants-in-Aid for Scientific Research
  01 Apr. 2023 - 31 Mar. 2026
  大西 俊介; 大久保 直登
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 23K07388
• Comprehensive search for host factors related to liver fibrosis mechanisms and development of novel therapeutic strategies
  Grants-in-Aid for Scientific Research
  01 Apr. 2022 - 31 Mar. 2025
  坂本 直哉; 大西 俊介; 須田 剛生
  本研究は，従来非可逆的とされていた肝硬変症の組織病態を積極的に修復する手法を開発するために，肝硬変の組織病態の修復機構を解析し、肝星細胞を標的とした細胞・薬物療法による肝線維化の組織修復を促進する治療法の効果、作用機構等を解析することを目的として遂行し、以下の成果を得た。
  1. 血清組織糖鎖修飾構造の網羅的探索： ●NAFLDの線維化の進展に伴い患者血清中のA2F bisect 糖鎖の発現が疾患特異的に上昇することを示した。●プロテオグリカンの主要成分の一つであるグリコサミノグリカン（GAG）のヘテロ多糖の構造分析系を構築した。2. 培養星細胞をもちいた肝線維化・修復に関連する成分分析：● A2F bisect糖鎖のキャリア蛋白としてIgAをはじめとする複数の蛋白を同定した。●同定された糖鎖修飾構造、キャリア蛋白の修飾の線維化進展に与える影響を解析する。また、糖鎖修飾構造に対する特異抗体を用いた星細胞活性化抑制効果についても解析を進める。● 培養肝星細胞活性化に関連するmicro RNAの包括的解析を施行し、miR-29a、miR-449a、その他特定のmiRNAが活性化星細胞で高発現し、knock downにより星細胞alpha-SMA、type-I collagen発現が抑制されることを示した。Pathway解析では、これらのmiRNAは細胞骨格、細胞外マトリックス、chemotaxis関連経路の蛋白の発現を調節していることが明らかとなった。● C型肝炎SVR後発癌症例では血清中のAng2が有意に高値であり、治療標的としての可能性が示された。
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 23K24311
• Comprehensive search for host factors related to liver fibrosis mechanisms and development of novel therapeutic strategies
  Grants-in-Aid for Scientific Research
  01 Apr. 2022 - 31 Mar. 2025
  坂本 直哉; 大西 俊介; 須田 剛生
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 22H03050
• ゲル化されたMSC由来エクソソームの内視鏡的粘膜下層剥離術後食道狭窄に対する効果
  科学研究費助成事業
  01 Apr. 2022 - 31 Mar. 2025
  小野 尚子; 大西 俊介; 黒川 孝幸; 大野 正芳
  日本学術振興会, 基盤研究(C), 北海道大学, 22K08001
• Development of a new minimally invasive treatment for bile duct disease using a bioabsorbable bile duct substitute
  Grants-in-Aid for Scientific Research
  01 Apr. 2021 - 31 Mar. 2024
  宮澤 光男; 大西 俊介; 高島 順平
  本研究の目的は、胆管欠損部に生体吸収性胆管代替物（Bioabsorbable bile duct substitute: BBDS）を移植し、その部位に胆管を再生させる新規低侵襲治療法の開発である。現在、外科治療の方向性は機能温存および低侵襲にあるが、肝外胆管欠損の治療法は、乳頭部機能を廃絶した胆管―腸再建が通常行われ、機能温存の方向にはない。この再建法では、逆行性胆管炎が起こり理想的ではなく、他の治療法が求められている。本研究では、胆管欠損部を直接修復可能で、その部位に狭窄なく胆管再生が可能な胆管再建用BBDSの開発を目指す。具体的には、BBDSを用い、肝門部領域胆管癌手術の低侵襲化を目指し、Y字（左右肝管を模倣）に胆管を再生させること、さらに内視鏡的に胆管欠損部を修復させること（腹腔鏡下胆嚢摘出術時の胆管損傷治療を想定）が可能かを検討し、胆管系疾患に対する新規低侵襲治療法を開発する。
  本年度は、BBDSを用いて、Y字に胆管を再生させる手技の実験研究を行った。（外部の動物実験施設にて）。本BBDSにて、肝外胆管を再生させることは可能となったが、確実にY字に再生させることにおいては、さらなる改善が必要である段階である（時々、再生胆管の狭窄が認められた）。内視鏡を用いた、胆管修復、再生の研究は、順調に進行しており、論文作成の段階である。
  生体吸収性材料の消化器系疾患への応用は、一部、吻合部組織補強材として用いられているが、始まったばかりであり、本BBDSの臨床研究施行のための実験を重ねていく予定である。
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Teikyo University, 21K08786
• Examination of the therapeutic effect on inflammatory bowel disease using HSPB6-positive exosomes derived from amnion-derived MSCs
  Grants-in-Aid for Scientific Research
  01 Apr. 2021 - 31 Mar. 2024
  桂田 武彦; 山本 幸司; 大西 俊介; 武井 則雄
  本研究では、羊膜MSCから産生されるHSPB6陽性エクソソームを用いた抗炎症効果の詳細を細胞実験ならびに炎症性腸疾患誘導性動物モデルを用いて、未だ適切な治療法がないヒト炎症性腸疾患に対する臨床応用への基盤を整える。本研究では、以下の通り、HSPB6過剰発現ならびにHSPB6欠損羊膜MSCの作成およびそれらエクソソームの樹立することを明らかにした。羊膜MSCのHSPB6過剰発現株ならびに遺伝子欠損株を樹立する。HSPB6過剰発現株の作成には、CMVプロモーター下にHSPB6遺伝子を挿入したプラスミドをMSCに導入後、薬剤選択による選別を行い、得られたクローンはウエスタンブロット法による野生型およびmockコントロールとの比較解析から、有意に発現増加の認められるクローンを選別することで樹立した。HSPB6欠損株の作成にはCRISPR/Cas9システムを採用し、ヒトHSPB6エクソン領域に特異的なgRNAを設計し、CAGプロモーター下でCas9およびT3プロモーター下でgRNAを発現するプラスミドを構築、MSCに導入し、genotypingによる標的遺伝子座での塩基の欠損が認められ、ウエスタンブロット法で標的分子の翻訳消失が認められるクローンを選別した。結果、20個のクローン中4～5個程度の目的クローンが選別することができた。さらに、その細胞からエクソソームを精製し、HSPB6の発現について確認したところ、HSPB6過剰発現株ではMOCKに比べてHSPB6の発現が増加していた一方、HSPB6欠損株では、HSPB6の発現が消失していることを確認した。これらのことから、本研究において、HSPB6過剰発現株ならびにHSPB6欠損発現株が樹立され、さらに両株から産生される目的となるエクソソームも精製することができた。
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 21K07952
• Spine-gut relationship in the treatment of spinal cord injury with stem cell
  Grants-in-Aid for Scientific Research
  01 Apr. 2020 - 31 Mar. 2023
  関 俊隆; 大西 俊介; 川堀 真人
  【背景】脊髄損傷に対する再生治療・細胞治療は多くの基礎研究において有効性が報告され始めているが, その作用機序は全身の炎症制御や損傷部位への幹細胞生着によるネットワークの回復など多岐にわたると考えられている. 近年, 全身の免疫センターとしての機能を有する腸管と他臓器の関連が注目されており, 脊髄損傷においても腸管との関連（脊髄-腸相関）が報告されているが, 幹細胞投与がこの相関にどのように関与しているかは未だ明らかになっていない. 本研究では, 急性期脊髄損傷に対する羊膜由来間葉系幹細胞（AMSC）静脈投与が, “脊髄-腸相関”に与える影響を検討した.
  【方法】SDラットを用い, Th6/7高位で, クリップ圧挫脊髄損傷モデルを作成した. 脊髄損傷の翌日, 一定以上の麻痺を認めたラットに対し, 無作為にヒトAMSC（1x107個, A群）または生理食塩水（C群）を尾静脈投与した. AMSCの分布は, XenoLight DiRで標識し, Fusionでin-vivo imagingを行った. 腸管評価は3日後と2週間後に, 運動機能評価は4週間後まで行い, その後に病理学的検討を加えた.
  【結果】AMSCは1週間後まで主に肺と肝臓に集積していたが, 急性期には脊髄内にも確認された. A群はC群に比較し, 脊髄損傷3日後以降で回腸の絨毛構造の改善を認めた. 運動機能は2週以降, A群で有意に改善し, 病理学的評価においても, 損傷部位の縮小および炎症細胞浸潤が減少していた.
  【考察・結語】本研究の結果から, 脊髄損傷により回腸絨毛構造が悪化するが, 羊膜細胞投与により, 運動機能回復に先立って回腸絨毛構造が改善することが明らかとなった. 今後、bacterial translocationの関与を検討する
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 20K09361
• Identification of novel anti-inflammatory factor secreted by amnion-derived mesenchymal stem cells and investigation of therapeutic effect
  Grants-in-Aid for Scientific Research
  01 Apr. 2020 - 31 Mar. 2023
  山本 桂子; 大西 俊介; 山本 幸司; 和泉 自泰
  間葉系幹細胞は、出産時に廃棄される羊膜にも存在していることが知られており、次世代の再生医療材料として期待されている。申請者らは、ヒト卵膜から短期 間で簡便に間葉系幹細胞 を分離培養する技術を確立し、腸炎、肝炎、膵炎などの複数の炎症性疾患動物モデルに対して、細胞ならびにその培養上清を投与した ところ、いずれも高い治療効果を発揮することを明らかにしてきた。本研究では、羊膜由来間葉系幹細胞のもつ新規抗炎症因子の同定を行い、難治性として知られる炎症性腸疾患における新規治療効果の検討を探索することを目的としている。そこで本研究では、羊膜MSC由来新規物質の抗炎症効果の検証するために培養細胞を用いて検証を行った。具体的には以下の通り実施した。
  マウス由来マクロファージを用いて、LPSで刺激後、羊膜MSC由来新規物質を処理し、LPS刺激後に産生される複数の炎症性サイトカインをELISA法で検証した。結果、LPS刺激後のマクロファージに羊膜MSC由来新規物質処理するとTNF-αやIL-6などの炎症性サイトカインの発現が著しく低下したほか、培養上清中の炎症性サイトカインの産生も低下していた。さらに、ウエスタンブロット法を用いて、炎症性サイトカインの産生に重要な転写因子であるNF-kBやIkBなどの活性化を確認した。結果、LPS刺激後のマクロファージではNF-kBやIkBなどの活性化が確認されたが、羊膜MSC由来新規物質を処理するとこれら転写因子の活性化が抑制されていることが明らかとなった。これらのことから、in vitroの系を用いた細胞培養実験において羊膜MSC由来新規物質の抗炎症効果が明らかとなった。
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 20K08347
• Effect of amnion-derived mesenchymal stem cells for the treatment of radiation-induced oral mucositis
  Grants-in-Aid for Scientific Research
  01 Apr. 2019 - 31 Mar. 2022
  Yuki Satoshi
  The aim of this study was to investigate the effect of amnion-derived mesenchymal stem cells (AMSCs) for the treatment of radiation-induced oral mucositis.
  We prepared conditioned medium from AMSCs, and applied the conditioned medium on the tongue after irradiation. Body weight loss was slightly improved by the treatment, but there was no statistical significance. Pathological score was not improved by the treatment, and the expressions of several inflammatory cytokines were not improved by the treatment.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 19K08192
• Comprehensive screening of miviroenvirinmental factors that affect liver fibrosis
  Grants-in-Aid for Scientific Research
  01 Apr. 2019 - 31 Mar. 2022
  Sakamoto Naoya
  1. Comprehensive analysis of serum glycan modification structures revealed that the expression of A2F bisect glycans is upregulated in patients with advanced liver fibrosis in NASH. 2. We identified several carrier proteins of A2F bisect glycans including IgA. We identified several carrier proteins of A2F bisect glycans, including IgA. 3. Comprehensive analysis of micro RNAs associated with the activation of cultured hepatic astrocytes revealed that miR-29a, miR-449a, and other specific miRNAs were highly expressed in activated astrocytes and regulated the expression of proteins in the cytoskeleton, extracellular matrix, and chemotaxis-related pathways by pathway analysis. 4. serum Ang2 was significantly elevated in hepatitis C post-SVR carcinoma cases.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 19H03630
• Effect of EPA-resolvin secreted from amnion-derived mesenchymal stem cells on premature birth
  Grants-in-Aid for Scientific Research
  01 Apr. 2018 - 31 Mar. 2021
  Ohnishi Shunsuke
  Mesenchymal stem cells have been reported to be a promising cell source in regenerative medicine. We analyzed secretory factors from amnion-derived mesenchymal stem cells, and identified eicosapentaenoic acid (EPA) and its metabolite resovlin E1 (RvE1).
  When we administered EPA to LPS-induced premature birth model rats, it improved premature birth, and the concentrations of EPA and RvE1 in amniotic fluid were recovered. These results suggest that EPA prevents preterm birth via RvE1.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 18K09214
• Development of new treatment method for prevention of gastrointestinal perforation and closure of perforation with bioabsorbable material
  Grants-in-Aid for Scientific Research
  01 Apr. 2017 - 31 Mar. 2020
  Miyazawa Mitsuo
  The purpose of this study is to prevent perforation and close perforation after endoscopic submucosal dissection (ESD) of the esophagus, stomach, and large intestine by regenerating the digestive tract using a bioabsorbable material. It is the result of this study that an animal experiment was conducted at Hokkaido University from the middle of the research period, and the establishment of a procedure for perforation of the duodenum after ESD was almost developed. The new bioabsorbable materials used in this study are currently under consideration for facilities where clinical research can be conducted.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Teikyo University, 17K09481
• Multicenter study to detect early esophageal and esophagogastric junctional adenocarcinoma using a fluorescent probe
  Grants-in-Aid for Scientific Research
  01 Apr. 2017 - 31 Mar. 2020
  Yamamoto Keiko
  Recent advances in endoscopic diagnostics and techniques have enabled early detection and resection of gastrointestinal cancer. But it is still difficult to detect and diagnose early adenocarcinoma of the esophagogastric junction (EGJ) using conventional endoscopy or image-enhanced endoscopy.
  Recently, a glutamylprolyl hydroxymethyl rhodamine green (EP-HMRG) fluorescent probe that can be enzymatically activated by a dipeptidyl peptidase (DPP)-IV expressed on the surface of several cancers has been developed.This study showed that the tumor lesions were visualized within a few minutes after the application of EP-HMRG and suggested that Fluorescence imaging with EP-HMRG could be useful for the detection of early EGJ adenocarcinoma lesions.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 17K09343
• Prevention of stricture formation after endoscopic submucosal dissection using mesenchymal stem cell culture supernatant
  Grants-in-Aid for Scientific Research
  01 Apr. 2017 - 31 Mar. 2020
  Ono Shoko
  Endoscopic submucosal dissection (ESD) for esophageal cancer often causes postoperative stricture when more than three-quarters of the circumference of the esophagus is dissected. Mesenchymal stem cells are a valuable cell source in regenerative medicine, and conditioned medium (CM) obtained from mesenchymal stem cells reportedly inhibits inflammation. In this study, we evaluated whether CM could prevent esophageal stricture after ESD.
  In a pig model of esophageal stricture after ESD, CM gel prevented esophageal stricture formation by suppressing myofibroblast activation and fibrosis following the infiltration of neutrophils and macrophages in acute phase. Oral administration of CM gel would be a promising treatment for the prevention of post-ESD stricture. We are currently evaluating the effect of CM on the prevention of re-stricture after balloon dilation.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 17K09342
• Search for new cell- or small molecule-based therapies to promote regression of liver cirrohsis
  Grants-in-Aid for Scientific Research
  01 Apr. 2016 - 31 Mar. 2019
  Sakamoto Naoya
  The present study was conducted to search for therapeutic candidates (peptides, small molecules and miRNAs) to target liver fibrosis and activation of hepatic stellate cells and to analyze their mechanisms of action. The main results are as follows; (1) We confirmed suppressive effects of liver fibrosis and inflammation of exosomes derived from the culture supernatant of human amniotic membrane-derived mesenchymal stem cells. (2) palmitoylethanolamide (PEA) inhibited activation of hepatic stellate cells through PPAR-independent mechanisms. (3) Comprehensive glycan modification structure analysis indentified fucosyl modification of serum proteins as markers that associate with NAFL to NASH progression. (4) Comprehensive analysis of microRNAs related to cultured hepatic stellate cell activation identified miRNAs that up- or down-regulated in activated stellate cells.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 16H05282
• Regenerative medicine with the low-molecular-weight secretory factors from fetal membrane-derived mesenchymal stem cells
  Grants-in-Aid for Scientific Research
  01 Apr. 2014 - 31 Mar. 2017
  Ohnishi Shunsuke; Masahiro Mori
  In this study, I focused on the secretory factors from fetal membrane-derived mesenchymal stem cells, and found that low-molecular-weight fraction of conditioned medium had an anti-inflammatory effect. In addition, I identified a novel secretory lipid that attenuates rats with non-alcoholic steatohepatitis.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 26501001
• Detection of head and neck cancer by spraying cancer-specific fluorescent probe
  Grants-in-Aid for Scientific Research
  01 Apr. 2014 - 31 Mar. 2017
  Ono Shoko; Urano Yasuteru; Shimizu Yuichi; Ohnishi Shunsuke; Hatanaka Kanako
  γ-glutamyltranspeptidase (GGT), a cell surface enzyme, is overexpressed in several cancers, and it has been reported that γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG), a fluorescent targeting agent which can be enzymatically activated and becomes fluorescent after cleavage of a GGT-specific sequence. We investigated whether early HNSCC can be detected by applying gGlu-HMRG to clinical samples.
  All four gGlu-HMRG-applied cell lines emitted green fluorescence. Immunohistological examination demonstrated that GGT was highly expressed in HNSCC of the recent three ESD cases but barely expressed in the normal mucosa. Fluorescence imaging showed that iodine-voiding lesions became fluorescent within a few minutes after application of gGlu-HMRG in all eight resected cases. Tumor ROI fluorescence intensity was significantly higher than in the normal mucosa five minutes after gGlu-HMRG application. Fluorescence imaging with gGlu-HMRG would be useful for early detection of HNSCC.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 26461043
• Role of Macrophage migration inhibitory factor in non-alcoholic steatohepatitis
  Grants-in-Aid for Scientific Research
  01 Apr. 2013 - 31 Mar. 2016
  OHKAWARA Tatsuya; TAKEDA Hiroshi; OHNISHI Shunsuke
  We investigate the role of macrophage migration inhibitory factor (MIF) in non alcoholic steatohepatitis (NASH) using animal model. Methionine and choline-deficient diet(MCD) induces NASH in mice. The expression of MIF was up-regulated in liver of mice given MCD. However, ISO-1, an inhibitor of MIF bioactivity, did not ameliorated the severity of NASH in mice. In another hepatitis model induced by acetaminophene, ISO-1 reduced the severity of liver injury and decrease the level of inflammatory mediater. Taken together, our data suggest that the role of MIF is perplexing in NASH.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 25460968
• Effect of fetal membrane-derived mesenchymal stem cells in rats with acute pancreatitis
  Grants-in-Aid for Scientific Research
  01 Apr. 2012 - 31 Mar. 2015
  KUWATANI Masaki; KAWAKUBO Kazumichi; OHNISHI Shunsuke
  Objectives: We investigated the effect of rat FM-derived mesenchymal stem cells (FM-MSCs) and human amnion-derived MSCs (AMSCs) on the therapeutic effects in rats with acute and chronic pancreatitis.
  Methods: Acute pancreatitis was induced by intraductal injection of taurocholate, and rat FM-MSCs were transplanted intravenously. Chronic pancreatitis was induced by intravenous injection of 5 mg/kg dibutyltin dichloride, and human AMSCs were transplanted intravenously.
  Results: Transplantation of rat FM-MSCs significantly reduced the histological score and infiltration of CD68-positive macrophages in the rat pancreas. Human AMSC transplantation significantly decreased the expression of MCP-1 and attenuated the downregulation of amylase expression in the pancreas. Conclusions: Transplantation of FM-MSCs and AMSCs suppressed the inflammatory reaction of acute and chronic pancreatitis in rats.
  Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists (B), Hokkaido University, 24790670
• Development of a novel treatment with fetal membrane-derived mesenchymal stem cells to enteritis by chemoradiation
  Grants-in-Aid for Scientific Research
  2011 - 2013
  Ohnishi Shunsuke
  Radiation enteritis is caused by radiation therapy to cancer patients, or by an accident in nuclear power plants. The aim of the study was to explore the new strategy to treat radiation enteritis, and I investigated the effect of fetal membrane-derived mesenchymal stem cells in vivo and in vitro.
  Treatment with human amnion-derived mesenchymal stem cells in rats with radiation enteritis ameliorated histological observations and the expression of proinflammatory cytokines. In vitro experiments demonstrated that radiation-induced cell injury was suppressed by human amnion-derived mesenchymal stem cells.
  Taken together, amnion-derived mesenchymal cells could be considered as a new treatment for radiation enteritis.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 23618001
• siRNAを用いた肺高血圧治療法の開発
  科学研究費助成事業
  2007 - 2008
  永谷 憲歳; 佐田 正晴; 大西 俊介; 山原 研一
  肺動脈性肺高血圧症は、肺血管内皮細胞の機能障害により肺動脈の収縮や肺血管内皮・平滑筋細胞の増殖を来たす難治性疾患である。既存の治療薬は血管拡張を主な作用点としており、治療抵抗例が存在するため、我々は治療のターゲットを主たる病因である肺動脈の血管内皮・血管平滑筋細胞の増殖へ転換する必要があると考えた。肺高血圧症では、細胞増殖・分化を制御するMAPKシグナリングが病態へ関与していると考えられており、まずこのシグナル蛋白であるMEKを標的としたsiRNAをデサインし、その効果を確認した。ラットMEK1および2の双方に相同性をもつ21merのsiRNAを合成し、培養ラット血管平滑筋細胞(A7r5)にリポフェクションさせ、標的遺伝子、蛋白の抑制効率をそれぞれ定量的Real time PCR法、Western blotting法により検討したところ、siRNA濃度が1nMの低濃度でも85%以上の抑制効率を示し、また濃度10nMにおける経時的検討では少なくとも96時間以上その抑制効果が持続していた。次に、このsiRNAの血管平滑筋細胞に対する増殖抑制効果を、MAPKカスケードを下流とする増殖因子であるPDGF-BB刺激下にMTS assayを用いて検討したところ、siRNA濃度依存的に血管平滑筋細胞の増殖が抑制されていた。さらに、アポトーシス誘導効果をカスパーゼ3および7の細胞内活性を測定し検討したところ、やはり濃度依存的にアポトーシス誘導が起こっていた。以上より、我々のデザインした合成siRNAはラノト血管平滑筋細胞の標的蛋白合成を効率的に阻害し、期待された増殖抑制およびアポトーシス誘導の表現型を示すことが証明された。現在、このsiRNAを脂質化合物を用いて生体内での安定性を確保した薬物送達システムを開発中であり、ラット肺高血圧モデルを用いて標的となる肺動脈への導入効率を検討する予定である。
  日本学術振興会, 基盤研究(C), 国立循環器病センター(研究所), 19590927

• 内視鏡用生体吸収性シート及びその製造方法
  Patent right, 吉田 蓮実; 山内 康治; 大野 正芳; 大西 俊介, グンゼ株式会社, 国立大学法人北海道大学
  特願2021-001429, 07 Jan. 2021
  特開2022-106435, 20 Jul. 2022
  特許第7692557号
  202503017588275280
• 間葉系幹細胞を含む細胞集団を含有する軟部組織再生用医薬組成物
  Patent right, 林 真広; 中石 智之; 大西 俊介; 伊藤 梨里, 株式会社カネカ, 国立大学法人北海道大学
  特願2021-017768, 05 Feb. 2021
  特開2022-120698, 18 Aug. 2022
  特許第7672647号
  202503006384584878
• 抗炎症作用を有する細胞外小胞製剤
  Patent right, 林 真広; 中石 智之; 大西 俊介; 山本 幸司; 武井 則雄; 大久保 直登, 株式会社カネカ, 国立大学法人北海道大学
  特願2022-073684, 27 Apr. 2022
  特開2023-162956, 09 Nov. 2023
  202303006301784736
• 内視鏡治療用キット及び生体吸収性シート
  Patent right, 大野 正芳; 大西 俊介; 黒川 孝幸, 国立大学法人北海道大学
  特願2022-017121, 07 Feb. 2022
  特開2023-114677, 18 Aug. 2023
  202303015445682864
• 間葉系幹細胞を含む細胞集団を含有する軟部組織再生用医薬組成物
  Patent right, 林 真広; 中石 智之; 大西 俊介; 伊藤 梨里, 株式会社カネカ, 国立大学法人北海道大学
  特願2021-017768, 05 Feb. 2021
  特開2022-120698, 18 Aug. 2022
  202203013770969843
• 内視鏡用生体吸収性シート及びその製造方法
  Patent right, 吉田 蓮実; 山内 康治; 大野 正芳; 大西 俊介, グンゼ株式会社, 国立大学法人北海道大学
  特願2021-001429, 07 Jan. 2021
  特開2022-106435, 20 Jul. 2022
  202203016788786087
• 羊膜間葉系細胞組成物の製造方法及び凍結保存方法、並びに治療剤
  Patent right, 山原 研一; 田口 明彦; 相馬 俊裕; 大西 俊介; 小林 明, 国立研究開発法人国立循環器病研究センター, 公益財団法人神戸医療産業都市推進機構, 学校法人兵庫医科大学, 国立大学法人北海道大学, 株式会社カネカ
  特願2019-038143, 04 Mar. 2019
  特開2019-080580, 30 May 2019
  特許第6754459号
  202003008831332004
• 羊膜間葉系細胞組成物の製造方法及び凍結保存方法、並びに治療剤
  Patent right, 山原 研一; 田口 明彦; 相馬 俊裕; 大西 俊介; 小林 明, 国立研究開発法人国立循環器病研究センター, 公益財団法人神戸医療産業都市推進機構, 学校法人兵庫医科大学, 国立大学法人北海道大学, 株式会社カネカ
  特願2019-038143, 04 Mar. 2019
  特開2019-080580, 30 May 2019
  201903007336180314
• 羊膜間葉系細胞組成物の製造方法及び凍結保存方法、並びに治療剤
  Patent right, 山原 研一; 田口 明彦; 相馬 俊裕; 大西 俊介; 小林 明, 国立研究開発法人国立循環器病研究センター, 公益財団法人神戸医療産業都市推進機構, 学校法人兵庫医科大学, 国立大学法人北海道大学, 株式会社カネカ
  特願2014-130142, 25 Jun. 2014
  特開2015-061520, 02 Apr. 2015
  特許第6512759号
  201903014828016192
• 狭窄抑制剤、組成物、及び抗炎症剤
  Patent right, 大西 俊介; 水島 健; 細野 秀崇; 宮本 秀一, 国立大学法人北海道大学, 株式会社カネカ
  特願2016-020423, 05 Feb. 2016
  特開2017-137268, 10 Aug. 2017
  201703013199194197
• 羊膜間葉系細胞組成物の製造方法及び凍結保存方法、並びに治療剤
  Patent right, 山原 研一; 田口 明彦; 相馬 俊裕; 大西 俊介; 小林 明, 独立行政法人国立循環器病研究センター, 公益財団法人先端医療振興財団, 学校法人兵庫医科大学, 国立大学法人北海道大学, 株式会社カネカ
  特願2014-130142, 25 Jun. 2014
  特開2015-061520, 02 Apr. 2015
  201503062882081883